DDI-MedLine.d180.s0|0-11|Determinants|group
DDI-MedLine.d180.s0|45-53|apoptosis|group
DDI-MedLine.d180.s0|75-79|cells|group
DDI-MedLine.d180.s1|82-91|inhibitors|group
DDI-MedLine.d180.s1|114-123|activities|group
DDI-MedLine.d180.s1|151-156|tumors|group
DDI-MedLine.d180.s2|22-28|effects|group
DDI-MedLine.d180.s2|55-59|cells|group
DDI-MedLine.d180.s2|100-108|inhibited|group
DDI-MedLine.d180.s2|129-137|apoptosis|group
DDI-MedLine.d180.s2|157-161|lines|group
DDI-MedLine.d180.s3|38-42|cells|group
DDI-MedLine.d180.s3|79-82|Plus|group
DDI-MedLine.d180.s3|103-107|genes|group
DDI-MedLine.d180.s3|186-193|analysis|group
DDI-MedLine.d180.s4|63-67|cells|group
DDI-MedLine.d180.s4|63-67|cells|group
DDI-MedLine.d180.s5|4-10|results|group
DDI-MedLine.d180.s6|13-20|analysis|group
DDI-MedLine.d180.s7|65-69|cells|group
DDI-MedLine.d180.s8|76-84|apoptosis|group
DDI-MedLine.d180.s9|16-23|analysis|group
DDI-MedLine.d180.s9|105-112|patients|group
DDI-MedLine.d180.s9|140-144|cells|group
DDI-MedLine.d180.s10|64-68|cells|group
DDI-MedLine.d180.s10|126-134|inhibitor|group
DDI-MedLine.d180.s10|153-161|inhibited|group
DDI-MedLine.d180.s10|182-190|apoptosis|group
DDI-MedLine.d180.s10|64-68|cells|group
DDI-MedLine.d180.s11|27-31|shows|group
DDI-MedLine.d180.s11|40-49|mechanisms|group
DDI-MedLine.d180.s11|79-88|correlates|group
DDI-MedLine.d180.s11|134-139|levels|group
DDI-MedLine.d180.s12|154-162|apoptosis|group
DDI-MedLine.d180.s13|6-12|results|group
DDI-DrugBank.d278.s0|0-9|Enoxaparin|drug
DDI-DrugBank.d278.s0|32-43|subcutaneous|group
DDI-DrugBank.d278.s0|69-73|doses|group
DDI-DrugBank.d278.s0|93-108|pharmacokinetics|group
DDI-DrugBank.d278.s0|174-179|adults|group
DDI-DrugBank.d41.s0|0-13|Cholestyramine|drug
DDI-DrugBank.d41.s0|46-59|cholestyramine|drug
DDI-DrugBank.d41.s0|86-93|patients|group
DDI-DrugBank.d41.s0|106-115|volunteers|group
DDI-DrugBank.d41.s1|12-16|Drugs|group
DDI-DrugBank.d41.s1|33-39|effects|group
DDI-DrugBank.d41.s1|108-117|substances|group
DDI-DrugBank.d41.s2|0-3|This|group
DDI-DrugBank.d41.s2|77-81|drugs|group
DDI-DrugBank.d41.s3|39-43|ARAVA|brand
DDI-DrugBank.d41.s3|50-61|methotrexate|drug
DDI-DrugBank.d41.s3|98-104|enzymes|group
DDI-DrugBank.d41.s3|126-133|patients|group
DDI-DrugBank.d41.s4|4-13|elevations|group
DDI-DrugBank.d41.s4|53-57|drugs|group
DDI-DrugBank.d41.s5|41-48|patients|group
DDI-DrugBank.d41.s6|56-60|drugs|group
DDI-DrugBank.d41.s7|6-13|patients|group
DDI-DrugBank.d41.s9|0-5|NSAIDs|group
DDI-DrugBank.d41.s9|20-26|studies|group
DDI-DrugBank.d41.s9|51-59|increases|group
DDI-DrugBank.d41.s9|135-148|concentrations|group
DDI-DrugBank.d41.s11|48-53|NSAIDs|group
DDI-DrugBank.d41.s11|67-73|studies|group
DDI-DrugBank.d41.s12|25-31|studies|group
DDI-DrugBank.d41.s12|56-64|increases|group
DDI-DrugBank.d41.s12|127-140|concentrations|group
DDI-DrugBank.d41.s14|67-71|ARAVA|brand
DDI-DrugBank.d41.s14|76-83|subjects|group
DDI-DrugBank.d41.s14|104-108|doses|group
DDI-DrugBank.d41.s14|131-136|levels|group
DDI-DrugBank.d41.s14|67-71|ARAVA|brand
DDI-DrugBank.d41.s15|29-33|ARAVA|brand
DDI-DrugBank.d41.s15|35-40|levels|group
DDI-DrugBank.d41.s15|114-121|patients|group
DDI-DrugBank.d41.s15|29-33|ARAVA|brand
DDI-DrugBank.d41.s16|0-7|Warfarin|drug
DDI-DrugBank.d41.s16|62-66|ARAVA|brand
DDI-DrugBank.d41.s16|72-79|warfarin|drug
DDI-MedLine.d118.s0|0-8|Sirolimus|group
DDI-MedLine.d118.s0|31-39|rapamycin|drug
DDI-MedLine.d118.s0|41-49|inhibitor|group
DDI-MedLine.d118.s1|26-34|therapies|group
DDI-MedLine.d118.s1|97-105|reactions|group
DDI-MedLine.d118.s2|0-8|Sirolimus|group
DDI-MedLine.d118.s2|10-14|works|group
DDI-MedLine.d118.s2|37-54|immunosuppressants|group
DDI-MedLine.d118.s2|108-113|levels|group
DDI-MedLine.d118.s2|148-156|sirolimus|group
DDI-MedLine.d118.s2|231-242|cyclosporine|drug
DDI-MedLine.d118.s2|247-256|tacrolimus|group
DDI-MedLine.d118.s3|73-82|recipients|group
DDI-MedLine.d118.s3|97-105|sirolimus|group
DDI-MedLine.d118.s3|128-139|cyclosporine|drug
DDI-MedLine.d118.s3|144-153|tacrolimus|group
DDI-MedLine.d118.s3|218-225|episodes|group
DDI-MedLine.d118.s3|235-244|reductions|group
DDI-MedLine.d118.s3|128-139|cyclosporine|drug
DDI-MedLine.d118.s3|144-153|tacrolimus|group
DDI-MedLine.d118.s3|295-301|steroid|group
DDI-DrugBank.d179.s0|0-10|Interations|group
DDI-DrugBank.d179.s1|0-12|Sulfapyridine|drug
DDI-DrugBank.d179.s1|77-83|Tylenol|drug
DDI-DrugBank.d179.s3|11-18|steroids|group
DDI-DrugBank.d179.s3|108-117|stanozolol|drug
DDI-DrugBank.d179.s4|2-10|Androgens|group
DDI-DrugBank.d179.s4|18-25|hormones|group
DDI-DrugBank.d179.s5|14-19|agents|group
DDI-DrugBank.d179.s6|2-14|Carbamazepine|drug
DDI-DrugBank.d179.s7|2-11|Carmustine|drug
DDI-DrugBank.d179.s10|22-31|Cerubidine|drug
DDI-DrugBank.d179.s13|2-10|Estrogens|group
DDI-DrugBank.d179.s13|20-27|hormones|group
DDI-DrugBank.d179.s15|7-11|salts|group
DDI-DrugBank.d179.s15|27-35|arthritis|group
DDI-DrugBank.d179.s17|24-33|Purinethol|drug
DDI-DrugBank.d179.s19|7-20|contraceptives|group
DDI-DrugBank.d179.s19|37-41|pills|group
DDI-DrugBank.d179.s21|2-15|Phenothiazines|group
DDI-DrugBank.d179.s21|302-316|trifluoperazine|drug_n
DDI-DrugBank.d179.s22|2-11|Plicamycin|drug
DDI-DrugBank.d179.s23|40-52|sulfapyridine|drug
DDI-DrugBank.d179.s23|65-73|medicines|group
DDI-DrugBank.d179.s23|107-113|effects|group
DDI-DrugBank.d179.s27|2-15|Nitrofurantoin|drug
DDI-DrugBank.d179.s30|2-10|Quinidine|drug
DDI-DrugBank.d179.s33|52-64|sulfapyridine|drug
DDI-DrugBank.d179.s33|77-85|medicines|group
DDI-DrugBank.d179.s33|119-125|effects|group
DDI-DrugBank.d179.s34|2-15|Anticoagulants|group
DDI-DrugBank.d179.s34|24-31|thinners|group
DDI-DrugBank.d179.s35|2-9|Ethotoin|drug
DDI-DrugBank.d179.s36|2-12|Mephenytoin|drug
DDI-DrugBank.d179.s36|21-29|Mesantoin|drug
DDI-DrugBank.d179.s36|39-51|sulfapyridine|drug
DDI-DrugBank.d179.s36|64-72|medicines|group
DDI-DrugBank.d179.s36|106-112|effects|group
DDI-DrugBank.d179.s36|64-72|medicines|group
DDI-DrugBank.d179.s37|2-14|Antidiabetics|group
DDI-DrugBank.d179.s37|23-30|diabetes|group
DDI-DrugBank.d179.s37|72-84|antidiabetics|group
DDI-DrugBank.d179.s37|91-103|sulfapyridine|drug
DDI-DrugBank.d179.s37|137-143|effects|group
DDI-DrugBank.d179.s37|137-143|effects|group
DDI-DrugBank.d179.s37|72-84|antidiabetics|group
DDI-DrugBank.d179.s38|2-13|Methotrexate|drug
DDI-DrugBank.d179.s38|22-27|Mexate|drug
DDI-DrugBank.d179.s38|37-48|methotrexate|drug
DDI-DrugBank.d179.s38|55-67|sulfapyridine|drug
DDI-DrugBank.d179.s38|101-107|effects|group
DDI-DrugBank.d179.s38|101-107|effects|group
DDI-DrugBank.d179.s38|37-48|methotrexate|drug
DDI-DrugBank.d179.s39|2-11|Methyldopa|drug_n
DDI-DrugBank.d179.s39|36-45|methyldopa|drug_n
DDI-DrugBank.d179.s39|52-64|sulfapyridine|drug
DDI-DrugBank.d179.s39|98-104|effects|group
DDI-DrugBank.d179.s40|2-10|Phenytoin|drug
DDI-DrugBank.d179.s40|36-44|phenytoin|drug
DDI-DrugBank.d179.s40|51-63|sulfapyridine|drug
DDI-DrugBank.d179.s40|97-103|effects|group
DDI-DrugBank.d179.s40|97-103|effects|group
DDI-DrugBank.d179.s40|36-44|phenytoin|drug
DDI-DrugBank.d78.s0|0-7|Antacids|group
DDI-DrugBank.d78.s0|28-34|Cations|group
DDI-DrugBank.d78.s0|37-49|Multivitamins|group
DDI-DrugBank.d78.s0|51-60|Quinolones|group
DDI-DrugBank.d78.s0|67-74|chelates|group
DDI-DrugBank.d78.s0|117-123|cations|group
DDI-DrugBank.d78.s1|18-27|quinolones|group
DDI-DrugBank.d78.s1|34-41|antacids|group
DDI-DrugBank.d78.s1|115-121|cations|group
DDI-DrugBank.d78.s1|145-157|multivitamins|group
DDI-DrugBank.d78.s1|192-203|formulations|group
DDI-DrugBank.d78.s1|115-121|cations|group
DDI-DrugBank.d78.s1|255-259|VIDEX|brand
DDI-DrugBank.d78.s1|292-298|tablets|group
DDI-DrugBank.d78.s1|18-27|quinolones|group
DDI-DrugBank.d78.s1|428-441|concentrations|group
DDI-DrugBank.d78.s2|6-11|agents|group
DDI-DrugBank.d78.s2|42-46|hours|group
DDI-DrugBank.d78.s2|42-46|hours|group
DDI-DrugBank.d78.s3|47-56|quinolones|group
DDI-DrugBank.d78.s3|63-69|inhibit|group
DDI-DrugBank.d78.s4|6-15|stimulants|group
DDI-DrugBank.d78.s5|8-15|patients|group
DDI-DrugBank.d78.s5|101-107|effects|group
DDI-DrugBank.d78.s6|45-53|inhibitor|group
DDI-DrugBank.d78.s7|19-32|concentrations|group
DDI-DrugBank.d78.s8|231-244|concentrations|group
DDI-DrugBank.d78.s8|295-305|adjustments|group
DDI-DrugBank.d78.s9|0-7|Warfarin|drug
DDI-DrugBank.d78.s9|13-20|subjects|group
DDI-DrugBank.d78.s9|32-39|warfarin|drug
DDI-DrugBank.d78.s10|22-31|quinolones|group
DDI-DrugBank.d78.s10|67-73|effects|group
DDI-DrugBank.d78.s10|78-85|warfarin|drug
DDI-DrugBank.d78.s10|94-104|derivatives|group
DDI-DrugBank.d78.s10|142-156|anticoagulation|group
DDI-DrugBank.d78.s10|78-85|warfarin|drug
DDI-DrugBank.d78.s10|94-104|derivatives|group
DDI-DrugBank.d78.s11|0-4|Drugs|group
DDI-DrugBank.d78.s11|37-43|Enzymes|group
DDI-DrugBank.d78.s11|127-135|indicates|group
DDI-DrugBank.d78.s11|156-163|inhibits|group
DDI-DrugBank.d78.s12|18-24|studies|group
DDI-DrugBank.d78.s13|0-9|substrates|group
DDI-DrugBank.d78.s13|42-48|effects|group
DDI-DrugBank.d78.s14|19-28|quinolones|group
DDI-DrugBank.d78.s14|95-106|cyclosporine|drug
DDI-DrugBank.d78.s15|6-10|drugs|group
DDI-DrugBank.d78.s16|44-52|midazolam|drug
DDI-DrugBank.d78.s16|59-67|triazolam|drug
DDI-DrugBank.d78.s17|92-101|substrates|group
DDI-DrugBank.d78.s18|0-7|Patients|group
DDI-DrugBank.d78.s18|48-57|substrates|group
DDI-DrugBank.d78.s18|101-106|trials|group
DDI-DrugBank.d78.s19|0-11|Nonsteroidal|group
DDI-DrugBank.d78.s19|31-35|Drugs|group
DDI-DrugBank.d78.s19|38-43|NSAIDs|group
DDI-DrugBank.d78.s19|83-94|nonsteroidal|group
DDI-DrugBank.d78.s19|153-157|risks|group
DDI-DrugBank.d78.s19|182-192|convulsions|group
DDI-DrugBank.d78.s20|13-18|Agents|group
DDI-DrugBank.d78.s20|21-32|Disturbances|group
DDI-DrugBank.d78.s20|116-123|patients|group
DDI-DrugBank.d78.s20|152-161|quinolones|group
DDI-DrugBank.d78.s20|183-187|agent|group
DDI-DrugBank.d78.s21|73-78|agents|group
DDI-DrugBank.d250.s0|14-24|antibiotics|group
DDI-DrugBank.d250.s0|27-41|aminoglycosides|group
DDI-DrugBank.d250.s2|18-26|relaxants|group
DDI-DrugBank.d250.s2|57-61|drugs|group
DDI-DrugBank.d250.s2|98-106|gallamine|drug
DDI-DrugBank.d250.s2|172-179|blocking|group
DDI-DrugBank.d250.s2|231-238|patients|group
DDI-MedLine.d159.s0|116-126|lymphocytes|group
DDI-MedLine.d159.s1|36-41|stress|group
DDI-MedLine.d159.s1|115-125|lymphocytes|group
DDI-MedLine.d159.s1|150-157|patients|group
DDI-MedLine.d159.s2|0-3|Thus|group
DDI-MedLine.d159.s2|37-46|inhibitors|group
DDI-MedLine.d159.s2|129-136|defenses|group
DDI-MedLine.d159.s2|209-213|cells|group
DDI-MedLine.d159.s3|71-78|pathways|group
DDI-MedLine.d159.s3|131-141|suspensions|group
DDI-MedLine.d159.s3|153-162|inhibitors|group
DDI-MedLine.d159.s3|175-184|hydrolases|group
DDI-MedLine.d159.s3|153-162|inhibitors|group
DDI-MedLine.d159.s3|212-218|enzymes|group
DDI-MedLine.d159.s3|307-316|inhibition|group
DDI-MedLine.d159.s3|329-337|synthesis|group
DDI-MedLine.d159.s4|37-45|compounds|group
DDI-MedLine.d159.s4|58-69|antioxidants|group
DDI-MedLine.d159.s4|101-106|agents|group
DDI-MedLine.d159.s5|18-24|reports|group
DDI-MedLine.d159.s5|36-43|findings|group
DDI-MedLine.d159.s5|146-156|lymphocytes|group
DDI-MedLine.d159.s5|165-171|results|group
DDI-MedLine.d159.s5|201-204|loss|group
DDI-MedLine.d159.s6|24-30|elicits|group
DDI-MedLine.d159.s7|20-27|findings|group
DDI-MedLine.d159.s7|129-135|studies|group
DDI-MedLine.d159.s7|142-152|lymphocytes|group
DDI-MedLine.d159.s7|162-169|patients|group
DDI-MedLine.d159.s7|206-210|agent|group
DDI-MedLine.d159.s7|220-230|spontaneous|group
DDI-DrugBank.d590.s0|20-25|TRITEC|brand
DDI-DrugBank.d590.s0|32-45|clarithromycin|drug
DDI-DrugBank.d590.s0|76-85|ranitidine|drug
DDI-DrugBank.d590.s0|87-100|concentrations|group
DDI-DrugBank.d590.s0|87-100|concentrations|group
DDI-DrugBank.d590.s0|32-45|clarithromycin|drug
DDI-DrugBank.d590.s0|87-100|concentrations|group
DDI-DrugBank.d590.s1|30-36|results|group
DDI-DrugBank.d590.s2|55-61|results|group
DDI-DrugBank.d590.s2|91-104|concentrations|group
DDI-DrugBank.d590.s2|109-118|ranitidine|drug
DDI-DrugBank.d590.s2|91-104|concentrations|group
DDI-DrugBank.d590.s2|175-180|TRITEC|brand
DDI-DrugBank.d590.s3|6-12|effects|group
DDI-DrugBank.d590.s4|24-35|interactions|group
DDI-DrugBank.d590.s4|53-62|ranitidine|drug
DDI-DrugBank.d590.s4|78-83|ZANTAC|brand
DDI-MedLine.d47.s0|53-64|azithromycin|drug
DDI-MedLine.d47.s1|87-98|azithromycin|drug
DDI-MedLine.d47.s3|69-80|azithromycin|drug
DDI-MedLine.d47.s4|28-37|inhibiting|group
DDI-MedLine.d47.s4|107-118|azithromycin|drug
DDI-DrugBank.d308.s0|4-15|POTENTIATING|brand
DDI-DrugBank.d308.s0|17-22|ACTION|brand
DDI-DrugBank.d308.s0|27-37|HYDROXYZINE|brand
DDI-DrugBank.d308.s0|39-42|MUST|brand
DDI-DrugBank.d308.s0|47-56|CONSIDERED|brand
DDI-DrugBank.d308.s0|58-61|WHEN|brand
DDI-DrugBank.d308.s0|67-70|DRUG|brand
DDI-DrugBank.d308.s0|75-78|USED|brand
DDI-DrugBank.d308.s0|83-93|CONJUNCTION|brand
DDI-DrugBank.d308.s0|95-98|WITH|brand
DDI-DrugBank.d308.s0|100-106|CENTRAL|brand
DDI-DrugBank.d308.s0|108-114|NERVOUS|brand
DDI-DrugBank.d308.s0|116-121|SYSTEM|brand
DDI-DrugBank.d308.s0|123-133|DEPRESSANTS|brand
DDI-DrugBank.d308.s0|135-138|SUCH|brand
DDI-DrugBank.d308.s0|143-151|NARCOTICS|brand
DDI-DrugBank.d308.s0|167-176|ANALGESICS|brand
DDI-DrugBank.d308.s0|182-193|BARBITURATES|brand
DDI-DrugBank.d308.s1|23-29|nervous|group
DDI-DrugBank.d308.s1|38-48|depressants|group
DDI-DrugBank.d308.s2|6-15|drowsiness|group
DDI-DrugBank.d308.s2|50-57|patients|group
DDI-DrugBank.d308.s2|145-153|dangerous|group
DDI-DrugBank.d308.s3|0-7|Patients|group
DDI-DrugBank.d308.s3|39-50|simultaneous|group
DDI-DrugBank.d308.s3|80-84|drugs|group
DDI-DrugBank.d308.s3|120-126|alcohol|drug
DDI-DrugBank.d181.s0|18-26|oxytocics|group
DDI-DrugBank.d181.s0|81-90|hypertonus|group
DDI-DrugBank.d181.s1|9-20|combinations|group
DDI-DrugBank.d181.s1|26-34|sometimes|group
DDI-DrugBank.d318.s0|46-50|drugs|group
DDI-DrugBank.d318.s0|101-106|agents|group
DDI-DrugBank.d318.s1|15-20|agents|group
DDI-DrugBank.d318.s2|0-14|Corticosteroids|group
DDI-DrugBank.d318.s2|35-38|ACTH|brand
DDI-DrugBank.d318.s3|22-27|unless|group
DDI-DrugBank.d318.s3|55-61|effects|group
DDI-DrugBank.d318.s4|45-56|electrolytes|group
DDI-DrugBank.d318.s5|0-8|Digitalis|group
DDI-DrugBank.d318.s5|10-19|glycosides|group
DDI-DrugBank.d318.s5|72-80|digitalis|group
DDI-DrugBank.d318.s6|16-21|levels|group
DDI-DrugBank.d318.s8|0-9|Imidazoles|group
DDI-DrugBank.d318.s8|19-30|ketoconazole|drug
DDI-DrugBank.d318.s8|33-42|miconazole|drug
DDI-DrugBank.d318.s8|45-56|clotrimazole|drug
DDI-DrugBank.d318.s8|59-69|fluconazole|drug
DDI-DrugBank.d318.s8|99-105|studies|group
DDI-DrugBank.d318.s8|150-159|imidazoles|group
DDI-DrugBank.d318.s8|150-159|imidazoles|group
DDI-DrugBank.d318.s9|89-96|patients|group
DDI-DrugBank.d318.s10|18-28|medications|group
DDI-DrugBank.d318.s10|31-36|agents|group
DDI-DrugBank.d318.s10|46-60|aminoglycosides|group
DDI-DrugBank.d318.s10|63-74|cyclosporine|drug
DDI-DrugBank.d318.s10|81-91|pentamidine|drug
DDI-DrugBank.d318.s11|57-64|patients|group
DDI-DrugBank.d318.s11|107-117|medications|group
DDI-DrugBank.d318.s12|16-24|relaxants|group
DDI-DrugBank.d318.s12|16-24|relaxants|group
DDI-DrugBank.d318.s13|16-21|levels|group
DDI-DrugBank.d318.s13|47-58|deficiencies|group
DDI-DrugBank.d318.s14|10-21|transfusions|group
DDI-DrugBank.d318.s14|70-77|patients|group
DDI-DrugBank.d318.s14|89-99|intravenous|group
DDI-DrugBank.d318.s14|10-21|transfusions|group
DDI-DrugBank.d766.s0|6-17|trimetrexate|drug
DDI-DrugBank.d766.s0|59-63|drugs|group
DDI-DrugBank.d766.s0|80-86|inhibit|group
DDI-DrugBank.d766.s0|156-167|interactions|group
DDI-DrugBank.d766.s0|6-17|trimetrexate|drug
DDI-DrugBank.d766.s0|204-217|concentrations|group
DDI-DrugBank.d766.s1|0-5|Agents|group
DDI-DrugBank.d766.s1|41-52|trimetrexate|drug
DDI-DrugBank.d766.s1|57-60|AIDS|brand
DDI-DrugBank.d766.s1|62-69|patients|group
DDI-DrugBank.d766.s1|81-91|indications|group
DDI-DrugBank.d766.s1|133-144|erythromycin|drug
DDI-DrugBank.d766.s1|168-179|ketoconazole|drug
DDI-DrugBank.d766.s1|186-196|fluconazole|drug
DDI-DrugBank.d766.s2|56-65|cimetidine|drug
DDI-DrugBank.d766.s2|101-112|trimetrexate|drug
DDI-DrugBank.d766.s2|101-112|trimetrexate|drug
DDI-DrugBank.d766.s2|199-209|metabolites|group
DDI-DrugBank.d766.s2|199-209|metabolites|group
DDI-DrugBank.d766.s3|59-67|imidazole|drug
DDI-DrugBank.d766.s3|69-73|drugs|group
DDI-DrugBank.d766.s3|76-87|clotrimazole|drug
DDI-DrugBank.d766.s3|90-101|ketoconazole|drug
DDI-DrugBank.d766.s3|104-113|miconazole|drug
DDI-DrugBank.d766.s3|145-154|inhibitors|group
DDI-DrugBank.d766.s3|159-170|trimetrexate|drug
DDI-DrugBank.d766.s4|0-7|Patients|group
DDI-DrugBank.d766.s4|30-34|drugs|group
DDI-DrugBank.d766.s4|40-51|trimetrexate|drug
DDI-DrugBank.d454.s0|2-11|Lofexidine|drug
DDI-DrugBank.d454.s0|44-50|effects|group
DDI-DrugBank.d454.s0|55-61|alcohol|drug
DDI-DrugBank.d454.s0|64-75|barbiturates|group
DDI-DrugBank.d454.s0|87-95|sedatives|group
DDI-DrugBank.d454.s2|2-11|Lofexidine|drug
DDI-DrugBank.d454.s2|29-35|effects|group
DDI-DrugBank.d454.s4|31-45|antidepressants|group
DDI-DrugBank.d454.s4|74-83|lofexidine|drug
DDI-DrugBank.d124.s0|0-3|DRUG|brand
DDI-DrugBank.d124.s0|5-16|INTERACTIONS|brand
DDI-DrugBank.d124.s1|25-31|studies|group
DDI-DrugBank.d124.s1|63-70|INVIRASE|brand
DDI-DrugBank.d124.s1|76-84|FORTOVASE|brand
DDI-DrugBank.d124.s2|0-11|Observations|group
DDI-DrugBank.d124.s2|35-41|studies|group
DDI-DrugBank.d124.s2|48-56|FORTOVASE|brand
DDI-DrugBank.d124.s2|84-91|INVIRASE|brand
DDI-DrugBank.d124.s3|37-47|prescribers|group
DDI-DrugBank.d124.s3|127-138|interactions|group
DDI-DrugBank.d124.s3|161-165|agent|group
DDI-DrugBank.d124.s6|11-15|drugs|group
DDI-DrugBank.d124.s6|63-78|pharmacokinetics|group
DDI-DrugBank.d124.s7|44-59|pharmacokinetics|group
DDI-DrugBank.d124.s7|70-74|drugs|group
DDI-DrugBank.d124.s7|85-94|substrates|group
DDI-DrugBank.d124.s8|0-4|Drugs|group
DDI-DrugBank.d124.s8|107-113|serious|group
DDI-DrugBank.d124.s8|123-128|events|group
DDI-DrugBank.d124.s8|141-157|CONTRAINDICATIONS|brand
DDI-DrugBank.d124.s9|11-15|drugs|group
DDI-DrugBank.d124.s9|68-75|INVIRASE|brand
DDI-DrugBank.d124.s10|6-20|recommendations|group
DDI-DrugBank.d124.s10|59-65|studies|group
DDI-DrugBank.d124.s10|80-91|interactions|group
DDI-DrugBank.d124.s10|156-162|serious|group
DDI-DrugBank.d124.s10|164-169|events|group
DDI-DrugBank.d124.s10|174-177|loss|group
DDI-DrugBank.d124.s11|10-15|agents|group
DDI-DrugBank.d124.s11|72-85|concentrations|group
DDI-DrugBank.d124.s12|0-4|Drugs|group
DDI-DrugBank.d124.s13|5-9|Class|group
DDI-DrugBank.d124.s14|0-14|Antiarrhythmics|group
DDI-DrugBank.d124.s14|64-72|quinidine|drug
DDI-DrugBank.d124.s14|74-88|CONTRAINDICATED|brand
DDI-DrugBank.d124.s14|111-117|serious|group
DDI-DrugBank.d124.s14|143-151|reactions|group
DDI-DrugBank.d124.s15|0-13|Antihistamines|group
DDI-DrugBank.d124.s15|42-56|CONTRAINDICATED|brand
DDI-DrugBank.d124.s15|79-85|serious|group
DDI-DrugBank.d124.s15|119-129|arrhythmias|group
DDI-DrugBank.d124.s16|6-16|Derivatives|group
DDI-DrugBank.d124.s16|19-35|Dihydroergotamine|drug
DDI-DrugBank.d124.s16|26-35|ergotamine|drug
DDI-DrugBank.d124.s16|62-77|methylergonovine|drug_n
DDI-DrugBank.d124.s16|79-93|CONTRAINDICATED|brand
DDI-DrugBank.d124.s16|116-122|serious|group
DDI-DrugBank.d124.s16|145-153|reactions|group
DDI-DrugBank.d124.s16|242-252|extremities|group
DDI-DrugBank.d124.s16|264-270|tissues|group
DDI-DrugBank.d124.s17|18-23|Agents|group
DDI-DrugBank.d124.s17|35-49|CONTRAINDICATED|brand
DDI-DrugBank.d124.s17|139-145|reduces|group
DDI-DrugBank.d124.s17|158-171|concentrations|group
DDI-DrugBank.d124.s18|7-14|Capsules|group
DDI-DrugBank.d124.s18|23-30|capsules|group
DDI-DrugBank.d124.s18|76-84|FORTOVASE|brand
DDI-DrugBank.d124.s18|108-116|inhibitor|group
DDI-DrugBank.d124.s18|165-178|concentrations|group
DDI-DrugBank.d124.s19|103-110|capsules|group
DDI-DrugBank.d124.s20|30-44|CONTRAINDICATED|brand
DDI-DrugBank.d124.s20|67-73|serious|group
DDI-DrugBank.d124.s20|99-107|reactions|group
DDI-DrugBank.d124.s20|125-135|arrhythmias|group
DDI-DrugBank.d124.s21|7-14|Products|group
DDI-DrugBank.d124.s21|56-62|WARNING|brand
DDI-DrugBank.d124.s21|93-96|loss|group
DDI-DrugBank.d124.s21|147-154|INVIRASE|brand
DDI-DrugBank.d124.s21|166-170|class|group
DDI-DrugBank.d124.s21|184-193|inhibitors|group
DDI-DrugBank.d124.s22|18-27|Inhibitors|group
DDI-DrugBank.d124.s22|54-60|WARNING|brand
DDI-DrugBank.d124.s22|76-82|serious|group
DDI-DrugBank.d124.s22|84-92|reactions|group
DDI-DrugBank.d124.s22|129-142|rhabdomyolysis|group
DDI-DrugBank.d124.s23|21-29|triazolam|drug
DDI-DrugBank.d124.s23|32-40|midazolam|drug
DDI-DrugBank.d124.s23|42-56|CONTRAINDICATED|brand
DDI-DrugBank.d124.s23|79-85|serious|group
DDI-DrugBank.d124.s23|111-119|reactions|group
DDI-DrugBank.d124.s25|0-4|Drugs|group
DDI-DrugBank.d124.s26|18-24|studies|group
DDI-DrugBank.d124.s26|73-77|drugs|group
DDI-DrugBank.d124.s26|138-145|blockers|group
DDI-DrugBank.d124.s26|192-200|quinidine|drug
DDI-DrugBank.d124.s26|203-210|warfarin|drug
DDI-DrugBank.d124.s26|213-222|tacrolimus|group
DDI-DrugBank.d124.s26|225-236|cyclosporine|drug
DDI-DrugBank.d124.s26|245-255|derivatives|group
DDI-DrugBank.d124.s26|268-280|carbamazepine|drug
DDI-DrugBank.d124.s26|305-314|alprazolam|drug
DDI-DrugBank.d124.s26|321-329|triazolam|drug
DDI-DrugBank.d124.s26|357-370|concentrations|group
DDI-DrugBank.d124.s27|17-28|combinations|group
DDI-DrugBank.d124.s28|6-13|INVIRASE|brand
DDI-DrugBank.d124.s28|103-107|drugs|group
DDI-DrugBank.d124.s29|0-7|Inducers|group
DDI-DrugBank.d124.s30|22-30|compounds|group
DDI-DrugBank.d124.s30|48-55|inducers|group
DDI-DrugBank.d124.s30|87-95|phenytoin|drug
DDI-DrugBank.d124.s30|113-125|carbamazepine|drug
DDI-DrugBank.d124.s30|159-164|levels|group
DDI-DrugBank.d756.s0|0-6|Dosages|group
DDI-DrugBank.d756.s0|38-44|opioids|group
DDI-DrugBank.d756.s0|111-119|amplifies|group
DDI-DrugBank.d756.s0|137-143|actions|group
DDI-DrugBank.d756.s0|38-44|opioids|group
DDI-DrugBank.d756.s1|72-79|seizures|group
DDI-DrugBank.d756.s2|18-24|effects|group
DDI-DrugBank.d756.s2|42-47|states|group
DDI-DrugBank.d756.s2|93-107|benzodiazepines|group
DDI-DrugBank.d756.s2|112-123|barbiturates|group
DDI-DrugBank.d756.s3|0-3|This|group
DDI-DrugBank.d756.s3|63-72|substances|group
DDI-DrugBank.d756.s4|81-85|drugs|group
DDI-DrugBank.d756.s4|98-112|antidepressants|group
DDI-DrugBank.d756.s4|228-232|ileus|group
DDI-DrugBank.d756.s6|24-35|combinations|group
DDI-DrugBank.d756.s7|16-26|stimulantes|group
DDI-DrugBank.d756.s7|90-96|actions|group
DDI-DrugBank.d756.s8|25-34|substances|group
DDI-DrugBank.d756.s10|21-28|antacids|group
DDI-DrugBank.d756.s11|29-33|hours|group
DDI-DrugBank.d69.s0|7-16|Cerubidine|drug
DDI-DrugBank.d69.s0|71-79|increases|group
DDI-DrugBank.d69.s1|0-9|Cerubidine|drug
DDI-DrugBank.d69.s1|33-40|patients|group
DDI-DrugBank.d69.s1|106-110|doses|group
DDI-DrugBank.d69.s1|0-9|Cerubidine|drug
DDI-DrugBank.d69.s2|40-49|Cerubidine|drug
DDI-DrugBank.d69.s3|20-29|Cerubidine|drug
DDI-DrugBank.d69.s3|98-103|agents|group
DDI-DrugBank.d69.s4|12-22|medications|group
DDI-DrugBank.d69.s4|43-54|methotrexate|drug
DDI-MedLine.d181.s0|52-56|drops|group
DDI-MedLine.d181.s1|16-27|Laboratories|group
DDI-MedLine.d181.s1|116-123|symptoms|group
DDI-MedLine.d181.s1|128-135|neonates|group
DDI-MedLine.d181.s1|141-147|infants|group
DDI-MedLine.d181.s3|8-19|interactions|group
DDI-MedLine.d181.s3|86-100|characteristics|group
DDI-MedLine.d181.s4|4-10|authors|group
DDI-MedLine.d181.s6|50-54|drops|group
DDI-MedLine.d181.s6|63-67|feeds|group
DDI-MedLine.d181.s7|10-14|drops|group
DDI-MedLine.d181.s9|0-9|Clinicians|group
DDI-MedLine.d181.s9|15-21|parents|group
DDI-DrugBank.d359.s0|0-7|PEGANONE|brand
DDI-DrugBank.d359.s0|40-44|drugs|group
DDI-DrugBank.d359.s1|44-51|PEGANONE|brand
DDI-DrugBank.d359.s1|98-108|phenacemide|drug
DDI-DrugBank.d359.s1|126-133|symptoms|group
DDI-DrugBank.d359.s2|34-42|hydantoin|drug
DDI-DrugBank.d359.s2|59-67|phenytoin|drug
DDI-DrugBank.d359.s2|78-85|coumarin|drug
DDI-DrugBank.d359.s2|87-100|anticoagulants|group
DDI-DrugBank.d359.s3|12-20|phenytoin|drug
DDI-DrugBank.d359.s3|22-25|acts|group
DDI-DrugBank.d359.s3|46-53|coumarin|drug
DDI-DrugBank.d359.s3|113-118|levels|group
DDI-DrugBank.d359.s3|46-53|coumarin|drug
DDI-DrugBank.d359.s3|136-149|anticoagulants|group
DDI-DrugBank.d359.s3|190-203|concentrations|group
DDI-DrugBank.d359.s4|16-23|coumarin|drug
DDI-DrugBank.d359.s4|25-38|anticoagulants|group
DDI-DrugBank.d359.s4|81-86|levels|group
DDI-DrugBank.d359.s4|123-131|phenytoin|drug
DDI-DrugBank.d359.s4|136-145|inhibiting|group
DDI-DrugBank.d359.s5|74-81|ethotoin|drug
DDI-DrugBank.d359.s5|91-98|coumarin|drug
DDI-DrugBank.d359.s5|100-113|anticoagulants|group
DDI-DrugBank.d359.s6|48-55|PEGANONE|brand
DDI-DrugBank.d359.s6|60-67|patients|group
DDI-DrugBank.d359.s6|79-86|coumarin|drug
DDI-DrugBank.d359.s6|88-101|anticoagulants|group
DDI-DrugBank.d736.s0|79-85|effects|group
DDI-DrugBank.d736.s0|90-98|digitalis|group
DDI-DrugBank.d736.s1|50-57|steroids|group
DDI-DrugBank.d736.s1|62-65|ACTH|brand
DDI-DrugBank.d736.s2|8-19|requirements|group
DDI-DrugBank.d736.s2|33-40|patients|group
DDI-DrugBank.d736.s3|0-8|Thiazides|group
DDI-DrugBank.d736.s3|32-45|responsiveness|group
DDI-DrugBank.d736.s3|50-63|norepinephrine|drug
DDI-DrugBank.d736.s4|0-3|This|group
DDI-DrugBank.d736.s4|46-58|effectiveness|group
DDI-DrugBank.d736.s4|75-79|agent|group
DDI-DrugBank.d736.s5|9-13|drugs|group
DDI-DrugBank.d736.s5|32-45|responsiveness|group
DDI-DrugBank.d736.s6|38-46|thiazides|group
DDI-DrugBank.d736.s7|0-8|Thiazides|group
DDI-DrugBank.d736.s7|72-76|drugs|group
DDI-DrugBank.d736.s8|13-18|occurs|group
DDI-DrugBank.d736.s8|61-68|blocking|group
DDI-DrugBank.d736.s8|70-74|drugs|group
DDI-DrugBank.d105.s0|0-13|Anticoagulants|group
DDI-DrugBank.d105.s0|25-32|coumarin|drug
DDI-DrugBank.d105.s0|34-44|derivatives|group
DDI-DrugBank.d105.s0|34-44|derivatives|group
DDI-DrugBank.d105.s0|96-105|inhibitors|group
DDI-DrugBank.d105.s0|115-126|nonsteroidal|group
DDI-DrugBank.d105.s0|146-150|drugs|group
DDI-DrugBank.d105.s0|153-158|NSAIDs|group
DDI-DrugBank.d105.s0|245-253|ardeparin|drug
DDI-MedLine.d86.s0|48-52|doses|group
DDI-MedLine.d86.s0|71-79|sirolimus|group
DDI-MedLine.d86.s0|92-101|volunteers|group
DDI-MedLine.d86.s1|8-17|BACKGROUND|brand
DDI-MedLine.d86.s1|60-68|sirolimus|group
DDI-MedLine.d86.s1|148-154|blocker|group
DDI-MedLine.d86.s1|192-199|subjects|group
DDI-MedLine.d86.s2|29-40|interactions|group
DDI-MedLine.d86.s2|100-104|drugs|group
DDI-MedLine.d86.s2|162-172|antagonists|group
DDI-MedLine.d86.s3|0-6|METHODS|brand
DDI-MedLine.d86.s3|17-24|subjects|group
DDI-MedLine.d86.s3|44-48|years|group
DDI-MedLine.d86.s3|128-143|pharmacokinetics|group
DDI-MedLine.d86.s3|176-184|sirolimus|group
DDI-MedLine.d86.s3|239-243|drugs|group
DDI-MedLine.d86.s4|16-22|periods|group
DDI-MedLine.d86.s5|0-6|RESULTS|brand
DDI-MedLine.d86.s5|66-74|sirolimus|group
DDI-MedLine.d86.s5|281-287|whereas|group
DDI-MedLine.d86.s5|66-74|sirolimus|group
DDI-MedLine.d86.s5|367-371|hours|group
DDI-MedLine.d86.s6|54-62|sirolimus|group
DDI-MedLine.d86.s6|54-62|sirolimus|group
DDI-MedLine.d86.s7|122-139|desmethyldiltiazem|drug_n
DDI-MedLine.d86.s7|182-190|sirolimus|group
DDI-MedLine.d86.s7|220-226|effects|group
DDI-MedLine.d86.s7|312-321|parameters|group
DDI-MedLine.d86.s8|0-10|CONCLUSIONS|brand
DDI-MedLine.d86.s8|52-56|leads|group
DDI-MedLine.d86.s8|68-76|sirolimus|group
DDI-MedLine.d86.s8|102-111|inhibition|group
DDI-MedLine.d86.s8|68-76|sirolimus|group
DDI-MedLine.d86.s9|72-80|sirolimus|group
DDI-MedLine.d86.s9|127-140|concentrations|group
DDI-MedLine.d86.s9|173-180|patients|group
DDI-MedLine.d86.s9|203-207|drugs|group
DDI-DrugBank.d671.s0|19-24|CYLERT|brand
DDI-DrugBank.d671.s0|48-52|drugs|group
DDI-DrugBank.d671.s0|78-83|humans|group
DDI-DrugBank.d671.s1|0-7|Patients|group
DDI-DrugBank.d671.s1|27-32|CYLERT|brand
DDI-DrugBank.d671.s1|58-62|drugs|group
DDI-DrugBank.d671.s1|58-62|drugs|group
DDI-DrugBank.d671.s2|49-56|patients|group
DDI-DrugBank.d671.s2|68-73|CYLERT|brand
DDI-DrugBank.d671.s2|108-118|medications|group
DDI-DrugBank.d515.s0|57-63|actions|group
DDI-DrugBank.d515.s0|187-191|drugs|group
DDI-DrugBank.d515.s0|187-191|drugs|group
DDI-DrugBank.d185.s0|65-70|ACZONE|brand
DDI-DrugBank.d185.s1|35-40|levels|group
DDI-DrugBank.d185.s2|48-60|hydroxylamine|drug
DDI-DrugBank.d185.s4|20-30|medications|group
DDI-DrugBank.d185.s4|51-65|anticonvulsants|group
DDI-DrugBank.d185.s5|51-63|hydroxylamine|drug
DDI-DrugBank.d185.s5|106-114|hemolysis|group
DDI-DrugBank.d185.s6|40-50|antagonists|group
DDI-DrugBank.d185.s6|60-72|pyrimethamine|drug
DDI-DrugBank.d185.s6|141-149|reactions|group
DDI-DrugBank.d706.s0|24-28|drugs|group
DDI-DrugBank.d706.s0|37-45|reserpine|drug
DDI-DrugBank.d706.s0|106-111|agents|group
DDI-DrugBank.d706.s1|0-7|Patients|group
DDI-DrugBank.d706.s1|39-48|metoprolol|drug
DDI-DrugBank.d706.s1|60-63|plus|group
DDI-DrugBank.d706.s1|67-79|catecholamine|drug
DDI-DrugBank.d104.s0|0-11|Fenfluramine|drug
DDI-DrugBank.d104.s0|66-70|drugs|group
DDI-DrugBank.d104.s0|79-90|guanethidine|drug
DDI-DrugBank.d104.s0|93-102|methyldopa|drug_n
DDI-DrugBank.d104.s0|105-113|reserpine|drug
DDI-DrugBank.d104.s1|21-25|drugs|group
DDI-DrugBank.d104.s1|58-65|patients|group
DDI-DrugBank.d104.s1|74-85|fenfluramine|drug
DDI-DrugBank.d104.s1|98-104|effects|group
DDI-DrugBank.d317.s0|16-19|TEST|brand
DDI-DrugBank.d317.s0|21-32|INTERACTIONS|brand
DDI-DrugBank.d317.s3|10-16|factors|group
DDI-DrugBank.d317.s3|35-38|VIII|brand
DDI-DrugBank.d317.s3|35-38|VIII|brand
DDI-DrugBank.d317.s3|54-62|coagulant|group
DDI-DrugBank.d317.s4|10-15|levels|group
DDI-DrugBank.d317.s5|10-15|levels|group
DDI-DrugBank.d317.s8|41-46|levels|group
DDI-DrugBank.d317.s8|41-46|levels|group
DDI-DrugBank.d317.s8|41-46|levels|group
DDI-DrugBank.d317.s8|41-46|levels|group
DDI-DrugBank.d317.s10|20-33|concentrations|group
DDI-DrugBank.d317.s11|0-7|Patients|group
DDI-DrugBank.d317.s11|59-63|doses|group
DDI-DrugBank.d317.s13|14-21|proteins|group
DDI-DrugBank.d317.s13|56-69|corticosteroid|group
DDI-DrugBank.d317.s13|125-128|SHBG|brand
DDI-DrugBank.d317.s13|171-185|corticosteroids|group
DDI-DrugBank.d317.s13|178-185|steroids|group
DDI-DrugBank.d317.s14|13-26|concentrations|group
DDI-DrugBank.d317.s15|13-20|proteins|group
DDI-DrugBank.d317.s17|54-67|concentrations|group
DDI-DrugBank.d317.s17|132-137|levels|group
DDI-DrugBank.d739.s0|120-126|changes|group
DDI-DrugBank.d739.s0|135-142|kinetics|group
DDI-DrugBank.d739.s0|156-166|intravenous|group
DDI-DrugBank.d739.s1|48-55|warfarin|drug
DDI-DrugBank.d739.s1|73-83|cytochromes|group
DDI-DrugBank.d739.s1|48-55|warfarin|drug
DDI-DrugBank.d739.s2|84-90|digoxin|drug
DDI-DrugBank.d739.s4|15-19|Doses|group
DDI-DrugBank.d739.s4|121-134|concentrations|group
DDI-DrugBank.d739.s5|60-67|profiles|group
DDI-DrugBank.d739.s5|153-163|intravenous|group
DDI-DrugBank.d739.s6|21-27|induces|group
DDI-DrugBank.d739.s8|94-101|inducers|group
DDI-DrugBank.d739.s9|45-53|therapies|group
DDI-DrugBank.d739.s9|77-87|prophylaxis|group
DDI-DrugBank.d739.s9|158-166|reactions|group
DDI-DrugBank.d739.s10|20-26|studies|group
DDI-DrugBank.d739.s10|108-114|effects|group
DDI-DrugBank.d739.s10|123-138|pharmacokinetics|group
DDI-DrugBank.d739.s10|157-161|drugs|group
DDI-DrugBank.d739.s10|209-222|contraceptives|group
DDI-DrugBank.d739.s10|284-290|digoxin|drug
DDI-DrugBank.d739.s10|297-304|warfarin|drug
DDI-DrugBank.d739.s11|41-47|studies|group
DDI-DrugBank.d739.s11|145-149|drugs|group
DDI-DrugBank.d739.s11|41-47|studies|group
DDI-DrugBank.d739.s11|208-219|interactions|group
DDI-DrugBank.d739.s12|6-16|medications|group
DDI-DrugBank.d739.s12|35-42|hormones|group
DDI-DrugBank.d739.s12|54-62|hypnotics|group
DDI-DrugBank.d739.s12|97-102|agents|group
DDI-DrugBank.d739.s12|105-119|benzodiazepines|group
DDI-DrugBank.d739.s12|126-138|decongestants|group
DDI-DrugBank.d739.s13|21-27|induces|group
DDI-DrugBank.d739.s15|94-101|inducers|group
DDI-MedLine.d65.s0|5-16|interactions|group
DDI-MedLine.d65.s1|0-11|Interactions|group
DDI-MedLine.d65.s1|32-37|agents|group
DDI-MedLine.d65.s1|86-91|causes|group
DDI-MedLine.d65.s1|152-161|conditions|group
DDI-MedLine.d65.s1|201-211|proportions|group
DDI-MedLine.d65.s2|54-65|interactions|group
DDI-MedLine.d65.s2|91-100|physciains|group
DDI-MedLine.d65.s3|0-3|This|group
DDI-MedLine.d65.s3|11-18|attempts|group
DDI-MedLine.d65.s3|33-37|basis|group
DDI-MedLine.d65.s3|65-79|identifications|group
DDI-MedLine.d65.s3|99-110|interactions|group
DDI-MedLine.d65.s4|0-9|Guidelines|group
DDI-MedLine.d65.s4|102-113|interactions|group
DDI-MedLine.d65.s4|120-126|serious|group
DDI-MedLine.d65.s5|107-112|levels|group
DDI-MedLine.d65.s5|127-131|drugs|group
DDI-DrugBank.d737.s0|62-77|pharmacokinetics|group
DDI-DrugBank.d737.s0|105-114|volunteers|group
DDI-DrugBank.d737.s1|2-6|hours|group
DDI-DrugBank.d737.s2|23-32|volunteers|group
DDI-DrugBank.d737.s2|76-91|pharmacokinetics|group
DDI-DrugBank.d737.s3|39-46|analysis|group
DDI-DrugBank.d737.s3|48-55|suggests|group
DDI-DrugBank.d737.s4|0-9|Cimetidine|drug
DDI-DrugBank.d737.s4|0-9|Cimetidine|drug
DDI-DrugBank.d737.s4|32-40|inhibitor|group
DDI-DrugBank.d737.s4|80-84|bases|group
DDI-DrugBank.d737.s5|32-40|inhibitor|group
DDI-DrugBank.d737.s5|80-84|acids|group
DDI-DrugBank.d737.s5|156-171|pharmacokinetics|group
DDI-DrugBank.d737.s6|6-10|drugs|group
DDI-DrugBank.d737.s6|71-78|analysis|group
DDI-DrugBank.d737.s6|80-87|suggests|group
DDI-DrugBank.d737.s6|6-10|drugs|group
DDI-DrugBank.d737.s6|178-187|cimetidine|drug
DDI-DrugBank.d737.s6|190-199|ranitidine|drug
DDI-DrugBank.d737.s6|237-245|quinidine|drug
DDI-DrugBank.d737.s6|261-269|decreases|group
DDI-DrugBank.d737.s6|379-392|cephalosporins|group
DDI-DrugBank.d737.s6|395-405|penicillins|group
DDI-DrugBank.d737.s7|4-15|interactions|group
DDI-DrugBank.d737.s7|18-27|Inhibitors|group
DDI-DrugBank.d737.s7|48-54|enzymes|group
DDI-DrugBank.d737.s7|48-54|enzymes|group
DDI-DrugBank.d737.s8|21-27|inhibit|group
DDI-DrugBank.d737.s8|33-39|enzymes|group
DDI-DrugBank.d737.s9|101-107|inhibit|group
DDI-DrugBank.d737.s9|113-119|enzymes|group
DDI-DrugBank.d737.s9|131-144|concentrations|group
DDI-DrugBank.d737.s10|0-7|Dopamine|drug
DDI-DrugBank.d737.s10|9-19|antagonists|group
DDI-DrugBank.d737.s10|45-52|dopamine|drug
DDI-DrugBank.d737.s10|45-52|dopamine|drug
DDI-DrugBank.d737.s10|9-19|antagonists|group
DDI-DrugBank.d737.s10|117-128|neuroleptics|group
DDI-DrugBank.d737.s10|131-144|phenothiazines|group
DDI-DrugBank.d737.s10|147-160|butyrophenones|group
DDI-DrugBank.d737.s10|163-175|thioxanthenes|group
DDI-DrugBank.d737.s10|214-226|effectiveness|group
DDI-DrugBank.d737.s10|231-237|MIRAPEX|brand
DDI-DrugBank.d737.s11|22-33|Interactions|group
DDI-DrugBank.d737.s11|54-65|interactions|group
DDI-DrugBank.d737.s11|75-81|MIRAPEX|brand
DDI-DrugBank.d737.s11|98-102|tests|group
DDI-DrugBank.d723.s0|10-14|drops|group
DDI-DrugBank.d723.s0|19-29|medications|group
DDI-DrugBank.d723.s0|63-69|Miochol|drug
DDI-DrugBank.d723.s0|76-84|carbachol|drug
DDI-DrugBank.d723.s0|105-113|Carbachol|drug
DDI-DrugBank.d723.s0|133-139|effects|group
DDI-MedLine.d179.s0|114-117|EGFR|brand
DDI-MedLine.d179.s1|0-7|Previous|group
DDI-MedLine.d179.s1|9-15|studies|group
DDI-MedLine.d179.s1|115-119|NSCLC|brand
DDI-MedLine.d179.s2|0-3|This|group
DDI-MedLine.d179.s2|158-162|NSCLC|brand
DDI-MedLine.d179.s2|169-173|lines|group
DDI-MedLine.d179.s2|197-200|EGFR|brand
DDI-MedLine.d179.s2|202-205|TKIs|group
DDI-MedLine.d179.s3|0-4|NSCLC|brand
DDI-MedLine.d179.s3|11-15|lines|group
DDI-MedLine.d179.s3|22-25|EGFR|brand
DDI-MedLine.d179.s3|124-130|various|group
DDI-MedLine.d179.s3|143-157|administrations|group
DDI-MedLine.d179.s4|122-132|alterations|group
DDI-MedLine.d179.s5|42-51|inhibition|group
DDI-MedLine.d179.s5|56-60|NSCLC|brand
DDI-MedLine.d179.s5|67-71|lines|group
DDI-MedLine.d179.s5|110-116|whereas|group
DDI-MedLine.d179.s6|89-95|effects|group
DDI-MedLine.d179.s6|113-127|administrations|group
DDI-MedLine.d179.s6|137-141|drugs|group
DDI-MedLine.d179.s7|5-9|cells|group
DDI-MedLine.d179.s8|14-18|basis|group
DDI-MedLine.d179.s8|60-67|pathways|group
DDI-MedLine.d179.s9|116-122|effects|group
DDI-MedLine.d179.s10|22-26|agent|group
DDI-MedLine.d179.s10|28-35|exhibits|group
DDI-MedLine.d179.s10|56-62|effects|group
DDI-MedLine.d179.s10|76-80|NSCLC|brand
DDI-MedLine.d179.s10|87-91|lines|group
DDI-MedLine.d179.s10|98-101|EGFR|brand
DDI-MedLine.d179.s10|119-127|mutations|group
DDI-DrugBank.d8.s0|43-49|nervous|group
DDI-DrugBank.d8.s0|77-83|effects|group
DDI-DrugBank.d8.s0|106-112|ALFENTA|brand
DDI-DrugBank.d8.s0|160-170|depressants|group
DDI-DrugBank.d8.s0|180-191|barbiturates|group
DDI-DrugBank.d8.s0|194-206|tranquilizers|group
DDI-DrugBank.d8.s0|209-215|opioids|group
DDI-DrugBank.d8.s0|240-250|anesthetics|group
DDI-DrugBank.d8.s1|75-80|agents|group
DDI-DrugBank.d8.s2|8-12|cases|group
DDI-DrugBank.d8.s2|61-66|agents|group
DDI-DrugBank.d8.s3|28-36|indicates|group
DDI-DrugBank.d8.s3|43-54|requirements|group
DDI-DrugBank.d8.s3|80-90|anesthetics|group
DDI-DrugBank.d8.s3|142-148|minutes|group
DDI-DrugBank.d8.s3|160-166|ALFENTA|brand
DDI-DrugBank.d8.s3|201-212|erythromycin|drug
DDI-DrugBank.d8.s3|160-166|ALFENTA|brand
DDI-DrugBank.d8.s3|245-251|inhibit|group
DDI-DrugBank.d8.s3|160-166|ALFENTA|brand
DDI-DrugBank.d8.s4|0-9|Cimetidine|drug
DDI-DrugBank.d8.s4|11-17|reduces|group
DDI-DrugBank.d8.s4|36-42|ALFENTA|brand
DDI-DrugBank.d8.s5|18-24|ALFENTA|brand
DDI-DrugBank.d8.s5|26-30|doses|group
DDI-DrugBank.d8.s5|18-24|ALFENTA|brand
DDI-DrugBank.d8.s6|32-36|drugs|group
DDI-DrugBank.d746.s0|0-6|ARAMINE|brand
DDI-DrugBank.d746.s0|51-58|patients|group
DDI-DrugBank.d746.s0|86-94|digitalis|group
DDI-DrugBank.d746.s0|116-121|amines|group
DDI-DrugBank.d746.s0|141-151|arrhythmias|group
DDI-DrugBank.d746.s1|0-8|Monoamine|drug
DDI-DrugBank.d746.s1|18-27|inhibitors|group
DDI-DrugBank.d746.s1|42-56|antidepressants|group
DDI-DrugBank.d746.s1|103-108|amines|group
DDI-DrugBank.d746.s2|46-53|patients|group
DDI-DrugBank.d746.s2|71-75|drugs|group
DDI-DrugBank.d73.s0|24-28|drugs|group
DDI-DrugBank.d73.s0|35-43|reserpine|drug
DDI-DrugBank.d73.s0|104-109|agents|group
DDI-DrugBank.d73.s1|0-7|Patients|group
DDI-DrugBank.d73.s1|22-29|TENORMIN|brand
DDI-DrugBank.d73.s1|31-34|plus|group
DDI-DrugBank.d73.s1|38-50|catecholamine|drug
DDI-DrugBank.d73.s2|16-23|blockers|group
DDI-DrugBank.d73.s2|74-81|TENORMIN|brand
DDI-DrugBank.d73.s3|5-12|blockers|group
DDI-DrugBank.d73.s3|89-97|clonidine|drug
DDI-DrugBank.d73.s4|11-15|drugs|group
DDI-DrugBank.d73.s4|46-52|blocker|group
DDI-DrugBank.d73.s4|82-85|days|group
DDI-DrugBank.d73.s4|120-128|clonidine|drug
DDI-DrugBank.d73.s5|13-21|clonidine|drug
DDI-DrugBank.d73.s5|73-80|blockers|group
DDI-DrugBank.d73.s5|112-115|days|group
DDI-DrugBank.d73.s5|13-21|clonidine|drug
DDI-DrugBank.d73.s6|42-51|inhibiting|group
DDI-DrugBank.d73.s6|53-57|drugs|group
DDI-DrugBank.d73.s6|107-113|effects|group
DDI-DrugBank.d73.s6|123-130|blockers|group
DDI-DrugBank.d73.s7|35-42|atenolol|drug
DDI-DrugBank.d73.s8|18-24|studies|group
DDI-DrugBank.d73.s8|123-130|blockers|group
DDI-DrugBank.d73.s9|18-25|blockers|group
DDI-DrugBank.d73.s9|28-35|patients|group
DDI-DrugBank.d73.s9|93-101|allergens|group
DDI-DrugBank.d73.s10|5-12|patients|group
DDI-DrugBank.d73.s10|47-51|doses|group
DDI-DrugBank.d73.s10|56-66|epinephrine|drug
DDI-DrugBank.d101.s0|20-28|digitoxin|drug
DDI-DrugBank.d101.s0|30-43|concentrations|group
DDI-DrugBank.d101.s1|32-38|digoxin|drug
DDI-DrugBank.d101.s1|40-45|levels|group
DDI-DrugBank.d101.s1|67-74|patients|group
DDI-DrugBank.d101.s1|119-126|regimens|group
DDI-DrugBank.d101.s2|19-27|digitoxin|drug
DDI-DrugBank.d101.s2|38-45|patients|group
DDI-DrugBank.d241.s0|11-20|reductions|group
DDI-DrugBank.d241.s0|55-60|FLOLAN|brand
DDI-DrugBank.d241.s0|83-91|diuretics|group
DDI-DrugBank.d241.s0|111-116|agents|group
DDI-DrugBank.d241.s0|128-139|vasodilators|group
DDI-DrugBank.d241.s1|24-29|agents|group
DDI-DrugBank.d241.s1|34-47|anticoagulants|group
DDI-DrugBank.d241.s1|100-105|FLOLAN|brand
DDI-DrugBank.d241.s2|9-16|patients|group
DDI-DrugBank.d241.s2|28-36|infusions|group
DDI-DrugBank.d241.s2|41-46|FLOLAN|brand
DDI-DrugBank.d241.s2|60-65|trials|group
DDI-DrugBank.d241.s2|86-99|anticoagulants|group
DDI-DrugBank.d241.s3|12-17|trials|group
DDI-DrugBank.d241.s3|20-25|FLOLAN|brand
DDI-DrugBank.d241.s3|41-47|digoxin|drug
DDI-DrugBank.d241.s3|50-58|diuretics|group
DDI-DrugBank.d241.s3|61-74|anticoagulants|group
DDI-DrugBank.d241.s3|82-93|vasodilators|group
DDI-DrugBank.d241.s3|153-160|patients|group
DDI-DrugBank.d241.s3|202-211|furosemide|drug
DDI-DrugBank.d241.s3|41-47|digoxin|drug
DDI-DrugBank.d241.s3|20-25|FLOLAN|brand
DDI-DrugBank.d241.s3|291-296|values|group
DDI-DrugBank.d241.s3|202-211|furosemide|drug
DDI-DrugBank.d241.s3|41-47|digoxin|drug
DDI-DrugBank.d241.s3|291-296|values|group
DDI-DrugBank.d241.s4|14-23|furosemide|drug
DDI-DrugBank.d241.s5|9-16|patients|group
DDI-DrugBank.d241.s5|21-27|digoxin|drug
DDI-DrugBank.d241.s5|38-47|elevations|group
DDI-DrugBank.d241.s5|21-27|digoxin|drug
DDI-DrugBank.d241.s5|60-73|concentrations|group
DDI-DrugBank.d241.s5|108-113|FLOLAN|brand
DDI-DrugBank.d241.s5|9-16|patients|group
DDI-DrugBank.d241.s5|21-27|digoxin|drug
DDI-DrugBank.d95.s0|0-11|Cyclosporine|drug
DDI-DrugBank.d95.s2|8-15|nitrates|group
DDI-DrugBank.d95.s2|30-40|supplements|group
DDI-DrugBank.d95.s2|75-81|effects|group
DDI-DrugBank.d95.s2|8-15|nitrates|group
DDI-DrugBank.d95.s3|47-57|supplements|group
DDI-DrugBank.d95.s3|123-129|effects|group
DDI-DrugBank.d186.s0|46-53|weakness|group
DDI-DrugBank.d186.s0|73-85|tremulousness|group
DDI-DrugBank.d186.s0|117-124|symptoms|group
DDI-DrugBank.d186.s0|127-138|leukocytosis|group
DDI-DrugBank.d186.s0|156-162|enzymes|group
DDI-DrugBank.d186.s0|239-246|patients|group
DDI-DrugBank.d186.s0|269-272|plus|group
DDI-DrugBank.d186.s0|274-279|HALDOL|brand
DDI-DrugBank.d186.s1|36-41|events|group
DDI-DrugBank.d186.s1|93-98|HALDOL|brand
DDI-DrugBank.d186.s2|9-16|patients|group
DDI-DrugBank.d186.s2|166-170|signs|group
DDI-DrugBank.d186.s3|0-1|As|group
DDI-DrugBank.d186.s3|28-33|agents|group
DDI-DrugBank.d186.s3|60-65|HALDOL|brand
DDI-DrugBank.d186.s3|102-112|depressants|group
DDI-DrugBank.d186.s3|122-132|anesthetics|group
DDI-DrugBank.d186.s3|135-141|opiates|group
DDI-DrugBank.d186.s3|148-154|alcohol|drug
DDI-DrugBank.d186.s4|31-38|patients|group
DDI-DrugBank.d186.s4|105-110|levels|group
DDI-DrugBank.d186.s4|153-158|scores|group
DDI-DrugBank.d186.s5|25-32|patients|group
DDI-DrugBank.d186.s5|155-168|concentrations|group
DDI-DrugBank.d186.s6|0-3|Thus|group
DDI-DrugBank.d186.s6|37-42|status|group
DDI-DrugBank.d186.s6|126-133|patients|group
DDI-DrugBank.d367.s1|99-105|digoxin|drug
DDI-DrugBank.d367.s1|108-115|warfarin|drug
DDI-DrugBank.d367.s1|118-126|phenytoin|drug
DDI-DrugBank.d367.s2|75-79|drugs|group
DDI-DrugBank.d367.s3|96-103|patients|group
DDI-DrugBank.d367.s3|124-132|diuretics|group
DDI-DrugBank.d367.s3|149-154|agents|group
DDI-DrugBank.d367.s3|161-172|nonsteroidal|group
DDI-DrugBank.d367.s3|192-196|drugs|group
DDI-DrugBank.d367.s4|40-49|volunteers|group
DDI-DrugBank.d367.s4|145-154|cimetidine|drug
DDI-DrugBank.d367.s6|12-17|trials|group
DDI-DrugBank.d367.s6|39-45|tablets|group
DDI-DrugBank.d367.s6|73-80|patients|group
DDI-DrugBank.d367.s6|110-120|medications|group
DDI-DrugBank.d367.s7|28-34|studies|group
DDI-DrugBank.d367.s7|60-71|interactions|group
DDI-DrugBank.d367.s8|19-25|tablets|group
DDI-DrugBank.d367.s8|61-65|drugs|group
DDI-DrugBank.d367.s8|75-81|classes|group
DDI-DrugBank.d367.s9|79-90|combinations|group
DDI-DrugBank.d367.s11|0-10|Antibiotics|group
DDI-DrugBank.d367.s11|19-30|erythromycin|drug
DDI-DrugBank.d367.s11|50-65|sulfamethoxazole|drug
DDI-DrugBank.d367.s13|0-13|Antihistamines|group
DDI-DrugBank.d367.s13|22-37|chlorpheniramine|drug
DDI-DrugBank.d367.s15|15-20|agents|group
DDI-DrugBank.d367.s15|29-36|atenolol|drug
DDI-DrugBank.d367.s15|60-70|propranolol|drug
DDI-DrugBank.d367.s17|0-14|Corticosteroids|group
DDI-DrugBank.d367.s19|17-22|agents|group
DDI-DrugBank.d367.s19|31-38|antacids|group
DDI-DrugBank.d367.s21|0-12|Hypoglycemics|group
DDI-DrugBank.d367.s21|28-32|drugs|group
DDI-DrugBank.d367.s23|0-8|Sedatives|group
DDI-DrugBank.d367.s23|14-26|tranquilizers|group
DDI-DrugBank.d367.s23|35-42|diazepam|drug
DDI-DrugBank.d367.s25|13-20|remedies|group
DDI-DrugBank.d433.s0|27-33|studies|group
DDI-DrugBank.d433.s1|80-87|patients|group
DDI-DrugBank.d433.s1|157-162|agents|group
DDI-DrugBank.d433.s2|106-113|products|group
DDI-DrugBank.d433.s2|159-164|agents|group
DDI-DrugBank.d433.s2|194-201|patients|group
DDI-DrugBank.d253.s0|16-23|blocking|group
DDI-DrugBank.d253.s0|25-30|agents|group
DDI-DrugBank.d253.s0|74-83|arbutamine|drug
DDI-DrugBank.d253.s1|16-23|blocking|group
DDI-DrugBank.d253.s1|25-30|agents|group
DDI-DrugBank.d253.s1|64-68|hours|group
DDI-DrugBank.d253.s1|111-116|stress|group
DDI-DrugBank.d253.s2|15-20|agents|group
DDI-DrugBank.d253.s2|23-27|class|group
DDI-DrugBank.d253.s2|66-74|quinidine|drug
DDI-DrugBank.d253.s2|98-107|arbutamine|drug
DDI-DrugBank.d253.s3|0-14|Antidepressants|group
DDI-DrugBank.d253.s3|29-36|atropine|drug
DDI-DrugBank.d253.s3|63-68|agents|group
DDI-DrugBank.d253.s3|74-82|digitalis|group
DDI-DrugBank.d253.s3|84-93|glycosides|group
DDI-DrugBank.d253.s3|116-125|arbutamine|drug
DDI-DrugBank.d253.s3|178-184|effects|group
DDI-DrugBank.d439.s0|45-48|loss|group
DDI-MedLine.d185.s0|39-48|inhibition|group
DDI-MedLine.d185.s0|62-77|pharmacokinetics|group
DDI-MedLine.d185.s0|142-150|inhibitor|group
DDI-MedLine.d185.s2|0-3|This|group
DDI-MedLine.d185.s2|50-58|inhibitor|group
DDI-MedLine.d185.s2|61-72|ketoconazole|drug
DDI-MedLine.d185.s2|82-97|pharmacokinetics|group
DDI-MedLine.d185.s3|0-7|Patients|group
DDI-MedLine.d185.s3|75-78|days|group
DDI-MedLine.d185.s4|3-6|days|group
DDI-MedLine.d185.s4|13-24|ketoconazole|drug
DDI-MedLine.d185.s5|62-73|ketoconazole|drug
DDI-MedLine.d185.s6|40-44|agent|group
DDI-MedLine.d185.s6|52-56|times|group
DDI-MedLine.d185.s7|19-30|ketoconazole|drug
DDI-MedLine.d185.s9|55-62|patients|group
DDI-MedLine.d185.s9|101-107|alleles|group
DDI-MedLine.d185.s10|33-38|events|group
DDI-MedLine.d185.s11|0-7|Patients|group
DDI-MedLine.d185.s11|60-67|analysis|group
DDI-MedLine.d185.s12|45-54|inhibitors|group
DDI-MedLine.d185.s12|112-121|parameters|group
DDI-MedLine.d185.s13|57-66|inhibition|group
DDI-MedLine.d185.s13|144-153|inhibitors|group
DDI-MedLine.d185.s13|205-210|events|group
DDI-DrugBank.d418.s0|27-33|studies|group
DDI-DrugBank.d465.s0|17-23|effects|group
DDI-DrugBank.d465.s0|85-96|vasodilators|group
DDI-DrugBank.d465.s1|0-6|Alcohol|drug
DDI-DrugBank.d465.s1|59-65|effects|group
DDI-DrugBank.d632.s0|11-17|effects|group
DDI-DrugBank.d632.s0|40-45|SYMLIN|brand
DDI-DrugBank.d632.s0|84-91|patients|group
DDI-DrugBank.d632.s0|100-104|drugs|group
DDI-DrugBank.d632.s0|166-171|agents|group
DDI-DrugBank.d632.s0|181-188|atropine|drug
DDI-DrugBank.d632.s0|166-171|agents|group
DDI-DrugBank.d632.s0|241-249|nutrients|group
DDI-DrugBank.d632.s0|276-285|inhibitors|group
DDI-DrugBank.d632.s1|0-7|Patients|group
DDI-DrugBank.d632.s1|21-25|drugs|group
DDI-DrugBank.d632.s1|61-66|trials|group
DDI-DrugBank.d632.s2|0-5|SYMLIN|brand
DDI-DrugBank.d632.s2|84-94|medications|group
DDI-DrugBank.d632.s3|58-62|agent|group
DDI-DrugBank.d632.s3|93-105|effectiveness|group
DDI-DrugBank.d632.s3|116-125|analgesics|group
DDI-DrugBank.d632.s3|58-62|agent|group
DDI-DrugBank.d632.s3|192-196|hours|group
DDI-DrugBank.d632.s3|204-209|SYMLIN|brand
DDI-DrugBank.d632.s4|12-17|trials|group
DDI-DrugBank.d632.s4|43-55|sulfonylureas|group
DDI-DrugBank.d632.s4|60-69|biguanides|group
DDI-DrugBank.d632.s4|114-119|SYMLIN|brand
DDI-DrugBank.d632.s5|22-28|studies|group
DDI-DrugBank.d632.s5|53-58|assess|group
DDI-DrugBank.d632.s5|74-79|SYMLIN|brand
DDI-DrugBank.d632.s5|88-95|kinetics|group
DDI-DrugBank.d632.s5|118-123|agents|group
DDI-DrugBank.d632.s6|7-12|SYMLIN|brand
DDI-DrugBank.d632.s6|46-55|parameters|group
DDI-DrugBank.d632.s6|7-12|SYMLIN|brand
DDI-DrugBank.d632.s6|129-140|formulations|group
DDI-DrugBank.d632.s7|0-3|Thus|group
DDI-DrugBank.d632.s7|6-11|SYMLIN|brand
DDI-MedLine.d193.s1|161-166|events|group
DDI-MedLine.d193.s1|171-178|patients|group
DDI-MedLine.d193.s3|86-91|months|group
DDI-DrugBank.d464.s0|43-52|analgesics|group
DDI-DrugBank.d464.s0|63-73|anesthetics|group
DDI-DrugBank.d464.s0|76-89|phenothiazines|group
DDI-DrugBank.d464.s0|92-104|tranquilizers|group
DDI-DrugBank.d464.s0|140-150|depressants|group
DDI-DrugBank.d464.s0|163-169|alcohol|drug
DDI-DrugBank.d464.s0|196-202|effects|group
DDI-DrugBank.d464.s2|63-68|agents|group
DDI-DrugBank.d223.s0|0-4|Drugs|group
DDI-DrugBank.d223.s0|202-211|Caucasians|group
DDI-DrugBank.d223.s0|232-243|metabolizers|group
DDI-DrugBank.d223.s1|9-17|estimates|group
DDI-DrugBank.d223.s1|105-115|populations|group
DDI-DrugBank.d223.s2|5-16|metabolizers|group
DDI-DrugBank.d223.s2|51-64|concentrations|group
DDI-DrugBank.d223.s2|79-93|antidepressants|group
DDI-DrugBank.d223.s2|96-99|TCAs|group
DDI-DrugBank.d223.s2|119-123|doses|group
DDI-DrugBank.d223.s4|21-25|drugs|group
DDI-DrugBank.d223.s4|27-33|inhibit|group
DDI-DrugBank.d223.s4|80-91|metabolizers|group
DDI-DrugBank.d223.s4|80-91|metabolizers|group
DDI-DrugBank.d223.s5|101-110|inhibiting|group
DDI-DrugBank.d223.s5|112-116|drugs|group
DDI-DrugBank.d223.s6|4-8|drugs|group
DDI-DrugBank.d223.s6|15-21|inhibit|group
DDI-DrugBank.d223.s6|96-104|quinidine|drug
DDI-DrugBank.d223.s7|0-9|cimetidine|drug
DDI-DrugBank.d223.s7|30-39|substrates|group
DDI-DrugBank.d223.s7|66-80|antidepressants|group
DDI-DrugBank.d223.s7|83-96|phenothiazines|group
DDI-DrugBank.d223.s7|115-129|antiarrhythmics|group
DDI-DrugBank.d223.s8|43-52|inhibitors|group
DDI-DrugBank.d223.s8|55-59|SSRIs|group
DDI-DrugBank.d223.s8|69-78|citalopram|drug
DDI-DrugBank.d223.s8|81-92|escitalopram|drug
DDI-DrugBank.d223.s8|95-104|fluoxetine|drug
DDI-DrugBank.d223.s8|123-132|paroxetine|drug
DDI-DrugBank.d223.s8|43-49|inhibit|group
DDI-DrugBank.d223.s8|184-193|inhibition|group
DDI-DrugBank.d223.s9|29-40|interactions|group
DDI-DrugBank.d223.s9|60-67|problems|group
DDI-DrugBank.d223.s9|98-107|inhibition|group
DDI-DrugBank.d223.s9|117-132|pharmacokinetics|group
DDI-DrugBank.d223.s9|20-23|SSRI|brand
DDI-DrugBank.d223.s10|0-11|Nevertheless|group
DDI-DrugBank.d223.s10|63-66|TCAs|group
DDI-DrugBank.d223.s10|84-88|SSRIs|group
DDI-DrugBank.d223.s10|121-125|class|group
DDI-DrugBank.d223.s11|120-129|fluoxetine|drug
DDI-DrugBank.d223.s11|205-209|weeks|group
DDI-DrugBank.d223.s12|29-43|antidepressants|group
DDI-DrugBank.d223.s12|50-54|drugs|group
DDI-DrugBank.d223.s12|65-71|inhibit|group
DDI-DrugBank.d223.s12|111-115|doses|group
DDI-DrugBank.d223.s13|41-45|drugs|group
DDI-DrugBank.d223.s14|38-43|levels|group
DDI-DrugBank.d223.s14|124-132|inhibitor|group
DDI-DrugBank.d223.s15|78-85|pathways|group
DDI-DrugBank.d223.s16|0-9|Inhibitors|group
DDI-DrugBank.d223.s16|14-23|substrates|group
DDI-DrugBank.d223.s16|42-50|quinidine|drug
DDI-DrugBank.d223.s16|82-91|inhibitors|group
DDI-DrugBank.d223.s16|94-98|SSRIs|group
DDI-DrugBank.d223.s17|26-32|depends|group
DDI-DrugBank.d223.s19|4-13|Inhibitors|group
DDI-DrugBank.d223.s19|16-22|Serious|group
DDI-DrugBank.d223.s19|29-35|effects|group
DDI-DrugBank.d223.s19|112-116|drugs|group
DDI-DrugBank.d223.s19|127-136|inhibitors|group
DDI-DrugBank.d223.s20|15-24|inhibitors|group
DDI-DrugBank.d223.s20|62-66|weeks|group
DDI-DrugBank.d223.s20|81-88|cautious|group
DDI-DrugBank.d223.s20|117-124|SINEQUAN|brand
DDI-DrugBank.d223.s21|75-83|inhibitor|group
DDI-DrugBank.d223.s22|0-9|Cimetidine|drug
DDI-DrugBank.d223.s22|0-9|Cimetidine|drug
DDI-DrugBank.d223.s22|75-86|fluctuations|group
DDI-DrugBank.d223.s22|110-123|concentrations|group
DDI-DrugBank.d223.s22|128-134|various|group
DDI-DrugBank.d223.s22|146-160|antidepressants|group
DDI-DrugBank.d223.s23|0-6|Serious|group
DDI-DrugBank.d223.s23|24-31|symptoms|group
DDI-DrugBank.d223.s23|122-131|elevations|group
DDI-DrugBank.d223.s23|146-151|levels|group
DDI-DrugBank.d223.s23|186-195|cimetidine|drug
DDI-DrugBank.d223.s24|60-65|levels|group
DDI-DrugBank.d223.s24|109-116|patients|group
DDI-DrugBank.d223.s24|133-142|cimetidine|drug
DDI-DrugBank.d223.s25|3-10|patients|group
DDI-DrugBank.d223.s25|70-84|antidepressants|group
DDI-DrugBank.d223.s25|107-116|cimetidine|drug
DDI-DrugBank.d223.s25|107-116|cimetidine|drug
DDI-DrugBank.d223.s25|243-248|levels|group
DDI-DrugBank.d223.s25|283-289|effects|group
DDI-DrugBank.d223.s26|0-6|Alcohol|drug
DDI-DrugBank.d223.s26|41-47|alcohol|drug
DDI-DrugBank.d223.s26|128-135|SINEQUAN|brand
DDI-DrugBank.d223.s27|0-3|This|group
DDI-DrugBank.d223.s27|32-39|patients|group
DDI-DrugBank.d223.s27|53-59|alcohol|drug
DDI-DrugBank.d223.s28|129-132|days|group
DDI-DrugBank.d525.s0|51-66|pharmacokinetics|group
DDI-DrugBank.d525.s0|71-77|digoxin|drug
DDI-DrugBank.d525.s0|87-102|pharmacodynamics|group
DDI-DrugBank.d525.s0|107-114|warfarin|drug
DDI-DrugBank.d525.s1|0-3|Thus|group
DDI-DrugBank.d525.s1|15-25|adjustments|group
DDI-DrugBank.d525.s1|75-80|agents|group
DDI-DrugBank.d525.s2|69-78|inhibitors|group
DDI-DrugBank.d525.s2|149-160|ketoconazole|drug
DDI-DrugBank.d525.s2|166-176|fluconazole|drug
DDI-DrugBank.d525.s2|69-78|inhibitors|group
DDI-DrugBank.d525.s2|277-292|pharmacokinetics|group
DDI-DrugBank.d525.s3|0-9|Ranitidine|drug
DDI-DrugBank.d525.s3|44-59|pharmacokinetics|group
DDI-DrugBank.d525.s4|48-52|doses|group
DDI-DrugBank.d525.s5|11-15|doses|group
DDI-DrugBank.d525.s5|115-122|blockers|group
DDI-DrugBank.d525.s5|143-152|nifedipine|drug
DDI-DrugBank.d525.s5|194-205|interactions|group
DDI-DrugBank.d197.s0|17-23|studies|group
DDI-DrugBank.d197.s0|40-49|microsomes|group
DDI-DrugBank.d197.s0|109-120|interactions|group
DDI-DrugBank.d197.s1|62-69|PRECEDEX|brand
DDI-DrugBank.d197.s1|76-86|anesthetics|group
DDI-DrugBank.d197.s1|89-97|sedatives|group
DDI-DrugBank.d197.s1|100-108|hypnotics|group
DDI-DrugBank.d197.s1|115-121|opioids|group
DDI-DrugBank.d197.s1|162-168|effects|group
DDI-DrugBank.d197.s2|9-15|studies|group
DDI-DrugBank.d197.s2|38-44|effects|group
DDI-DrugBank.d197.s2|102-110|midazolam|drug
DDI-DrugBank.d197.s3|19-30|interactions|group
DDI-DrugBank.d197.s3|40-54|dexmedetomidine|drug
DDI-DrugBank.d197.s3|98-106|midazolam|drug
DDI-DrugBank.d197.s4|41-52|interactions|group
DDI-DrugBank.d197.s4|81-88|PRECEDEX|brand
DDI-DrugBank.d197.s4|81-88|PRECEDEX|brand
DDI-DrugBank.d197.s5|14-21|Blockers|group
DDI-DrugBank.d197.s5|51-60|volunteers|group
DDI-DrugBank.d197.s5|81-88|PRECEDEX|brand
DDI-DrugBank.d197.s5|97-103|minutes|group
DDI-DrugBank.d197.s5|185-193|increases|group
DDI-DrugBank.d197.s5|229-236|blockade|group
DDI-DrugBank.d81.s0|26-35|isradipine|drug
DDI-DrugBank.d81.s1|47-56|volunteers|group
DDI-DrugBank.d81.s1|114-123|isradipine|drug
DDI-DrugBank.d81.s1|177-192|pharmacoktnetics|group
DDI-DrugBank.d81.s2|27-34|patients|group
DDI-DrugBank.d81.s2|49-58|isradipine|drug
DDI-DrugBank.d81.s2|141-147|effects|group
DDI-DrugBank.d81.s2|49-58|isradipine|drug
DDI-DrugBank.d81.s3|0-10|Propranolol|drug
DDI-DrugBank.d81.s3|46-55|volunteers|group
DDI-DrugBank.d81.s3|78-88|propranolol|drug
DDI-DrugBank.d81.s3|152-161|isradipine|drug
DDI-DrugBank.d81.s4|12-20|increases|group
DDI-DrugBank.d81.s4|54-62|decreases|group
DDI-DrugBank.d81.s4|81-91|propranolol|drug
DDI-DrugBank.d81.s5|51-60|isradipine|drug
DDI-DrugBank.d81.s6|0-10|propranolol|drug
DDI-DrugBank.d81.s6|23-32|volunteers|group
DDI-DrugBank.d81.s6|53-62|conditions|group
DDI-DrugBank.d81.s6|135-145|differences|group
DDI-DrugBank.d81.s6|165-174|isradipine|drug
DDI-DrugBank.d81.s6|0-10|propranolol|drug
DDI-DrugBank.d81.s6|0-10|propranolol|drug
DDI-DrugBank.d81.s6|165-174|isradipine|drug
DDI-DrugBank.d81.s7|0-9|Cimetidine|drug
DDI-DrugBank.d81.s7|34-43|volunteers|group
DDI-DrugBank.d81.s7|67-76|cimetidine|drug
DDI-DrugBank.d81.s7|122-131|isradipine|drug
DDI-DrugBank.d81.s7|122-131|isradipine|drug
DDI-DrugBank.d81.s7|200-213|concentrations|group
DDI-DrugBank.d81.s8|3-12|isradipine|drug
DDI-DrugBank.d81.s8|68-77|cimetidine|drug
DDI-DrugBank.d81.s8|110-118|reactions|group
DDI-DrugBank.d81.s9|34-43|volunteers|group
DDI-DrugBank.d81.s9|125-134|isradipine|drug
DDI-DrugBank.d81.s9|125-134|isradipine|drug
DDI-DrugBank.d81.s9|174-179|levels|group
DDI-DrugBank.d81.s9|201-206|limits|group
DDI-DrugBank.d81.s10|35-44|isradipine|drug
DDI-DrugBank.d81.s10|46-59|concentrations|group
DDI-DrugBank.d81.s10|77-83|effects|group
DDI-DrugBank.d81.s10|35-44|isradipine|drug
DDI-DrugBank.d81.s11|0-7|Warfarin|drug
DDI-DrugBank.d81.s11|32-41|volunteers|group
DDI-DrugBank.d81.s11|122-131|isradipine|drug
DDI-DrugBank.d81.s11|145-152|warfarin|drug
DDI-DrugBank.d81.s11|184-188|doses|group
DDI-DrugBank.d81.s11|145-152|warfarin|drug
DDI-DrugBank.d81.s11|254-257|days|group
DDI-DrugBank.d81.s11|122-131|isradipine|drug
DDI-DrugBank.d81.s12|16-23|warfarin|drug
DDI-DrugBank.d81.s12|29-38|isradipine|drug
DDI-DrugBank.d81.s12|58-65|proteins|group
DDI-DrugBank.d81.s13|0-6|Digoxin|drug
DDI-DrugBank.d81.s13|54-63|isradipine|drug
DDI-DrugBank.d81.s13|70-76|digoxin|drug
DDI-DrugBank.d81.s13|70-76|digoxin|drug
DDI-DrugBank.d81.s14|116-122|blocker|group
DDI-DrugBank.d81.s14|116-122|blocker|group
DDI-DrugBank.d81.s15|17-28|interactions|group
DDI-DrugBank.d81.s15|61-67|studies|group
DDI-DrugBank.d81.s15|85-94|isradipine|drug
DDI-DrugBank.d81.s15|133-138|fluids|group
DDI-DrugBank.d531.s1|6-14|compounds|group
DDI-DrugBank.d531.s1|25-34|substrates|group
DDI-DrugBank.d531.s1|72-85|concentrations|group
DDI-DrugBank.d531.s1|112-118|SUSTIVA|brand
DDI-DrugBank.d531.s2|9-15|studies|group
DDI-DrugBank.d531.s2|50-57|inhibits|group
DDI-DrugBank.d531.s2|78-85|isozymes|group
DDI-DrugBank.d531.s2|129-142|concentrations|group
DDI-DrugBank.d531.s3|35-39|drugs|group
DDI-DrugBank.d531.s3|72-79|isozymes|group
DDI-DrugBank.d531.s3|110-123|concentrations|group
DDI-DrugBank.d531.s4|28-38|adjustments|group
DDI-DrugBank.d531.s4|67-71|drugs|group
DDI-DrugBank.d531.s5|0-4|Drugs|group
DDI-DrugBank.d531.s5|161-174|concentrations|group
DDI-DrugBank.d531.s6|5-16|interactions|group
DDI-DrugBank.d531.s6|23-29|SUSTIVA|brand
DDI-DrugBank.d531.s7|10-14|Drugs|group
DDI-DrugBank.d531.s7|55-61|SUSTIVA|brand
DDI-DrugBank.d531.s8|5-9|Class|group
DDI-DrugBank.d531.s9|0-4|Drugs|group
DDI-DrugBank.d531.s9|13-17|Class|group
DDI-DrugBank.d531.s9|49-55|SUSTIVA|brand
DDI-DrugBank.d531.s10|0-13|Antihistamines|group
DDI-DrugBank.d531.s10|16-30|Benzodiazepines|group
DDI-DrugBank.d531.s10|44-49|Agents|group
DDI-DrugBank.d531.s11|11-19|midazolam|drug
DDI-DrugBank.d531.s11|22-30|triazolam|drug
DDI-DrugBank.d531.s11|48-58|derivatives|group
DDI-DrugBank.d531.s11|60-71|voriconazole|drug
DDI-DrugBank.d531.s12|17-28|Interactions|group
DDI-DrugBank.d531.s19|25-31|SUSTIVA|brand
DDI-DrugBank.d531.s19|52-59|patients|group
DDI-DrugBank.d531.s19|25-31|SUSTIVA|brand
DDI-DrugBank.d531.s20|7-21|recommendations|group
DDI-DrugBank.d531.s20|27-33|SUSTIVA|brand
DDI-DrugBank.d531.s20|75-82|patients|group
DDI-DrugBank.d531.s21|17-28|Interactions|group
DDI-DrugBank.d531.s25|0-13|Clarithromycin|drug
DDI-DrugBank.d531.s26|0-13|clarithromycin|drug
DDI-DrugBank.d531.s27|7-20|concentrations|group
DDI-DrugBank.d531.s27|35-41|SUSTIVA|brand
DDI-DrugBank.d531.s29|14-23|volunteers|group
DDI-DrugBank.d531.s29|61-67|SUSTIVA|brand
DDI-DrugBank.d531.s29|73-86|clarithromycin|drug
DDI-DrugBank.d531.s30|22-28|SUSTIVA|brand
DDI-DrugBank.d531.s30|61-74|clarithromycin|drug
DDI-DrugBank.d531.s31|0-11|Alternatives|group
DDI-DrugBank.d531.s31|16-29|clarithromycin|drug
DDI-DrugBank.d531.s31|40-51|azithromycin|drug
DDI-DrugBank.d531.s32|16-26|antibiotics|group
DDI-DrugBank.d531.s32|37-48|erythromycin|drug
DDI-DrugBank.d531.s32|93-99|SUSTIVA|brand
DDI-DrugBank.d531.s37|62-68|SUSTIVA|brand
DDI-DrugBank.d531.s38|49-53|hours|group
DDI-DrugBank.d531.s38|121-127|SUSTIVA|brand
DDI-DrugBank.d531.s39|53-57|hours|group
DDI-DrugBank.d531.s39|75-81|SUSTIVA|brand
DDI-DrugBank.d531.s39|53-57|hours|group
DDI-DrugBank.d531.s42|56-63|capsules|group
DDI-DrugBank.d531.s42|149-155|SUSTIVA|brand
DDI-DrugBank.d531.s45|33-43|individuals|group
DDI-DrugBank.d531.s45|111-116|levels|group
DDI-DrugBank.d531.s45|135-139|signs|group
DDI-DrugBank.d531.s46|70-77|symptoms|group
DDI-DrugBank.d531.s47|0-7|Patients|group
DDI-DrugBank.d531.s47|33-37|signs|group
DDI-DrugBank.d531.s47|124-131|symptoms|group
DDI-DrugBank.d531.s50|7-20|concentrations|group
DDI-DrugBank.d531.s50|35-41|SUSTIVA|brand
DDI-DrugBank.d531.s52|57-70|contraceptives|group
DDI-DrugBank.d531.s52|57-70|contraceptives|group
DDI-DrugBank.d531.s56|40-47|regimens|group
DDI-DrugBank.d531.s56|81-85|times|group
DDI-DrugBank.d531.s59|43-56|concentrations|group
DDI-DrugBank.d531.s62|71-81|experiences|group
DDI-DrugBank.d531.s62|88-96|dizziness|group
DDI-DrugBank.d531.s62|135-147|abnormalities|group
DDI-DrugBank.d531.s62|165-171|enzymes|group
DDI-DrugBank.d531.s63|20-26|enzymes|group
DDI-DrugBank.d531.s63|48-54|SUSTIVA|brand
DDI-DrugBank.d531.s67|36-44|inhibitor|group
DDI-DrugBank.d531.s67|66-72|SUSTIVA|brand
DDI-DrugBank.d531.s70|0-8|Increases|group
DDI-DrugBank.d531.s71|64-75|Interactions|group
DDI-DrugBank.d531.s72|0-13|Anticoagulants|group
DDI-DrugBank.d531.s72|16-23|Warfarin|drug
DDI-DrugBank.d531.s73|7-20|concentrations|group
DDI-DrugBank.d531.s73|26-32|effects|group
DDI-DrugBank.d531.s73|72-78|SUSTIVA|brand
DDI-DrugBank.d531.s74|0-14|Anticonvulsants|group
DDI-DrugBank.d531.s74|17-25|Phenytoin|drug
DDI-DrugBank.d531.s74|41-53|Carbamazepine|drug
DDI-DrugBank.d531.s75|66-71|levels|group
DDI-DrugBank.d531.s76|45-50|levels|group
DDI-DrugBank.d531.s77|0-10|Antifungals|group
DDI-DrugBank.d531.s77|13-24|Itraconazole|drug
DDI-DrugBank.d531.s77|26-37|Ketoconazole|drug
DDI-DrugBank.d531.s78|17-23|studies|group
DDI-DrugBank.d531.s78|30-36|SUSTIVA|brand
DDI-DrugBank.d531.s78|48-56|imidazole|drug
DDI-DrugBank.d531.s78|62-69|triazole|drug
DDI-DrugBank.d531.s78|71-81|antifungals|group
DDI-DrugBank.d531.s79|0-6|SUSTIVA|brand
DDI-DrugBank.d531.s79|45-58|concentrations|group
DDI-DrugBank.d531.s79|63-74|itraconazole|drug
DDI-DrugBank.d531.s79|80-91|ketoconazole|drug
DDI-DrugBank.d531.s80|18-27|inhibitors|group
DDI-DrugBank.d531.s83|0-9|SUSTIVAhas|group
DDI-DrugBank.d531.s83|43-56|concentrations|group
DDI-DrugBank.d531.s84|37-46|inhibitors|group
DDI-DrugBank.d531.s85|3-9|studies|group
DDI-DrugBank.d531.s85|42-47|NNRTIs|group
DDI-DrugBank.d531.s87|42-47|levels|group
DDI-DrugBank.d531.s87|103-109|SUSTIVA|brand
DDI-DrugBank.d531.s88|6-11|Tables|group
DDI-DrugBank.d531.s89|2-5|This|group
DDI-DrugBank.d531.s90|6-10|Drugs|group
DDI-DrugBank.d531.s90|26-32|results|group
DDI-DrugBank.d531.s90|54-60|studies|group
DDI-DrugBank.d531.s90|104-110|SUSTIVA|brand
DDI-DrugBank.d531.s90|182-189|antacids|group
DDI-DrugBank.d531.s90|192-203|azithromycin|drug
DDI-DrugBank.d531.s90|218-227|famotidine|drug
DDI-DrugBank.d531.s90|230-240|fluconazole|drug
DDI-DrugBank.d531.s90|255-263|lorazepam|drug
DDI-DrugBank.d531.s90|278-287|paroxetine|drug
DDI-DrugBank.d531.s91|26-32|studies|group
DDI-DrugBank.d531.s91|63-69|SUSTIVA|brand
DDI-DrugBank.d531.s91|75-79|NRTIs|group
DDI-DrugBank.d531.s92|23-34|interactions|group
DDI-DrugBank.d531.s92|68-72|NRTIs|group
DDI-DrugBank.d531.s92|183-189|enzymes|group
DDI-DrugBank.d531.s92|207-214|pathways|group
DDI-DrugBank.d152.s0|37-41|tests|group
DDI-DrugBank.d152.s0|87-100|contraceptives|group
DDI-DrugBank.d152.s1|22-28|changes|group
DDI-DrugBank.d152.s1|58-62|doses|group
DDI-DrugBank.d152.s2|26-32|factors|group
DDI-DrugBank.d152.s2|39-42|VIII|brand
DDI-DrugBank.d635.s0|43-57|bronchodilators|group
DDI-DrugBank.d635.s0|97-102|MAXAIR|brand
DDI-DrugBank.d635.s0|104-112|AUTOHALER|brand
DDI-DrugBank.d635.s0|145-151|effects|group
DDI-DrugBank.d639.s0|21-26|SUTENT|brand
DDI-DrugBank.d639.s0|40-49|inhibitors|group
DDI-DrugBank.d639.s0|79-90|ketoconazole|drug
DDI-DrugBank.d639.s0|93-104|itraconazole|drug
DDI-DrugBank.d639.s0|107-120|clarithromycin|drug
DDI-DrugBank.d639.s0|193-205|telithromycin|drug
DDI-DrugBank.d639.s0|226-234|increases|group
DDI-DrugBank.d639.s0|246-259|concentrations|group
DDI-DrugBank.d639.s1|36-49|concentrations|group
DDI-DrugBank.d639.s1|54-59|SUTENT|brand
DDI-DrugBank.d639.s2|21-26|SUTENT|brand
DDI-DrugBank.d639.s2|33-40|inducers|group
DDI-DrugBank.d639.s2|85-93|phenytoin|drug
DDI-DrugBank.d639.s2|96-108|carbamazepine|drug
DDI-DrugBank.d639.s2|163-167|Johns|group
DDI-DrugBank.d639.s2|198-211|concentrations|group
DDI-DrugBank.d639.s4|0-4|Johns|group
DDI-DrugBank.d639.s4|24-29|SUTENT|brand
DDI-DrugBank.d639.s4|38-51|concentrations|group
DDI-DrugBank.d639.s5|0-7|Patients|group
DDI-DrugBank.d639.s5|19-24|SUTENT|brand
DDI-DrugBank.d639.s6|0-4|Johns|group
DDI-DrugBank.d639.s7|0-5|SUTENT|brand
DDI-DrugBank.d639.s7|43-50|patients|group
DDI-DrugBank.d639.s7|77-86|inhibitors|group
DDI-DrugBank.d639.s7|91-98|inducers|group
DDI-DrugBank.d163.s0|65-72|patients|group
DDI-DrugBank.d163.s0|115-125|supplements|group
DDI-DrugBank.d163.s0|172-178|effects|group
DDI-DrugBank.d163.s2|0-12|Tetracyclines|group
DDI-DrugBank.d163.s2|55-67|tetracyclines|group
DDI-DrugBank.d163.s2|145-149|cases|group
DDI-DrugBank.d163.s2|55-67|tetracyclines|group
DDI-DrugBank.d163.s4|25-36|Preparations|group
DDI-DrugBank.d163.s4|64-75|preparations|group
DDI-DrugBank.d163.s4|78-86|minipills|group
DDI-DrugBank.d163.s5|24-37|contraceptives|group
DDI-DrugBank.d163.s5|77-83|reports|group
DDI-DrugBank.d163.s5|24-37|contraceptives|group
DDI-DrugBank.d163.s5|229-236|products|group
DDI-DrugBank.d163.s6|6-12|reports|group
DDI-DrugBank.d163.s7|28-41|contraceptives|group
DDI-DrugBank.d163.s7|59-71|effectiveness|group
DDI-DrugBank.d163.s8|104-108|forms|group
DDI-DrugBank.d163.s8|197-202|unless|group
DDI-DrugBank.d163.s10|0-8|Phenytoin|drug
DDI-DrugBank.d163.s10|52-67|pharmacokinetics|group
DDI-DrugBank.d163.s10|72-80|phenytoin|drug
DDI-DrugBank.d163.s10|110-119|volunteers|group
DDI-DrugBank.d163.s11|6-12|results|group
DDI-DrugBank.d163.s11|89-99|metabolites|group
DDI-DrugBank.d163.s11|111-117|inhibit|group
DDI-DrugBank.d163.s12|0-8|Phenytoin|drug
DDI-DrugBank.d163.s13|19-25|studies|group
DDI-DrugBank.d163.s13|50-55|assess|group
DDI-DrugBank.d163.s13|99-102|loss|group
DDI-DrugBank.d163.s13|112-120|phenytoin|drug
DDI-DrugBank.d163.s14|56-60|drugs|group
DDI-DrugBank.d163.s16|9-23|Corticosteroids|group
DDI-DrugBank.d163.s16|35-49|corticosteroids|group
DDI-DrugBank.d163.s16|70-81|osteoporosis|group
DDI-DrugBank.d163.s17|19-25|studies|group
DDI-DrugBank.d163.s17|50-55|assess|group
DDI-DrugBank.d163.s17|99-102|loss|group
DDI-DrugBank.d163.s17|121-135|corticosteroids|group
DDI-DrugBank.d163.s18|56-60|drugs|group
DDI-DrugBank.d163.s19|0-10|Prescribers|group
DDI-DrugBank.d163.s19|109-122|contraceptives|group
DDI-DrugBank.d163.s19|136-146|medications|group
DDI-DrugBank.d163.s19|165-177|effectiveness|group
DDI-DrugBank.d163.s19|202-209|products|group
DDI-DrugBank.d163.s20|51-58|patients|group
DDI-DrugBank.d163.s21|0-10|Pregnancies|group
DDI-DrugBank.d163.s21|34-38|users|group
DDI-DrugBank.d163.s21|61-74|contraceptives|group
DDI-DrugBank.d163.s21|107-111|Johns|group
DDI-DrugBank.d163.s22|11-15|Tests|group
DDI-DrugBank.d163.s22|39-46|patients|group
DDI-DrugBank.d163.s22|93-99|results|group
DDI-DrugBank.d163.s22|133-137|tests|group
DDI-DrugBank.d163.s24|82-85|days|group
DDI-DrugBank.d163.s25|4-11|patients|group
DDI-DrugBank.d163.s25|73-76|days|group
DDI-DrugBank.d163.s25|158-162|forms|group
DDI-DrugBank.d163.s29|0-5|Lipids|group
DDI-DrugBank.d163.s29|41-46|lipids|group
DDI-DrugBank.d163.s29|81-90|conditions|group
DDI-DrugBank.d163.s30|21-27|alcohol|drug
DDI-DrugBank.d163.s30|42-46|hours|group
DDI-DrugBank.d163.s30|75-88|determinations|group
DDI-DrugBank.d163.s31|29-33|tests|group
DDI-DrugBank.d163.s31|70-78|intervals|group
DDI-DrugBank.d163.s34|15-19|Tests|group
DDI-DrugBank.d163.s34|28-37|elevations|group
DDI-DrugBank.d163.s34|48-54|enzymes|group
DDI-DrugBank.d163.s34|91-96|trials|group
DDI-DrugBank.d163.s34|103-111|hepatitis|group
DDI-DrugBank.d163.s34|174-178|tests|group
DDI-DrugBank.d163.s34|222-230|intervals|group
DDI-DrugBank.d163.s36|14-21|patients|group
DDI-DrugBank.d163.s36|59-66|problems|group
DDI-DrugBank.d163.s37|17-21|cases|group
DDI-DrugBank.d163.s37|26-33|diabetes|group
DDI-DrugBank.d163.s39|10-17|patients|group
DDI-DrugBank.d163.s39|30-37|vigorous|group
DDI-DrugBank.d163.s39|113-118|levels|group
DDI-DrugBank.d163.s41|35-41|reports|group
DDI-DrugBank.d163.s41|46-59|rhabdomyolysis|group
DDI-DrugBank.d163.s41|83-91|strenuous|group
DDI-DrugBank.d163.s42|37-44|patients|group
DDI-DrugBank.d163.s42|56-60|years|group
DDI-DrugBank.d163.s42|112-121|elevations|group
DDI-DrugBank.d163.s42|37-44|patients|group
DDI-DrugBank.d163.s42|191-199|strenuous|group
DDI-DrugBank.d163.s42|272-277|events|group
DDI-DrugBank.d163.s43|9-16|patients|group
DDI-DrugBank.d163.s43|49-58|elevations|group
DDI-DrugBank.d163.s43|88-92|weeks|group
DDI-DrugBank.d163.s43|88-92|weeks|group
DDI-DrugBank.d163.s44|3-7|cases|group
DDI-DrugBank.d163.s44|12-25|rhabdomyolysis|group
DDI-DrugBank.d489.s0|14-18|drugs|group
DDI-DrugBank.d489.s0|83-98|pharmacokinetics|group
DDI-DrugBank.d489.s0|101-110|cimetidine|drug
DDI-DrugBank.d489.s0|113-122|nifedipine|drug
DDI-DrugBank.d489.s1|52-64|anticoagulant|group
DDI-DrugBank.d489.s1|66-73|warfarin|drug
DDI-DrugBank.d489.s1|52-64|anticoagulant|group
DDI-DrugBank.d489.s1|66-73|warfarin|drug
DDI-DrugBank.d489.s2|24-28|drugs|group
DDI-DrugBank.d489.s2|37-45|reserpine|drug
DDI-DrugBank.d489.s2|106-111|agents|group
DDI-DrugBank.d489.s3|0-7|Patients|group
DDI-DrugBank.d489.s3|49-56|blocking|group
DDI-DrugBank.d489.s3|58-62|agent|group
DDI-DrugBank.d489.s3|64-67|plus|group
DDI-DrugBank.d489.s3|71-83|catecholamine|drug
DDI-DrugBank.d489.s4|47-54|patients|group
DDI-DrugBank.d489.s4|84-92|clonidine|drug
DDI-DrugBank.d489.s4|168-171|days|group
DDI-DrugBank.d489.s4|84-92|clonidine|drug
DDI-DrugBank.d489.s5|11-17|reports|group
DDI-DrugBank.d489.s5|45-55|antagonists|group
DDI-DrugBank.d489.s5|105-112|blocking|group
DDI-DrugBank.d489.s5|114-119|agents|group
DDI-DrugBank.d489.s5|177-184|patients|group
DDI-DrugBank.d489.s6|27-38|disturbances|group
DDI-DrugBank.d489.s6|97-104|patients|group
DDI-DrugBank.d489.s6|132-139|blocking|group
DDI-DrugBank.d489.s6|141-146|agents|group
DDI-DrugBank.d489.s7|70-84|dihydropyridine|drug
DDI-DrugBank.d489.s7|104-113|nifedipine|drug
DDI-DrugBank.d489.s7|165-176|disturbances|group
DDI-DrugBank.d489.s7|204-208|block|group
DDI-DrugBank.d489.s8|57-64|patients|group
DDI-DrugBank.d489.s8|104-114|epinephrine|drug
DDI-DrugBank.d489.s8|293-299|attacks|group
DDI-DrugBank.d489.s9|16-24|reactions|group
DDI-DrugBank.d489.s9|36-46|anaphylaxis|group
DDI-DrugBank.d489.s9|70-77|patients|group
DDI-DrugBank.d489.s9|103-111|allergens|group
DDI-DrugBank.d489.s9|201-206|agents|group
DDI-DrugBank.d489.s10|5-12|patients|group
DDI-DrugBank.d489.s10|47-51|doses|group
DDI-DrugBank.d489.s10|56-66|epinephrine|drug
DDI-MedLine.d62.s0|54-68|methamphetamine|drug
DDI-MedLine.d62.s1|0-1|As|group
DDI-MedLine.d62.s1|19-23|genes|group
DDI-MedLine.d62.s1|26-29|IEGs|group
DDI-MedLine.d62.s1|141-155|methamphetamine|drug
DDI-MedLine.d62.s1|158-161|METH|brand
DDI-MedLine.d62.s1|201-207|changes|group
DDI-MedLine.d62.s1|274-280|effects|group
DDI-MedLine.d62.s2|52-55|IEGs|group
DDI-MedLine.d62.s2|52-55|IEGs|group
DDI-MedLine.d62.s3|31-34|METH|brand
DDI-MedLine.d62.s3|51-57|affects|group
DDI-MedLine.d62.s3|144-150|encodes|group
DDI-MedLine.d62.s4|46-49|METH|brand
DDI-MedLine.d62.s4|202-209|dopamine|drug
DDI-MedLine.d62.s4|279-287|clozapine|drug
DDI-MedLine.d62.s5|0-3|METH|brand
DDI-MedLine.d62.s5|25-30|layers|group
DDI-MedLine.d62.s5|62-69|dopamine|drug
DDI-MedLine.d62.s6|6-12|results|group
DDI-MedLine.d62.s6|30-38|receptors|group
DDI-MedLine.d62.s6|129-139|alterations|group
DDI-MedLine.d62.s6|183-186|METH|brand
DDI-DrugBank.d449.s0|34-39|agents|group
DDI-DrugBank.d449.s0|49-60|ketoconazole|drug
DDI-DrugBank.d449.s0|65-76|itraconazole|drug
DDI-DrugBank.d449.s1|12-22|fluvoxamine|drug
DDI-DrugBank.d449.s1|25-34|cimetidine|drug
DDI-DrugBank.d449.s2|0-9|Fluoxetine|drug
DDI-DrugBank.d449.s2|12-14|OCs|group
DDI-DrugBank.d449.s2|50-60|antibiotics|group
DDI-DrugBank.d153.s0|39-47|solutions|group
DDI-DrugBank.d153.s0|60-70|epinephrine|drug
DDI-DrugBank.d153.s0|75-88|norepinephrine|drug
DDI-DrugBank.d153.s0|93-100|patients|group
DDI-DrugBank.d153.s0|112-120|monoamine|drug
DDI-DrugBank.d153.s0|130-139|inhibitors|group
DDI-DrugBank.d153.s0|154-168|antidepressants|group
DDI-DrugBank.d153.s1|24-29|agents|group
DDI-DrugBank.d153.s2|3-12|situations|group
DDI-DrugBank.d153.s3|41-45|drugs|group
DDI-DrugBank.d153.s3|41-45|drugs|group
DDI-DrugBank.d153.s3|141-149|accidents|group
DDI-DrugBank.d153.s4|0-13|Phenothiazines|group
DDI-DrugBank.d153.s4|19-32|butyrophenones|group
DDI-DrugBank.d153.s4|78-88|epinephrine|drug
DDI-DrugBank.d546.s0|5-16|Interactions|group
DDI-DrugBank.d546.s0|57-66|fenoldopam|drug
DDI-DrugBank.d546.s1|7-11|drugs|group
DDI-DrugBank.d546.s1|122-131|inhibition|group
DDI-DrugBank.d546.s1|171-180|fenoldopam|drug
DDI-DrugBank.d546.s2|5-16|Interactions|group
DDI-DrugBank.d546.s2|75-81|studies|group
DDI-DrugBank.d546.s2|84-94|intravenous|group
DDI-DrugBank.d546.s2|96-105|fenoldopam|drug
DDI-DrugBank.d546.s2|141-145|drugs|group
DDI-DrugBank.d546.s2|155-163|digitalis|group
DDI-DrugBank.d546.s3|62-67|agents|group
DDI-DrugBank.d546.s3|123-132|inhibitors|group
DDI-DrugBank.d546.s3|139-147|diuretics|group
DDI-DrugBank.d520.s0|10-16|effects|group
DDI-DrugBank.d520.s0|33-41|compounds|group
DDI-DrugBank.d171.s0|67-73|systems|group
DDI-DrugBank.d171.s0|144-157|anticoagulants|group
DDI-DrugBank.d171.s0|160-168|phenytoin|drug
DDI-DrugBank.d171.s0|171-181|propranolol|drug
DDI-DrugBank.d171.s0|184-193|nifedipine|drug
DDI-DrugBank.d171.s0|214-221|diazepam|drug
DDI-DrugBank.d171.s0|242-256|antidepressants|group
DDI-DrugBank.d171.s0|287-299|metronidazole|drug
DDI-DrugBank.d171.s0|352-357|levels|group
DDI-DrugBank.d171.s0|368-372|drugs|group
DDI-DrugBank.d171.s1|23-29|effects|group
DDI-DrugBank.d171.s1|59-66|warfarin|drug
DDI-DrugBank.d171.s1|68-81|anticoagulants|group
DDI-DrugBank.d171.s2|86-98|anticoagulant|group
DDI-DrugBank.d171.s3|17-25|phenytoin|drug
DDI-DrugBank.d171.s3|106-112|effects|group
DDI-DrugBank.d171.s4|38-45|subjects|group
DDI-DrugBank.d171.s4|175-189|Pharmaceuticals|group
DDI-DrugBank.d171.s4|211-214|less|group
DDI-DrugBank.d171.s4|267-272|levels|group
DDI-DrugBank.d171.s4|38-45|subjects|group
DDI-DrugBank.d171.s4|337-341|years|group
DDI-DrugBank.d171.s5|15-18|days|group
DDI-DrugBank.d171.s6|11-18|patients|group
DDI-DrugBank.d171.s6|78-87|regardless|group
DDI-DrugBank.d171.s7|14-18|drugs|group
DDI-DrugBank.d171.s7|14-18|drugs|group
DDI-DrugBank.d171.s7|125-132|patients|group
DDI-DrugBank.d171.s7|294-299|levels|group
DDI-DrugBank.d171.s8|50-54|drugs|group
DDI-DrugBank.d171.s8|63-74|ketoconazole|drug
DDI-DrugBank.d171.s9|9-16|products|group
DDI-DrugBank.d171.s9|62-66|hours|group
DDI-DrugBank.d171.s9|75-84|cimetidine|drug
DDI-DrugBank.d171.s10|48-52|drugs|group
DDI-MedLine.d169.s0|17-23|inhibit|group
DDI-MedLine.d169.s0|45-54|milligrams|group
DDI-MedLine.d169.s0|83-87|doses|group
DDI-MedLine.d169.s0|89-92|less|group
DDI-MedLine.d169.s0|45-54|milligrams|group
DDI-MedLine.d169.s2|69-73|comes|group
DDI-MedLine.d169.s2|80-86|studies|group
DDI-MedLine.d169.s2|158-167|components|group
DDI-MedLine.d169.s2|80-86|studies|group
DDI-MedLine.d169.s3|41-47|effects|group
DDI-MedLine.d169.s4|88-94|studies|group
DDI-MedLine.d169.s4|119-125|tracers|group
DDI-MedLine.d169.s5|17-23|effects|group
DDI-MedLine.d169.s5|36-40|doses|group
DDI-MedLine.d169.s5|105-111|ferrous|group
DDI-MedLine.d169.s6|22-28|effects|group
DDI-MedLine.d169.s6|41-45|doses|group
DDI-MedLine.d169.s6|124-127|CRBC|brand
DDI-MedLine.d169.s7|52-58|studies|group
DDI-MedLine.d169.s7|64-71|minerals|group
DDI-MedLine.d169.s8|8-12|doses|group
DDI-MedLine.d169.s10|151-154|CRBC|brand
DDI-MedLine.d169.s11|0-3|This|group
DDI-MedLine.d169.s11|28-32|doses|group
DDI-MedLine.d169.s11|83-89|studies|group
DDI-DrugBank.d219.s0|15-21|Reports|group
DDI-DrugBank.d219.s0|36-41|NSAIDs|group
DDI-DrugBank.d219.s1|0-3|This|group
DDI-DrugBank.d219.s1|50-57|patients|group
DDI-DrugBank.d219.s1|66-71|NSAIDs|group
DDI-DrugBank.d219.s2|0-7|Antacids|group
DDI-DrugBank.d219.s2|44-51|antacids|group
DDI-DrugBank.d219.s3|9-16|antacids|group
DDI-DrugBank.d219.s6|23-28|NSAIDs|group
DDI-DrugBank.d219.s6|155-161|effects|group
DDI-DrugBank.d219.s7|0-11|Cyclosporine|drug
DDI-DrugBank.d219.s7|14-20|Digoxin|drug
DDI-DrugBank.d219.s7|23-34|Methotrexate|drug
DDI-DrugBank.d219.s7|55-60|NSAIDs|group
DDI-DrugBank.d219.s7|71-77|effects|group
DDI-DrugBank.d219.s7|88-101|prostaglandins|group
DDI-DrugBank.d219.s7|114-120|changes|group
DDI-DrugBank.d219.s7|150-154|drugs|group
DDI-DrugBank.d219.s7|182-187|levels|group
DDI-DrugBank.d219.s7|192-203|cyclosporine|drug
DDI-DrugBank.d219.s7|206-212|digoxin|drug
DDI-DrugBank.d219.s7|215-226|methotrexate|drug
DDI-DrugBank.d219.s8|31-42|cyclosporine|drug
DDI-DrugBank.d219.s9|0-7|Patients|group
DDI-DrugBank.d219.s9|25-29|drugs|group
DDI-DrugBank.d219.s9|66-70|NSAID|brand
DDI-DrugBank.d219.s9|96-103|patients|group
DDI-DrugBank.d219.s9|189-198|toxicities|group
DDI-DrugBank.d219.s9|25-29|drugs|group
DDI-DrugBank.d219.s10|0-8|Diuretics|group
DDI-DrugBank.d219.s10|87-96|furosemide|drug
DDI-DrugBank.d219.s11|0-11|Nevertheless|group
DDI-DrugBank.d219.s11|23-29|studies|group
DDI-DrugBank.d219.s11|57-68|observations|group
DDI-DrugBank.d219.s11|130-139|furosemide|drug
DDI-DrugBank.d219.s11|145-153|thiazides|group
DDI-DrugBank.d219.s11|163-170|patients|group
DDI-DrugBank.d219.s12|0-3|This|group
DDI-DrugBank.d219.s12|37-46|inhibition|group
DDI-DrugBank.d219.s12|71-79|synthesis|group
DDI-DrugBank.d219.s13|32-37|NSAIDs|group
DDI-DrugBank.d219.s13|83-87|signs|group
DDI-DrugBank.d219.s15|9-14|NSAIDs|group
DDI-DrugBank.d219.s15|61-66|levels|group
DDI-DrugBank.d219.s17|6-12|effects|group
DDI-DrugBank.d219.s17|38-47|inhibition|group
DDI-DrugBank.d219.s17|72-80|synthesis|group
DDI-DrugBank.d219.s17|89-93|NSAID|brand
DDI-DrugBank.d219.s18|0-3|Thus|group
DDI-DrugBank.d219.s18|11-16|NSAIDs|group
DDI-DrugBank.d219.s18|61-68|subjects|group
DDI-DrugBank.d219.s18|103-107|signs|group
DDI-DrugBank.d219.s19|31-36|causes|group
DDI-DrugBank.d219.s20|17-23|studies|group
DDI-DrugBank.d219.s20|107-120|phenylbutazone|drug_n
DDI-DrugBank.d219.s21|0-8|Phenytoin|drug
DDI-DrugBank.d219.s21|87-95|phenytoin|drug
DDI-DrugBank.d219.s22|0-7|Warfarin|drug
DDI-DrugBank.d219.s22|14-20|effects|group
DDI-DrugBank.d219.s22|25-32|warfarin|drug
DDI-DrugBank.d219.s22|38-43|NSAIDs|group
DDI-DrugBank.d219.s22|87-91|users|group
DDI-DrugBank.d219.s22|101-105|drugs|group
DDI-DrugBank.d219.s22|131-137|serious|group
DDI-DrugBank.d219.s22|87-91|users|group
DDI-DrugBank.d219.s23|27-33|studies|group
DDI-DrugBank.d219.s23|88-95|warfarin|drug
DDI-DrugBank.d219.s23|119-126|capsules|group
DDI-DrugBank.d219.s23|132-138|tablets|group
DDI-DrugBank.d219.s23|141-147|results|group
DDI-DrugBank.d219.s23|88-95|warfarin|drug
DDI-DrugBank.d219.s23|88-95|warfarin|drug
DDI-DrugBank.d219.s24|69-76|warfarin|drug
DDI-DrugBank.d219.s24|69-76|warfarin|drug
DDI-DrugBank.d219.s25|0-3|Thus|group
DDI-DrugBank.d219.s25|31-38|warfarin|drug
DDI-DrugBank.d219.s26|67-77|spontaneous|group
DDI-DrugBank.d219.s26|79-85|reports|group
DDI-DrugBank.d219.s26|112-116|times|group
DDI-DrugBank.d219.s26|165-172|patients|group
DDI-DrugBank.d219.s26|196-203|warfarin|drug
DDI-DrugBank.d219.s27|21-32|Interactions|group
DDI-DrugBank.d219.s27|47-54|patients|group
DDI-DrugBank.d219.s27|172-182|metabolites|group
DDI-DrugBank.d219.s28|56-61|bodies|group
DDI-DrugBank.d219.s28|104-111|findings|group
DDI-DrugBank.d219.s28|121-128|patients|group
DDI-DrugBank.d219.s29|85-90|events|group
DDI-DrugBank.d219.s31|72-77|levels|group
DDI-DrugBank.d219.s32|12-17|trials|group
DDI-DrugBank.d219.s32|25-33|decreases|group
DDI-DrugBank.d219.s32|78-85|patients|group
DDI-DrugBank.d219.s32|138-142|weeks|group
DDI-DrugBank.d219.s33|6-11|levels|group
DDI-DrugBank.d475.s0|3-14|interactions|group
DDI-DrugBank.d475.s0|43-52|nizatidine|drug
DDI-DrugBank.d475.s0|90-98|lorazepam|drug
DDI-DrugBank.d475.s0|112-120|phenytoin|drug
DDI-DrugBank.d475.s0|127-134|warfarin|drug
DDI-DrugBank.d475.s1|0-9|Nizatidine|drug
DDI-DrugBank.d475.s1|20-26|inhibit|group
DDI-DrugBank.d475.s2|16-27|interactions|group
DDI-DrugBank.d475.s2|41-50|inhibition|group
DDI-DrugBank.d475.s3|3-10|patients|group
DDI-DrugBank.d475.s3|28-32|doses|group
DDI-DrugBank.d475.s3|62-70|increases|group
DDI-DrugBank.d475.s3|92-97|levels|group
DDI-DrugBank.d475.s3|114-123|nizatidine|drug
DDI-DrugBank.d497.s0|0-4|AZOPT|brand
DDI-DrugBank.d497.s0|46-53|contains|group
DDI-DrugBank.d497.s0|76-84|inhibitor|group
DDI-DrugBank.d497.s1|26-36|alterations|group
DDI-DrugBank.d497.s1|72-77|trials|group
DDI-DrugBank.d497.s2|12-19|patients|group
DDI-DrugBank.d497.s2|58-67|inhibitors|group
DDI-DrugBank.d497.s2|75-83|instances|group
DDI-DrugBank.d497.s2|93-104|interactions|group
DDI-DrugBank.d497.s3|75-82|patients|group
DDI-DrugBank.d497.s3|94-98|AZOPT|brand
DDI-DrugBank.d761.s0|0-6|Alcohol|drug
DDI-DrugBank.d761.s0|54-61|subjects|group
DDI-DrugBank.d761.s0|84-90|XENICAL|brand
DDI-DrugBank.d761.s0|99-103|grams|group
DDI-DrugBank.d761.s0|108-114|alcohol|drug
DDI-DrugBank.d761.s0|139-145|glasses|group
DDI-DrugBank.d761.s0|108-114|alcohol|drug
DDI-DrugBank.d761.s0|196-211|pharmacokinetics|group
DDI-DrugBank.d761.s0|223-238|pharmacodynamics|group
DDI-DrugBank.d761.s1|0-11|Cyclosporine|drug
DDI-DrugBank.d761.s1|38-44|XENICAL|brand
DDI-DrugBank.d761.s1|50-61|cyclosporine|drug
DDI-DrugBank.d761.s1|50-61|cyclosporine|drug
DDI-DrugBank.d761.s1|130-135|levels|group
DDI-DrugBank.d761.s1|38-44|XENICAL|brand
DDI-DrugBank.d761.s1|50-61|cyclosporine|drug
DDI-DrugBank.d761.s2|0-6|Digoxin|drug
DDI-DrugBank.d761.s2|29-36|subjects|group
DDI-DrugBank.d761.s2|48-54|XENICAL|brand
DDI-DrugBank.d761.s2|69-73|times|group
DDI-DrugBank.d761.s2|87-90|days|group
DDI-DrugBank.d761.s2|48-54|XENICAL|brand
DDI-DrugBank.d761.s2|119-134|pharmacokinetics|group
DDI-DrugBank.d761.s2|156-162|digoxin|drug
DDI-DrugBank.d761.s3|20-30|Supplements|group
DDI-DrugBank.d761.s3|36-44|Analogues|group
DDI-DrugBank.d761.s3|182-188|XENICAL|brand
DDI-DrugBank.d761.s4|0-6|XENICAL|brand
DDI-DrugBank.d761.s4|8-16|inhibited|group
DDI-DrugBank.d761.s6|31-38|subjects|group
DDI-DrugBank.d761.s6|71-75|times|group
DDI-DrugBank.d761.s6|89-92|days|group
DDI-DrugBank.d761.s6|122-137|pharmacokinetics|group
DDI-DrugBank.d761.s6|142-157|pharmacodynamics|group
DDI-DrugBank.d761.s7|0-9|Nifedipine|drug
DDI-DrugBank.d761.s7|29-35|tablets|group
DDI-DrugBank.d761.s7|59-66|subjects|group
DDI-DrugBank.d761.s7|78-84|XENICAL|brand
DDI-DrugBank.d761.s7|99-103|times|group
DDI-DrugBank.d761.s7|117-120|days|group
DDI-DrugBank.d761.s7|78-84|XENICAL|brand
DDI-DrugBank.d761.s7|168-177|nifedipine|drug
DDI-DrugBank.d761.s7|29-35|tablets|group
DDI-DrugBank.d761.s8|5-18|Contraceptives|group
DDI-DrugBank.d761.s8|48-55|subjects|group
DDI-DrugBank.d761.s8|75-81|XENICAL|brand
DDI-DrugBank.d761.s8|96-100|times|group
DDI-DrugBank.d761.s8|115-118|days|group
DDI-DrugBank.d761.s8|135-141|changes|group
DDI-DrugBank.d761.s8|187-200|contraceptives|group
DDI-DrugBank.d761.s9|0-8|Phenytoin|drug
DDI-DrugBank.d761.s9|31-38|subjects|group
DDI-DrugBank.d761.s9|50-56|XENICAL|brand
DDI-DrugBank.d761.s9|71-75|times|group
DDI-DrugBank.d761.s9|89-92|days|group
DDI-DrugBank.d761.s9|50-56|XENICAL|brand
DDI-DrugBank.d761.s9|121-136|pharmacokinetics|group
DDI-DrugBank.d761.s9|165-173|phenytoin|drug
DDI-DrugBank.d761.s10|89-96|patients|group
DDI-DrugBank.d761.s10|108-114|XENICAL|brand
DDI-DrugBank.d761.s10|129-133|times|group
DDI-DrugBank.d761.s10|147-150|days|group
DDI-DrugBank.d761.s10|108-114|XENICAL|brand
DDI-DrugBank.d761.s10|180-195|pharmacokinetics|group
DDI-DrugBank.d761.s11|0-7|Warfarin|drug
DDI-DrugBank.d761.s11|30-37|subjects|group
DDI-DrugBank.d761.s11|58-64|XENICAL|brand
DDI-DrugBank.d761.s11|79-83|times|group
DDI-DrugBank.d761.s11|98-101|days|group
DDI-DrugBank.d761.s11|142-149|warfarin|drug
DDI-DrugBank.d761.s11|151-166|pharmacokinetics|group
DDI-DrugBank.d761.s11|199-214|pharmacodynamics|group
DDI-DrugBank.d761.s12|74-79|status|group
DDI-DrugBank.d761.s12|101-107|XENICAL|brand
DDI-DrugBank.d761.s12|135-140|levels|group
DDI-DrugBank.d761.s12|163-170|subjects|group
DDI-DrugBank.d761.s12|101-107|XENICAL|brand
DDI-DrugBank.d761.s13|57-63|XENICAL|brand
DDI-DrugBank.d761.s13|66-73|patients|group
DDI-DrugBank.d761.s13|93-97|doses|group
DDI-DrugBank.d761.s13|102-109|warfarin|drug
DDI-DrugBank.d761.s13|57-63|XENICAL|brand
DDI-DrugBank.d761.s13|170-176|changes|group
DDI-DrugBank.d761.s13|181-191|coagulation|group
DDI-DrugBank.d761.s13|193-202|parameters|group
DDI-DrugBank.d357.s0|5-15|Antagonists|group
DDI-DrugBank.d357.s0|27-33|reports|group
DDI-DrugBank.d357.s0|63-66|loss|group
DDI-DrugBank.d357.s0|71-83|consciousness|group
DDI-DrugBank.d357.s0|177-181|drugs|group
DDI-DrugBank.d357.s0|206-210|class|group
DDI-DrugBank.d357.s1|17-27|Medications|group
DDI-DrugBank.d357.s1|33-44|Vasodilators|group
DDI-DrugBank.d357.s1|69-74|events|group
DDI-DrugBank.d357.s1|110-117|patients|group
DDI-DrugBank.d357.s1|158-168|medications|group
DDI-DrugBank.d357.s1|173-184|vasodilators|group
DDI-DrugBank.d357.s1|110-117|patients|group
DDI-DrugBank.d357.s1|248-252|drugs|group
DDI-DrugBank.d357.s1|281-282|vs|group
DDI-DrugBank.d357.s1|281-282|vs|group
DDI-DrugBank.d357.s1|320-326|serious|group
DDI-DrugBank.d357.s1|281-282|vs|group
DDI-DrugBank.d357.s1|320-326|serious|group
DDI-DrugBank.d357.s1|356-360|falls|group
DDI-DrugBank.d357.s1|281-282|vs|group
DDI-DrugBank.d357.s1|391-398|injuries|group
DDI-DrugBank.d357.s1|281-282|vs|group
DDI-DrugBank.d357.s2|39-44|events|group
DDI-DrugBank.d357.s3|0-7|Dopamine|drug
DDI-DrugBank.d357.s3|9-19|Antagonists|group
DDI-DrugBank.d357.s3|45-52|dopamine|drug
DDI-DrugBank.d357.s3|45-52|dopamine|drug
DDI-DrugBank.d357.s3|92-102|antagonists|group
DDI-DrugBank.d357.s3|117-128|neuroleptics|group
DDI-DrugBank.d357.s3|131-144|phenothiazines|group
DDI-DrugBank.d357.s3|147-160|butyrophenones|group
DDI-DrugBank.d357.s3|163-175|thioxanthenes|group
DDI-DrugBank.d357.s3|214-226|effectiveness|group
DDI-DrugBank.d357.s3|231-236|APOKYN|brand
DDI-DrugBank.d357.s4|0-7|Patients|group
DDI-DrugBank.d357.s4|30-38|disorders|group
DDI-DrugBank.d357.s4|54-65|neuroleptics|group
DDI-DrugBank.d357.s4|91-98|dopamine|drug
DDI-DrugBank.d357.s4|100-107|agonists|group
DDI-DrugBank.d357.s4|131-138|benefits|group
DDI-DrugBank.d357.s4|153-157|risks|group
DDI-DrugBank.d357.s5|0-4|Drugs|group
DDI-DrugBank.d357.s5|113-117|drugs|group
DDI-DrugBank.d357.s6|21-32|Interactions|group
DDI-DrugBank.d357.s6|53-64|interactions|group
DDI-DrugBank.d357.s6|74-79|APOKYN|brand
DDI-DrugBank.d357.s6|96-100|tests|group
DDI-DrugBank.d509.s0|10-21|Interactions|group
DDI-DrugBank.d509.s0|45-51|effects|group
DDI-DrugBank.d509.s0|56-67|aripiprazole|drug
DDI-DrugBank.d509.s0|98-104|ABILIFY|brand
DDI-DrugBank.d509.s0|158-162|drugs|group
DDI-DrugBank.d509.s0|168-174|alcohol|drug
DDI-DrugBank.d509.s2|35-46|aripiprazole|drug
DDI-DrugBank.d509.s2|116-121|agents|group
DDI-DrugBank.d509.s3|20-24|Drugs|group
DDI-DrugBank.d509.s3|36-42|ABILIFY|brand
DDI-DrugBank.d509.s3|44-55|Aripiprazole|drug
DDI-DrugBank.d509.s3|146-152|enzymes|group
DDI-DrugBank.d509.s4|0-11|Aripiprazole|drug
DDI-DrugBank.d509.s5|0-3|This|group
DDI-DrugBank.d509.s5|5-12|suggests|group
DDI-DrugBank.d509.s5|37-48|aripiprazole|drug
DDI-DrugBank.d509.s5|55-64|inhibitors|group
DDI-DrugBank.d509.s5|69-76|inducers|group
DDI-DrugBank.d509.s5|87-93|enzymes|group
DDI-DrugBank.d509.s5|105-111|factors|group
DDI-DrugBank.d509.s6|43-54|aripiprazole|drug
DDI-DrugBank.d509.s7|0-5|Agents|group
DDI-DrugBank.d509.s7|31-43|carbamazepine|drug
DDI-DrugBank.d509.s7|73-84|aripiprazole|drug
DDI-DrugBank.d509.s7|112-117|levels|group
DDI-DrugBank.d509.s8|0-9|Inhibitors|group
DDI-DrugBank.d509.s8|26-37|ketoconazole|drug
DDI-DrugBank.d509.s8|55-63|quinidine|drug
DDI-DrugBank.d509.s8|66-75|fluoxetine|drug
DDI-DrugBank.d509.s8|81-90|paroxetine|drug
DDI-DrugBank.d509.s8|97-103|inhibit|group
DDI-DrugBank.d509.s8|105-116|aripiprazole|drug
DDI-DrugBank.d509.s8|156-161|levels|group
DDI-DrugBank.d509.s9|0-11|Ketoconazole|drug
DDI-DrugBank.d509.s9|34-45|ketoconazole|drug
DDI-DrugBank.d509.s9|66-69|days|group
DDI-DrugBank.d509.s9|100-111|aripiprazole|drug
DDI-DrugBank.d509.s9|100-111|aripiprazole|drug
DDI-DrugBank.d509.s10|23-34|ketoconazole|drug
DDI-DrugBank.d509.s11|35-46|ketoconazole|drug
DDI-DrugBank.d509.s11|53-64|aripiprazole|drug
DDI-DrugBank.d509.s11|66-71|occurs|group
DDI-DrugBank.d509.s11|53-64|aripiprazole|drug
DDI-DrugBank.d509.s12|13-22|inhibitors|group
DDI-DrugBank.d509.s12|35-46|itraconazole|drug
DDI-DrugBank.d509.s12|83-89|effects|group
DDI-DrugBank.d509.s12|113-122|reductions|group
DDI-DrugBank.d509.s13|7-16|inhibitors|group
DDI-DrugBank.d509.s13|19-30|erythromycin|drug
DDI-DrugBank.d509.s14|16-24|inhibitor|group
DDI-DrugBank.d509.s14|69-80|aripiprazole|drug
DDI-DrugBank.d509.s15|0-8|Quinidine|drug
DDI-DrugBank.d509.s15|54-65|aripiprazole|drug
DDI-DrugBank.d509.s15|72-80|quinidine|drug
DDI-DrugBank.d509.s15|101-104|days|group
DDI-DrugBank.d509.s15|117-125|inhibitor|group
DDI-DrugBank.d509.s15|54-65|aripiprazole|drug
DDI-DrugBank.d509.s15|228-246|dehydroaripiprazole|drug
DDI-DrugBank.d509.s16|0-11|Aripiprazole|drug
DDI-DrugBank.d509.s16|102-110|quinidine|drug
DDI-DrugBank.d509.s16|117-128|aripiprazole|drug
DDI-DrugBank.d509.s16|130-135|occurs|group
DDI-DrugBank.d509.s17|18-27|inhibitors|group
DDI-DrugBank.d509.s17|48-57|fluoxetine|drug
DDI-DrugBank.d509.s17|62-71|paroxetine|drug
DDI-DrugBank.d509.s17|108-114|effects|group
DDI-DrugBank.d509.s17|170-179|reductions|group
DDI-DrugBank.d509.s18|16-24|inhibitor|group
DDI-DrugBank.d509.s18|69-80|aripiprazole|drug
DDI-DrugBank.d509.s19|0-12|Carbamazepine|drug
DDI-DrugBank.d509.s19|35-47|carbamazepine|drug
DDI-DrugBank.d509.s19|93-104|aripiprazole|drug
DDI-DrugBank.d509.s19|173-178|values|group
DDI-DrugBank.d509.s19|93-104|aripiprazole|drug
DDI-DrugBank.d509.s20|5-17|carbamazepine|drug
DDI-DrugBank.d509.s20|31-42|aripiprazole|drug
DDI-DrugBank.d509.s20|31-42|aripiprazole|drug
DDI-DrugBank.d509.s21|16-24|increases|group
DDI-DrugBank.d509.s22|5-17|carbamazepine|drug
DDI-DrugBank.d509.s22|62-73|aripiprazole|drug
DDI-DrugBank.d509.s23|36-45|famotidine|drug
DDI-DrugBank.d509.s23|86-101|pharmacokinetics|group
DDI-DrugBank.d509.s23|106-117|aripiprazole|drug
DDI-DrugBank.d509.s23|124-131|CLINICAL|brand
DDI-DrugBank.d509.s23|133-144|PHARMACOLOGY|brand
DDI-DrugBank.d509.s23|158-169|Interactions|group
DDI-DrugBank.d509.s24|14-20|ABILIFY|brand
DDI-DrugBank.d509.s24|38-42|Drugs|group
DDI-DrugBank.d509.s24|44-55|Aripiprazole|drug
DDI-DrugBank.d509.s24|115-126|interactions|group
DDI-DrugBank.d509.s24|133-137|drugs|group
DDI-DrugBank.d509.s24|170-176|enzymes|group
DDI-DrugBank.d509.s25|11-17|studies|group
DDI-DrugBank.d509.s25|37-41|doses|group
DDI-DrugBank.d509.s25|46-57|aripiprazole|drug
DDI-DrugBank.d509.s25|137-144|warfarin|drug
DDI-DrugBank.d509.s25|157-166|omeprazole|drug
DDI-DrugBank.d509.s25|137-144|warfarin|drug
DDI-DrugBank.d509.s25|210-219|substrates|group
DDI-DrugBank.d509.s26|14-25|aripiprazole|drug
DDI-DrugBank.d509.s26|31-49|dehydroaripiprazole|drug
DDI-DrugBank.d509.s27|0-6|Alcohol|drug
DDI-DrugBank.d509.s27|53-64|aripiprazole|drug
DDI-DrugBank.d509.s27|86-92|ethanol|drug
DDI-DrugBank.d509.s27|86-92|ethanol|drug
DDI-DrugBank.d509.s27|152-156|gross|group
DDI-DrugBank.d509.s27|164-169|skills|group
DDI-DrugBank.d509.s27|174-181|stimulus|group
DDI-DrugBank.d509.s27|203-210|subjects|group
DDI-DrugBank.d509.s28|0-1|As|group
DDI-DrugBank.d509.s28|26-36|medications|group
DDI-DrugBank.d509.s28|39-46|patients|group
DDI-DrugBank.d509.s28|75-81|alcohol|drug
DDI-DrugBank.d509.s28|96-102|ABILIFY|brand
DDI-DrugBank.d19.s0|11-17|appears|group
DDI-DrugBank.d19.s0|57-61|drugs|group
DDI-DrugBank.d19.s0|116-121|levels|group
DDI-DrugBank.d19.s0|57-61|drugs|group
DDI-DrugBank.d19.s1|0-9|DISULFIRAM|brand
DDI-DrugBank.d19.s1|11-16|SHOULD|brand
DDI-DrugBank.d19.s1|21-24|USED|brand
DDI-DrugBank.d19.s1|26-29|WITH|brand
DDI-DrugBank.d19.s1|31-37|CAUTION|brand
DDI-DrugBank.d19.s1|42-46|THOSE|brand
DDI-DrugBank.d19.s1|48-55|PATIENTS|brand
DDI-DrugBank.d19.s1|57-65|REVEIVING|brand
DDI-DrugBank.d19.s1|67-75|PHENYTOIN|brand
DDI-DrugBank.d19.s1|85-93|CONGENERS|brand
DDI-DrugBank.d19.s2|0-4|SINCE|brand
DDI-DrugBank.d19.s2|10-20|CONCOMITANT|brand
DDI-DrugBank.d19.s2|22-35|ADMINISTRATION|brand
DDI-DrugBank.d19.s2|40-44|THESE|brand
DDI-DrugBank.d19.s2|50-54|DRUGS|brand
DDI-DrugBank.d19.s2|60-63|LEAD|brand
DDI-DrugBank.d19.s2|68-76|PHENYTOIN|brand
DDI-DrugBank.d19.s2|78-89|INTOXICATION|brand
DDI-DrugBank.d19.s2|92-96|PRIOR|brand
DDI-DrugBank.d19.s2|101-113|ADMINISTERING|brand
DDI-DrugBank.d19.s2|115-124|DISULFIRAM|brand
DDI-DrugBank.d19.s2|131-137|PATIENT|brand
DDI-DrugBank.d19.s2|68-76|PHENYTOIN|brand
DDI-DrugBank.d19.s2|152-158|THERAPY|brand
DDI-DrugBank.d19.s2|163-170|BASELINE|brand
DDI-DrugBank.d19.s2|68-76|PHENYTOIN|brand
DDI-DrugBank.d19.s2|182-186|SERUM|brand
DDI-DrugBank.d19.s2|188-192|LEVEL|brand
DDI-DrugBank.d19.s2|194-199|SHOULD|brand
DDI-DrugBank.d19.s2|204-211|OBTAINED|brand
DDI-DrugBank.d19.s3|0-9|SUBSEQUENT|brand
DDI-DrugBank.d19.s3|14-23|INITIATION|brand
DDI-DrugBank.d19.s3|28-37|DISULFIRAM|brand
DDI-DrugBank.d19.s3|39-45|THERAPY|brand
DDI-DrugBank.d19.s4|0-4|SERUM|brand
DDI-DrugBank.d19.s4|6-11|LEVELS|brand
DDI-DrugBank.d19.s4|16-24|PHENYTOIN|brand
DDI-DrugBank.d19.s4|26-31|SHOULD|brand
DDI-DrugBank.d19.s4|36-45|DETERMINED|brand
DDI-DrugBank.d19.s4|50-58|DIFFERENT|brand
DDI-DrugBank.d19.s4|60-63|DAYS|brand
DDI-DrugBank.d19.s4|69-76|EVIDENCE|brand
DDI-DrugBank.d19.s4|84-91|INCREASE|brand
DDI-DrugBank.d19.s4|102-111|CONTINUING|brand
DDI-DrugBank.d19.s4|113-116|RISE|brand
DDI-DrugBank.d19.s4|6-11|LEVELS|brand
DDI-DrugBank.d19.s5|0-8|INCREASED|brand
DDI-DrugBank.d19.s5|10-18|PHENYTOIN|brand
DDI-DrugBank.d19.s5|20-25|LEVELS|brand
DDI-DrugBank.d19.s5|27-32|SHOULD|brand
DDI-DrugBank.d19.s5|37-43|TREATED|brand
DDI-DrugBank.d19.s5|45-48|WITH|brand
DDI-DrugBank.d19.s5|50-60|APPROPRIATE|brand
DDI-DrugBank.d19.s5|62-67|DOSAGE|brand
DDI-DrugBank.d19.s5|69-78|ADJUSTMENT|brand
DDI-DrugBank.d19.s6|49-62|anticoagulants|group
DDI-DrugBank.d19.s7|0-7|Patients|group
DDI-DrugBank.d19.s7|116-122|changes|group
DDI-DrugBank.d19.s7|134-139|status|group
DDI-DrugBank.d19.s8|46-50|signs|group
DDI-DrugBank.d19.s9|3-6|rats|group
DDI-DrugBank.d19.s9|9-20|simultaneous|group
DDI-DrugBank.d19.s9|77-81|weeks|group
DDI-DrugBank.d19.s9|110-115|tumors|group
DDI-DrugBank.d19.s9|175-182|nitrites|group
DDI-DrugBank.d19.s9|213-223|nitrosamine|drug
DDI-DrugBank.d19.s10|56-61|tumors|group
DDI-DrugBank.d19.s11|33-38|humans|group
DDI-DrugBank.d530.s0|14-22|monoamine|drug
DDI-DrugBank.d530.s0|38-47|inhibitors|group
DDI-DrugBank.d530.s1|57-66|inhibitors|group
DDI-DrugBank.d530.s2|51-59|inhibitor|group
DDI-DrugBank.d530.s3|12-16|Drugs|group
DDI-DrugBank.d530.s3|79-87|reactions|group
DDI-DrugBank.d530.s3|104-108|drugs|group
DDI-DrugBank.d213.s0|17-22|excess|group
DDI-DrugBank.d213.s0|51-61|Carbimazole|drug
DDI-DrugBank.d213.s0|51-61|Carbimazole|drug
DDI-DrugBank.d213.s1|23-29|digoxin|drug
DDI-DrugBank.d213.s1|35-43|digitoxin|drug
DDI-DrugBank.d213.s1|63-70|patients|group
DDI-DrugBank.d213.s1|89-94|agents|group
DDI-DrugBank.d213.s2|55-61|becomes|group
DDI-DrugBank.d213.s3|12-17|agents|group
DDI-DrugBank.d213.s3|110-113|days|group
DDI-DrugBank.d213.s3|142-152|Carbimazole|drug
DDI-DrugBank.d213.s4|0-7|Patients|group
DDI-DrugBank.d213.s4|26-39|anticoagulants|group
DDI-DrugBank.d213.s4|90-95|status|group
DDI-DrugBank.d213.s5|55-67|anticoagulant|group
DDI-DrugBank.d320.s0|44-51|patients|group
DDI-DrugBank.d320.s0|75-85|anesthetics|group
DDI-DrugBank.d320.s0|90-95|agents|group
DDI-DrugBank.d320.s0|75-85|anesthetics|group
DDI-DrugBank.d320.s0|166-172|effects|group
DDI-DrugBank.d320.s0|183-187|drugs|group
DDI-DrugBank.d320.s1|9-15|studies|group
DDI-DrugBank.d320.s2|0-3|Thus|group
DDI-DrugBank.d320.s2|5-10|agents|group
DDI-DrugBank.d320.s3|21-27|studies|group
DDI-DrugBank.d320.s3|138-145|inducers|group
DDI-DrugBank.d320.s3|156-164|phenytoin|drug
DDI-DrugBank.d320.s3|200-209|inhibitors|group
DDI-DrugBank.d320.s3|212-216|azole|drug
DDI-DrugBank.d320.s3|218-229|antimycotics|group
DDI-DrugBank.d320.s3|237-248|ketoconazole|drug
DDI-DrugBank.d320.s4|17-26|inhibitors|group
DDI-DrugBank.d320.s5|10-20|antibiotics|group
DDI-DrugBank.d320.s5|28-39|erythromycin|drug
DDI-DrugBank.d320.s6|20-30|antagonists|group
DDI-DrugBank.d320.s6|57-64|inducers|group
DDI-DrugBank.d320.s6|67-76|omeprazole|drug
DDI-DrugBank.d320.s6|90-99|inhibitors|group
DDI-DrugBank.d320.s6|118-131|clarithromycin|drug
DDI-DrugBank.d320.s7|97-106|inhibitors|group
DDI-DrugBank.d320.s7|97-106|inhibitors|group
DDI-DrugBank.d320.s7|158-163|levels|group
DDI-DrugBank.d715.s0|44-49|DEMSER|brand
DDI-DrugBank.d715.s0|54-61|patients|group
DDI-DrugBank.d715.s0|73-86|phenothiazines|group
DDI-DrugBank.d715.s0|130-136|effects|group
DDI-DrugBank.d715.s0|147-151|drugs|group
DDI-DrugBank.d715.s0|190-199|inhibition|group
DDI-DrugBank.d715.s0|204-216|catecholamine|drug
DDI-DrugBank.d715.s0|218-226|synthesis|group
DDI-DrugBank.d715.s1|18-23|DEMSER|brand
DDI-DrugBank.d715.s1|30-36|alcohol|drug
DDI-DrugBank.d715.s1|51-61|depressants|group
DDI-DrugBank.d715.s1|91-97|effects|group
DDI-MedLine.d100.s0|29-36|blockers|group
DDI-MedLine.d100.s1|93-99|factors|group
DDI-MedLine.d100.s1|104-113|hemostasis|group
DDI-MedLine.d100.s2|58-61|ions|group
DDI-MedLine.d100.s2|133-140|contents|group
DDI-MedLine.d100.s3|42-54|phospholipids|group
DDI-MedLine.d100.s3|78-86|synthesis|group
DDI-MedLine.d100.s3|176-179|ions|group
DDI-MedLine.d100.s4|41-48|controls|group
DDI-MedLine.d100.s4|50-55|levels|group
DDI-MedLine.d100.s4|73-76|ions|group
DDI-MedLine.d100.s4|81-89|platelets|group
DDI-MedLine.d100.s4|95-103|regulates|group
DDI-MedLine.d100.s4|123-131|reactions|group
DDI-MedLine.d100.s5|21-28|blockers|group
DDI-MedLine.d100.s5|64-73|nifedipine|drug
DDI-MedLine.d100.s5|76-82|inhibit|group
DDI-MedLine.d100.s6|6-11|agents|group
DDI-MedLine.d100.s7|43-50|blockers|group
DDI-MedLine.d100.s8|6-12|effects|group
DDI-MedLine.d100.s8|25-32|blockers|group
DDI-MedLine.d100.s8|133-140|patients|group
DDI-DrugBank.d654.s0|26-37|ketoconazole|drug
DDI-DrugBank.d654.s0|212-216|males|group
DDI-DrugBank.d654.s1|77-84|patients|group
DDI-DrugBank.d654.s1|94-104|adjustments|group
DDI-DrugBank.d654.s1|171-180|inhibitors|group
DDI-DrugBank.d654.s1|191-202|ketoconazole|drug
DDI-DrugBank.d654.s2|23-32|inhibition|group
DDI-DrugBank.d654.s2|34-40|studies|group
DDI-DrugBank.d654.s2|114-120|ALTABAX|brand
DDI-DrugBank.d654.s2|186-195|substrates|group
DDI-DrugBank.d654.s3|40-46|ALTABAX|brand
DDI-DrugBank.d654.s3|66-73|products|group
DDI-DrugBank.d245.s0|70-74|drugs|group
DDI-DrugBank.d245.s0|86-97|nonsteroidal|group
DDI-DrugBank.d245.s0|117-122|agents|group
DDI-DrugBank.d245.s0|70-74|drugs|group
DDI-DrugBank.d245.s0|171-181|salicylates|group
DDI-DrugBank.d245.s0|184-195|sulfonamides|group
DDI-DrugBank.d245.s0|227-235|coumarins|group
DDI-DrugBank.d245.s0|238-246|monoamine|drug
DDI-DrugBank.d245.s0|256-265|inhibitors|group
DDI-DrugBank.d245.s0|288-295|blocking|group
DDI-DrugBank.d245.s0|117-122|agents|group
DDI-DrugBank.d245.s1|10-14|drugs|group
DDI-DrugBank.d245.s1|56-64|DIABINESE|brand
DDI-DrugBank.d245.s2|10-14|drugs|group
DDI-DrugBank.d245.s2|55-63|DIABINESE|brand
DDI-DrugBank.d245.s2|109-112|loss|group
DDI-DrugBank.d245.s3|8-12|drugs|group
DDI-DrugBank.d245.s3|60-63|loss|group
DDI-DrugBank.d245.s4|6-10|drugs|group
DDI-DrugBank.d245.s4|24-32|thiazides|group
DDI-DrugBank.d245.s4|44-52|diuretics|group
DDI-DrugBank.d245.s4|55-69|corticosteroids|group
DDI-DrugBank.d245.s4|72-85|phenothiazines|group
DDI-DrugBank.d245.s4|96-103|products|group
DDI-DrugBank.d245.s4|106-114|estrogens|group
DDI-DrugBank.d245.s4|122-135|contraceptives|group
DDI-DrugBank.d245.s4|138-146|phenytoin|drug
DDI-DrugBank.d245.s4|165-180|sympathomimetics|group
DDI-DrugBank.d245.s4|199-206|blocking|group
DDI-DrugBank.d245.s4|6-10|drugs|group
DDI-DrugBank.d245.s5|10-14|drugs|group
DDI-DrugBank.d245.s5|56-64|DIABINESE|brand
DDI-DrugBank.d245.s5|110-113|loss|group
DDI-DrugBank.d245.s6|10-14|drugs|group
DDI-DrugBank.d245.s6|55-63|DIABINESE|brand
DDI-DrugBank.d245.s7|13-19|studies|group
DDI-DrugBank.d245.s7|48-59|barbiturates|group
DDI-DrugBank.d245.s7|48-59|barbiturates|group
DDI-DrugBank.d245.s8|8-15|patients|group
DDI-DrugBank.d245.s8|81-87|alcohol|drug
DDI-DrugBank.d245.s9|37-46|miconazole|drug
DDI-DrugBank.d245.s9|70-75|agents|group
DDI-DrugBank.d245.s10|30-35|occurs|group
DDI-DrugBank.d245.s10|46-56|intravenous|group
DDI-DrugBank.d245.s10|79-90|preparations|group
DDI-DrugBank.d245.s10|95-104|miconazole|drug
DDI-DrugBank.d328.s0|21-27|studies|group
DDI-DrugBank.d328.s0|106-116|intravenous|group
DDI-DrugBank.d328.s1|4-10|results|group
DDI-DrugBank.d328.s1|17-22|trials|group
DDI-DrugBank.d328.s1|34-44|intravenous|group
DDI-DrugBank.d328.s1|132-143|interactions|group
DDI-DrugBank.d328.s2|12-17|humans|group
DDI-DrugBank.d328.s3|9-15|studies|group
DDI-DrugBank.d328.s3|56-64|inhibitor|group
DDI-DrugBank.d328.s3|56-64|inhibitor|group
DDI-DrugBank.d328.s4|116-128|complications|group
DDI-DrugBank.d328.s5|106-116|prophylaxis|group
DDI-DrugBank.d328.s6|57-67|intravenous|group
DDI-DrugBank.d328.s6|116-117|vs|group
DDI-DrugBank.d328.s6|188-197|inhibition|group
DDI-DrugBank.d328.s7|0-11|Methotrexate|drug
DDI-DrugBank.d328.s7|114-125|methotrexate|drug
DDI-DrugBank.d328.s8|15-21|Reports|group
DDI-DrugBank.d328.s8|36-41|NSAIDs|group
DDI-DrugBank.d328.s9|0-3|This|group
DDI-DrugBank.d328.s9|50-57|patients|group
DDI-DrugBank.d328.s9|66-71|BEXTRA|brand
DDI-DrugBank.d328.s10|0-9|Furosemide|drug
DDI-DrugBank.d328.s10|21-27|studies|group
DDI-DrugBank.d328.s10|56-67|observations|group
DDI-DrugBank.d328.s10|86-91|NSAIDs|group
DDI-DrugBank.d328.s10|130-139|furosemide|drug
DDI-DrugBank.d328.s10|145-153|thiazides|group
DDI-DrugBank.d328.s10|163-170|patients|group
DDI-DrugBank.d328.s11|0-3|This|group
DDI-DrugBank.d328.s11|37-46|inhibition|group
DDI-DrugBank.d328.s11|71-79|synthesis|group
DDI-DrugBank.d328.s12|0-14|Anticonvulsants|group
DDI-DrugBank.d328.s12|17-25|Phenytoin|drug
DDI-DrugBank.d328.s12|96-99|days|group
DDI-DrugBank.d328.s12|158-162|doses|group
DDI-DrugBank.d328.s12|96-99|days|group
DDI-DrugBank.d328.s12|191-199|phenytoin|drug
DDI-DrugBank.d328.s13|0-7|Patients|group
DDI-DrugBank.d328.s13|74-77|loss|group
DDI-DrugBank.d328.s13|103-111|phenytoin|drug
DDI-DrugBank.d328.s14|66-81|pharmacokinetics|group
DDI-DrugBank.d328.s14|86-94|phenytoin|drug
DDI-DrugBank.d328.s15|17-23|studies|group
DDI-DrugBank.d328.s15|36-50|anticonvulsants|group
DDI-DrugBank.d328.s16|0-6|Routine|drug
DDI-DrugBank.d328.s16|57-62|BEXTRA|brand
DDI-DrugBank.d328.s16|103-110|patients|group
DDI-DrugBank.d328.s18|50-53|days|group
DDI-DrugBank.d328.s18|118-123|levels|group
DDI-DrugBank.d328.s18|151-155|doses|group
DDI-DrugBank.d328.s18|179-187|inhibitor|group
DDI-DrugBank.d328.s19|32-45|concentrations|group
DDI-DrugBank.d328.s19|71-75|doses|group
DDI-DrugBank.d328.s19|148-159|metabolizers|group
DDI-DrugBank.d328.s20|36-39|days|group
DDI-DrugBank.d328.s20|62-70|decreases|group
DDI-DrugBank.d328.s21|14-27|concentrations|group
DDI-DrugBank.d328.s21|98-103|BEXTRA|brand
DDI-DrugBank.d328.s21|108-115|patients|group
DDI-DrugBank.d328.s22|36-39|days|group
DDI-DrugBank.d328.s22|70-85|pharmacokinetics|group
DDI-DrugBank.d328.s23|0-7|Warfarin|drug
DDI-DrugBank.d328.s23|42-54|anticoagulant|group
DDI-DrugBank.d328.s23|66-73|warfarin|drug
DDI-DrugBank.d328.s23|113-120|subjects|group
DDI-DrugBank.d328.s23|145-150|BEXTRA|brand
DDI-DrugBank.d328.s23|168-171|days|group
DDI-DrugBank.d328.s24|65-73|exposures|group
DDI-DrugBank.d328.s24|160-166|effects|group
DDI-DrugBank.d328.s24|80-87|warfarin|drug
DDI-DrugBank.d328.s25|15-20|values|group
DDI-DrugBank.d328.s25|15-20|values|group
DDI-DrugBank.d328.s26|0-12|Anticoagulant|group
DDI-DrugBank.d328.s26|77-81|weeks|group
DDI-DrugBank.d328.s26|114-119|BEXTRA|brand
DDI-DrugBank.d328.s26|124-131|patients|group
DDI-DrugBank.d328.s26|143-150|warfarin|drug
DDI-DrugBank.d328.s26|163-168|agents|group
DDI-DrugBank.d328.s27|0-10|Fluconazole|drug
DDI-DrugBank.d328.s27|16-27|Ketoconazole|drug
DDI-DrugBank.d328.s27|16-27|Ketoconazole|drug
DDI-DrugBank.d328.s27|47-57|fluconazole|drug
DDI-DrugBank.d328.s27|93-102|inhibitors|group
DDI-DrugBank.d328.s28|73-77|doses|group
DDI-DrugBank.d328.s28|82-93|ketoconazole|drug
DDI-DrugBank.d328.s28|99-109|fluconazole|drug
DDI-DrugBank.d328.s29|79-89|fluconazole|drug
DDI-DrugBank.d328.s29|124-135|ketoconazole|drug
DDI-DrugBank.d328.s31|48-51|days|group
DDI-DrugBank.d328.s31|111-126|pharmacokinetics|group
DDI-DrugBank.d328.s32|64-67|days|group
DDI-DrugBank.d328.s32|126-141|pharmacokinetics|group
DDI-DrugBank.d328.s32|161-176|pharmacodynamics|group
DDI-DrugBank.d328.s32|205-210|levels|group
DDI-DrugBank.d328.s33|64-67|days|group
DDI-DrugBank.d328.s34|8-17|parameters|group
DDI-DrugBank.d328.s35|8-14|changes|group
DDI-DrugBank.d328.s35|27-40|concentrations|group
DDI-DrugBank.d328.s35|27-40|concentrations|group
DDI-DrugBank.d328.s36|35-39|doses|group
DDI-DrugBank.d328.s37|0-9|Omeprazole|drug
DDI-DrugBank.d328.s37|0-9|Omeprazole|drug
DDI-DrugBank.d328.s37|73-81|inhibitor|group
DDI-DrugBank.d328.s38|31-44|concentrations|group
DDI-DrugBank.d328.s38|104-108|doses|group
DDI-DrugBank.d328.s38|113-122|omeprazole|drug
DDI-DrugBank.d328.s39|55-64|omeprazole|drug
DDI-DrugBank.d328.s40|0-4|Drugs|group
DDI-DrugBank.d328.s40|102-111|omeprazole|drug
DDI-DrugBank.d328.s41|24-28|doses|group
DDI-DrugBank.d328.s41|51-60|omeprazole|drug
DDI-DrugBank.d328.s41|102-109|patients|group
DDI-DrugBank.d328.s41|51-60|omeprazole|drug
DDI-DrugBank.d328.s41|24-28|doses|group
DDI-DrugBank.d328.s42|36-40|doses|group
DDI-DrugBank.d328.s42|63-72|omeprazole|drug
DDI-DrugBank.d328.s43|5-18|Contraceptives|group
DDI-DrugBank.d328.s45|34-37|loss|group
DDI-DrugBank.d328.s45|111-119|exposures|group
DDI-DrugBank.d328.s45|124-128|terms|group
DDI-DrugBank.d328.s46|16-24|exposures|group
DDI-DrugBank.d328.s47|0-7|Diazepam|drug
DDI-DrugBank.d328.s47|0-7|Diazepam|drug
DDI-DrugBank.d328.s48|19-26|diazepam|drug
DDI-DrugBank.d328.s48|119-122|days|group
DDI-DrugBank.d328.s48|19-26|diazepam|drug
DDI-DrugBank.d328.s48|119-122|days|group
DDI-DrugBank.d328.s49|26-32|changes|group
DDI-DrugBank.d328.s49|37-44|diazepam|drug
DDI-DrugBank.d328.s49|136-146|adjustments|group
DDI-DrugBank.d328.s49|149-156|patients|group
DDI-DrugBank.d328.s49|196-202|effects|group
DDI-DrugBank.d328.s49|37-44|diazepam|drug
DDI-DrugBank.d328.s50|0-7|Patients|group
DDI-DrugBank.d328.s50|49-57|hazardous|group
DDI-DrugBank.d328.s50|59-68|activities|group
DDI-DrugBank.d328.s50|96-104|alertness|group
DDI-MedLine.d31.s0|50-56|aspects|group
DDI-MedLine.d31.s1|24-32|increases|group
DDI-MedLine.d31.s2|0-13|Rearrangements|group
DDI-MedLine.d31.s2|18-24|genomes|group
DDI-MedLine.d31.s3|6-12|factors|group
DDI-MedLine.d31.s3|45-55|alterations|group
DDI-MedLine.d31.s3|162-168|persons|group
DDI-MedLine.d31.s5|0-3|This|group
DDI-MedLine.d31.s5|16-22|reviews|group
DDI-MedLine.d31.s5|31-42|developments|group
DDI-MedLine.d31.s5|53-57|areas|group
DDI-MedLine.d31.s5|60-67|examines|group
DDI-MedLine.d31.s5|73-79|effects|group
DDI-MedLine.d31.s5|112-123|implications|group
DDI-MedLine.d31.s5|145-153|discusses|group
DDI-DrugBank.d395.s0|72-78|minutes|group
DDI-DrugBank.d395.s1|0-3|Thus|group
DDI-DrugBank.d395.s2|31-39|inhibitor|group
DDI-DrugBank.d395.s2|65-72|isozymes|group
DDI-DrugBank.d395.s2|108-122|methylxanthines|group
DDI-DrugBank.d395.s4|23-28|levels|group
DDI-DrugBank.d395.s5|25-31|effects|group
DDI-DrugBank.d395.s5|50-57|patients|group
DDI-DrugBank.d395.s6|0-11|Cyclosporine|drug
DDI-DrugBank.d395.s6|29-34|levels|group
DDI-DrugBank.d395.s6|39-50|cyclosporine|drug
DDI-DrugBank.d395.s6|39-50|cyclosporine|drug
DDI-DrugBank.d395.s6|119-125|members|group
DDI-DrugBank.d395.s6|144-148|class|group
DDI-DrugBank.d395.s7|0-6|Digoxin|drug
DDI-DrugBank.d395.s7|34-40|digoxin|drug
DDI-DrugBank.d395.s7|42-47|levels|group
DDI-DrugBank.d395.s7|57-67|individuals|group
DDI-DrugBank.d395.s8|3-7|signs|group
DDI-DrugBank.d395.s8|13-20|symptoms|group
DDI-DrugBank.d395.s8|36-42|digoxin|drug
DDI-DrugBank.d395.s8|36-42|digoxin|drug
DDI-DrugBank.d395.s8|110-119|physicians|group
DDI-DrugBank.d395.s8|36-42|digoxin|drug
DDI-DrugBank.d395.s8|157-162|levels|group
DDI-DrugBank.d395.s8|36-42|digoxin|drug
DDI-DrugBank.d395.s8|183-187|doses|group
DDI-DrugBank.d395.s9|32-37|agents|group
DDI-DrugBank.d395.s9|40-47|Seizures|group
DDI-DrugBank.d395.s9|71-78|patients|group
DDI-DrugBank.d395.s9|119-130|nonsteroidal|group
DDI-DrugBank.d395.s10|7-13|studies|group
DDI-DrugBank.d395.s10|55-62|seizures|group
DDI-DrugBank.d395.s10|79-83|drugs|group
DDI-DrugBank.d395.s11|39-44|States|group
DDI-DrugBank.d395.s12|15-22|antacids|group
DDI-DrugBank.d395.s12|25-34|Quinolones|group
DDI-DrugBank.d395.s12|41-48|chelates|group
DDI-DrugBank.d395.s12|61-67|cations|group
DDI-DrugBank.d395.s13|29-38|quinolones|group
DDI-DrugBank.d395.s13|45-52|antacids|group
DDI-DrugBank.d395.s15|27-33|cations|group
DDI-DrugBank.d395.s16|8-20|multivitamins|group
DDI-DrugBank.d395.s16|142-155|concentrations|group
DDI-DrugBank.d395.s17|0-7|Antacids|group
DDI-DrugBank.d395.s18|80-89|ranitidine|drug
DDI-DrugBank.d395.s19|6-11|agents|group
DDI-DrugBank.d395.s19|39-43|hours|group
DDI-DrugBank.d395.s19|39-43|hours|group
DDI-DrugBank.d395.s20|35-43|inhibitor|group
DDI-DrugBank.d395.s20|69-76|isozymes|group
DDI-DrugBank.d395.s20|112-126|methylxanthines|group
DDI-DrugBank.d395.s21|9-18|interferes|group
DDI-DrugBank.d395.s21|191-196|levels|group
DDI-DrugBank.d395.s22|29-35|effects|group
DDI-DrugBank.d395.s22|54-61|patients|group
DDI-DrugBank.d395.s23|0-7|Warfarin|drug
DDI-DrugBank.d395.s23|10-19|Quinolones|group
DDI-DrugBank.d395.s23|84-87|less|group
DDI-DrugBank.d395.s23|70-77|warfarin|drug
DDI-DrugBank.d395.s24|67-73|changes|group
DDI-DrugBank.d395.s24|133-140|warfarin|drug
DDI-DrugBank.d395.s25|0-11|Nevertheless|group
DDI-DrugBank.d395.s25|53-63|coagulation|group
DDI-DrugBank.d395.s25|95-102|warfarin|drug
DDI-DrugBank.d395.s25|111-121|derivatives|group
DDI-DrugBank.d630.s0|45-52|patients|group
DDI-DrugBank.d630.s0|57-63|steroid|group
DDI-DrugBank.d630.s1|23-30|patients|group
DDI-DrugBank.d630.s1|226-235|inhibitors|group
DDI-MedLine.d164.s0|10-17|enhances|group
DDI-MedLine.d164.s1|153-160|patients|group
DDI-MedLine.d164.s1|328-333|agents|group
DDI-MedLine.d164.s2|27-35|interacts|group
DDI-MedLine.d164.s2|102-106|focus|group
DDI-MedLine.d164.s2|172-175|ADCC|brand
DDI-MedLine.d164.s3|112-116|lines|group
DDI-MedLine.d164.s3|168-171|ADCC|brand
DDI-MedLine.d164.s4|152-157|tumors|group
DDI-MedLine.d164.s5|88-93|tumors|group
DDI-DrugBank.d704.s0|10-21|Interactions|group
DDI-DrugBank.d704.s0|64-75|interactions|group
DDI-DrugBank.d704.s0|85-90|FLOMAX|brand
DDI-DrugBank.d704.s0|92-99|capsules|group
DDI-DrugBank.d704.s0|128-135|blocking|group
DDI-DrugBank.d704.s0|137-142|agents|group
DDI-DrugBank.d704.s1|9-20|interactions|group
DDI-DrugBank.d704.s1|42-47|FLOMAX|brand
DDI-DrugBank.d704.s1|49-56|capsules|group
DDI-DrugBank.d704.s1|120-127|blocking|group
DDI-DrugBank.d704.s1|129-134|agents|group
DDI-DrugBank.d704.s2|40-49|cimetidine|drug
DDI-DrugBank.d704.s2|55-60|FLOMAX|brand
DDI-DrugBank.d704.s2|62-69|capsules|group
DDI-DrugBank.d704.s3|4-10|results|group
DDI-DrugBank.d704.s3|33-39|changes|group
DDI-DrugBank.d704.s4|11-16|FLOMAX|brand
DDI-DrugBank.d704.s4|18-25|capsules|group
DDI-DrugBank.d704.s4|75-84|cimetidine|drug
DDI-DrugBank.d704.s4|103-107|doses|group
DDI-DrugBank.d704.s5|0-6|Results|group
DDI-DrugBank.d704.s5|64-70|studies|group
DDI-DrugBank.d704.s5|99-106|warfarin|drug
DDI-DrugBank.d704.s6|74-81|warfarin|drug
DDI-DrugBank.d704.s6|87-92|FLOMAX|brand
DDI-DrugBank.d704.s6|94-101|capsules|group
DDI-DrugBank.d141.s0|18-22|Drugs|group
DDI-DrugBank.d141.s0|37-47|Derivatives|group
DDI-DrugBank.d141.s0|74-85|Erythromycin|drug
DDI-DrugBank.d141.s0|94-104|Antifungals|group
DDI-DrugBank.d141.s1|0-6|ANTACID|brand
DDI-DrugBank.d141.s1|60-73|concentrations|group
DDI-DrugBank.d141.s2|32-45|concentrations|group
DDI-DrugBank.d141.s2|89-98|cimetidine|drug
DDI-DrugBank.d141.s3|0-13|CHOLESTYRAMINE|brand
DDI-DrugBank.d141.s3|59-63|agent|group
DDI-DrugBank.d141.s3|65-78|cholestyramine|drug
DDI-DrugBank.d141.s3|87-102|pharmacokinetits|group
DDI-DrugBank.d141.s3|155-159|males|group
DDI-DrugBank.d141.s3|196-202|studies|group
DDI-DrugBank.d141.s4|86-99|cholestyramine|drug
DDI-DrugBank.d141.s4|113-121|decreases|group
DDI-DrugBank.d141.s5|53-66|cholestyramine|drug
DDI-DrugBank.d141.s5|146-150|hours|group
DDI-DrugBank.d141.s5|230-233|less|group
DDI-DrugBank.d141.s6|99-112|cholestyramine|drug
DDI-DrugBank.d141.s7|0-6|DIGOXIN|brand
DDI-DrugBank.d141.s7|16-22|digoxin|drug
DDI-DrugBank.d141.s7|24-29|levels|group
DDI-DrugBank.d141.s7|16-22|digoxin|drug
DDI-DrugBank.d141.s8|20-33|concentrations|group
DDI-DrugBank.d141.s8|82-88|digoxin|drug
DDI-DrugBank.d141.s9|0-7|WARFARIN|brand
DDI-DrugBank.d141.s9|32-39|warfarin|drug
DDI-DrugBank.d141.s9|69-78|volunteers|group
DDI-DrugBank.d141.s9|102-108|changes|group
DDI-DrugBank.d141.s9|32-39|warfarin|drug
DDI-DrugBank.d141.s10|41-47|isomers|group
DDI-DrugBank.d141.s10|52-59|warfarin|drug
DDI-DrugBank.d141.s11|21-28|warfarin|drug
DDI-DrugBank.d141.s11|65-80|pharmacokinetics|group
DDI-DrugBank.d141.s12|0-11|ERYTHROMYCIN|brand
DDI-DrugBank.d141.s12|38-45|patients|group
DDI-DrugBank.d141.s12|145-148|days|group
DDI-DrugBank.d141.s12|176-187|erythromycin|drug
DDI-DrugBank.d141.s12|198-206|inhibitor|group
DDI-DrugBank.d141.s13|0-4|OTHER|brand
DDI-DrugBank.d141.s13|6-16|CONCOMITANT|brand
DDI-DrugBank.d141.s13|18-24|THERAPY|brand
DDI-DrugBank.d141.s13|57-63|studies|group
DDI-DrugBank.d141.s13|57-63|studies|group
DDI-DrugBank.d141.s13|191-200|inhibitors|group
DDI-DrugBank.d141.s13|203-214|betablockers|group
DDI-DrugBank.d141.s13|207-214|blockers|group
DDI-DrugBank.d141.s13|243-251|diuretics|group
DDI-DrugBank.d141.s13|258-269|nonsteroidal|group
DDI-DrugBank.d141.s13|289-293|drugs|group
DDI-DrugBank.d141.s13|296-301|NSAIDs|group
DDI-DrugBank.d141.s13|355-366|interactions|group
DDI-DrugBank.d97.s0|16-24|inhibitor|group
DDI-DrugBank.d97.s1|20-27|CRIXIVAN|brand
DDI-DrugBank.d97.s1|33-37|drugs|group
DDI-DrugBank.d97.s1|102-115|concentrations|group
DDI-DrugBank.d97.s1|196-202|effects|group
DDI-DrugBank.d97.s3|0-4|Drugs|group
DDI-DrugBank.d97.s3|120-133|concentrations|group
DDI-DrugBank.d97.s4|20-27|CRIXIVAN|brand
DDI-DrugBank.d97.s4|39-43|drugs|group
DDI-DrugBank.d97.s4|50-56|inhibit|group
DDI-DrugBank.d97.s4|140-153|concentrations|group
DDI-DrugBank.d97.s6|0-4|Drugs|group
DDI-DrugBank.d97.s6|45-52|CRIXIVAN|brand
DDI-DrugBank.d97.s7|5-9|Class|group
DDI-DrugBank.d97.s8|0-14|Antiarrhythmics|group
DDI-DrugBank.d97.s9|0-14|CONTRAINDICATED|brand
DDI-DrugBank.d97.s9|37-43|serious|group
DDI-DrugBank.d97.s9|69-77|reactions|group
DDI-DrugBank.d97.s9|95-105|arrhythmias|group
DDI-DrugBank.d97.s10|6-16|derivatives|group
DDI-DrugBank.d97.s10|19-35|dihydroergotamine|drug
DDI-DrugBank.d97.s10|26-35|ergotamine|drug
DDI-DrugBank.d97.s10|62-77|methylergonovine|drug_n
DDI-DrugBank.d97.s11|0-14|CONTRAINDICATED|brand
DDI-DrugBank.d97.s11|37-43|serious|group
DDI-DrugBank.d97.s11|69-77|reactions|group
DDI-DrugBank.d97.s11|166-176|extremities|group
DDI-DrugBank.d97.s11|188-194|tissues|group
DDI-DrugBank.d97.s12|20-28|midazolam|drug
DDI-DrugBank.d97.s12|31-39|triazolam|drug
DDI-DrugBank.d97.s13|0-14|CONTRAINDICATED|brand
DDI-DrugBank.d97.s13|37-43|serious|group
DDI-DrugBank.d97.s13|69-77|reactions|group
DDI-DrugBank.d97.s14|12-17|agents|group
DDI-DrugBank.d97.s15|0-14|CONTRAINDICATED|brand
DDI-DrugBank.d97.s15|37-43|serious|group
DDI-DrugBank.d97.s15|69-77|reactions|group
DDI-DrugBank.d97.s15|95-105|arrhythmias|group
DDI-DrugBank.d97.s17|0-14|CONTRAINDICATED|brand
DDI-DrugBank.d97.s17|37-43|serious|group
DDI-DrugBank.d97.s17|69-77|reactions|group
DDI-DrugBank.d97.s17|95-105|arrhythmias|group
DDI-DrugBank.d97.s18|7-14|products|group
DDI-DrugBank.d97.s19|12-15|loss|group
DDI-DrugBank.d97.s19|66-73|CRIXIVAN|brand
DDI-DrugBank.d97.s19|85-89|class|group
DDI-DrugBank.d97.s19|103-112|inhibitors|group
DDI-DrugBank.d97.s21|12-15|loss|group
DDI-DrugBank.d97.s21|66-73|CRIXIVAN|brand
DDI-DrugBank.d97.s21|85-89|class|group
DDI-DrugBank.d97.s21|103-112|inhibitors|group
DDI-DrugBank.d97.s21|153-158|agents|group
DDI-DrugBank.d97.s22|18-27|inhibitors|group
DDI-DrugBank.d97.s23|14-20|serious|group
DDI-DrugBank.d97.s23|22-30|reactions|group
DDI-DrugBank.d97.s23|67-80|rhabdomyolysis|group
DDI-DrugBank.d97.s24|9-17|inhibitor|group
DDI-DrugBank.d97.s25|5-12|CRIXIVAN|brand
DDI-DrugBank.d97.s26|0-11|Combinations|group
DDI-DrugBank.d97.s26|22-26|drugs|group
DDI-DrugBank.d97.s26|74-81|CRIXIVAN|brand
DDI-DrugBank.d97.s28|51-62|Interactions|group
DDI-DrugBank.d97.s28|140-146|Studies|group
DDI-DrugBank.d97.s32|14-19|Agents|group
DDI-DrugBank.d97.s35|18-25|CRIXIVAN|brand
DDI-DrugBank.d97.s35|45-49|hours|group
DDI-DrugBank.d97.s35|109-113|times|group
DDI-DrugBank.d97.s37|25-36|formulations|group
DDI-DrugBank.d97.s41|49-53|hours|group
DDI-DrugBank.d97.s44|16-20|doses|group
DDI-DrugBank.d97.s45|0-9|Nevirapine|drug
DDI-DrugBank.d97.s47|10-23|concentrations|group
DDI-DrugBank.d97.s47|61-70|nevirapine|drug
DDI-DrugBank.d97.s48|16-20|doses|group
DDI-DrugBank.d97.s51|16-20|doses|group
DDI-DrugBank.d97.s52|56-70|nephrolithiasis|group
DDI-DrugBank.d97.s52|85-92|patients|group
DDI-DrugBank.d97.s52|165-172|CRIXIVAN|brand
DDI-DrugBank.d97.s55|16-20|doses|group
DDI-DrugBank.d97.s56|6-11|Agents|group
DDI-DrugBank.d97.s57|0-14|Antiarrhythmics|group
DDI-DrugBank.d97.s57|52-60|quinidine|drug
DDI-DrugBank.d97.s58|15-20|agents|group
DDI-DrugBank.d97.s59|81-95|antiarrhythmics|group
DDI-DrugBank.d97.s59|122-129|CRIXIVAN|brand
DDI-DrugBank.d97.s60|0-14|Anticonvulsants|group
DDI-DrugBank.d97.s60|17-29|carbamazepine|drug
DDI-DrugBank.d97.s60|47-55|phenytoin|drug
DDI-DrugBank.d97.s63|0-7|CRIXIVAN|brand
DDI-DrugBank.d97.s63|57-70|concentrations|group
DDI-DrugBank.d97.s63|75-82|patients|group
DDI-DrugBank.d97.s63|97-102|agents|group
DDI-DrugBank.d97.s64|16-23|Blockers|group
DDI-DrugBank.d97.s64|26-40|Dihydropyridine|drug
DDI-DrugBank.d97.s64|49-58|felodipine|drug
DDI-DrugBank.d97.s64|61-70|nifedipine|drug
DDI-DrugBank.d97.s64|73-83|nicardipine|drug
DDI-DrugBank.d97.s65|0-14|dihydropyridine|drug
DDI-DrugBank.d97.s65|32-39|blockers|group
DDI-DrugBank.d97.s66|48-55|patients|group
DDI-DrugBank.d97.s67|0-13|Clarithromycin|drug
DDI-DrugBank.d97.s68|0-13|clarithromycin|drug
DDI-DrugBank.d97.s69|16-20|doses|group
DDI-DrugBank.d97.s72|96-105|inhibitors|group
DDI-DrugBank.d97.s72|223-230|CRIXIVAN|brand
DDI-DrugBank.d97.s73|0-17|Immunosuppressants|group
DDI-DrugBank.d97.s73|20-31|cyclosporine|drug
DDI-DrugBank.d97.s73|34-43|tacrolimus|group
DDI-DrugBank.d97.s73|46-54|sirolimus|group
DDI-DrugBank.d97.s74|18-23|agents|group
DDI-DrugBank.d97.s75|7-20|concentrations|group
DDI-DrugBank.d97.s75|42-49|CRIXIVAN|brand
DDI-DrugBank.d97.s76|0-11|Itraconazole|drug
DDI-DrugBank.d97.s78|18-25|CRIXIVAN|brand
DDI-DrugBank.d97.s78|45-49|hours|group
DDI-DrugBank.d97.s78|85-96|itraconazole|drug
DDI-DrugBank.d97.s79|0-11|Ketoconazole|drug
DDI-DrugBank.d97.s81|18-25|CRIXIVAN|brand
DDI-DrugBank.d97.s81|45-49|hours|group
DDI-DrugBank.d97.s84|77-84|CRIXIVAN|brand
DDI-DrugBank.d97.s84|111-118|capsules|group
DDI-DrugBank.d97.s84|129-133|hours|group
DDI-DrugBank.d97.s84|77-84|CRIXIVAN|brand
DDI-DrugBank.d97.s87|77-84|patients|group
DDI-DrugBank.d97.s90|76-83|patients|group
DDI-DrugBank.d97.s93|77-84|patients|group
DDI-DrugBank.d397.s0|0-11|Erythromycin|drug
DDI-DrugBank.d397.s0|20-27|patients|group
DDI-DrugBank.d397.s0|52-56|doses|group
DDI-DrugBank.d397.s0|131-136|levels|group
DDI-DrugBank.d397.s1|68-73|levels|group
DDI-DrugBank.d397.s1|162-173|erythromycin|drug
DDI-DrugBank.d397.s2|30-41|erythromycin|drug
DDI-DrugBank.d397.s2|47-53|digoxin|drug
DDI-DrugBank.d397.s2|47-53|digoxin|drug
DDI-DrugBank.d397.s2|109-114|levels|group
DDI-DrugBank.d397.s3|16-22|reports|group
DDI-DrugBank.d397.s3|37-49|anticoagulant|group
DDI-DrugBank.d397.s3|51-57|effects|group
DDI-DrugBank.d397.s3|64-75|erythromycin|drug
DDI-DrugBank.d397.s3|86-99|anticoagulants|group
DDI-DrugBank.d397.s4|10-24|anticoagulation|group
DDI-DrugBank.d397.s4|26-32|effects|group
DDI-DrugBank.d397.s4|41-52|interactions|group
DDI-DrugBank.d397.s4|57-68|erythromycin|drug
DDI-DrugBank.d397.s4|75-81|various|group
DDI-DrugBank.d397.s4|88-101|anticoagulents|group
DDI-DrugBank.d397.s5|18-29|erythromycin|drug
DDI-DrugBank.d397.s5|35-44|ergotamine|drug
DDI-DrugBank.d397.s5|49-65|dihydroergotamine|drug
DDI-DrugBank.d397.s5|95-102|patients|group
DDI-DrugBank.d397.s6|0-11|Erythromycin|drug
DDI-DrugBank.d397.s6|60-68|triazolam|drug
DDI-DrugBank.d397.s6|74-82|midazolam|drug
DDI-DrugBank.d397.s6|88-91|thus|group
DDI-DrugBank.d397.s6|140-154|benzodiazepines|group
DDI-DrugBank.d397.s7|11-22|erythromycin|drug
DDI-DrugBank.d397.s7|27-34|patients|group
DDI-DrugBank.d397.s7|56-60|drugs|group
DDI-DrugBank.d397.s7|127-136|elevations|group
DDI-DrugBank.d397.s7|147-152|levels|group
DDI-DrugBank.d397.s7|56-60|drugs|group
DDI-DrugBank.d397.s8|16-22|reports|group
DDI-DrugBank.d397.s8|27-38|interactions|group
DDI-DrugBank.d397.s8|43-54|erythromycin|drug
DDI-DrugBank.d397.s8|61-73|carbamazepine|drug
DDI-DrugBank.d397.s8|76-87|cyclosporine|drug
DDI-DrugBank.d397.s8|90-99|tacrolimus|group
DDI-DrugBank.d397.s8|116-124|phenytoin|drug
DDI-DrugBank.d397.s8|176-188|bromocriptine|drug
DDI-DrugBank.d397.s9|6-19|concentrations|group
DDI-DrugBank.d397.s9|24-28|drugs|group
DDI-DrugBank.d397.s9|103-110|patients|group
DDI-DrugBank.d397.s9|135-146|erythromycin|drug
DDI-DrugBank.d397.s10|0-11|Erythromycin|drug
DDI-DrugBank.d397.s10|84-97|antihistamines|group
DDI-DrugBank.d397.s11|5-9|cases|group
DDI-DrugBank.d397.s11|14-20|serious|group
DDI-DrugBank.d397.s11|45-50|events|group
DDI-DrugBank.d397.s11|130-137|torsades|group
DDI-DrugBank.d397.s11|142-148|pointes|group
DDI-DrugBank.d397.s11|173-183|arrhythmias|group
DDI-DrugBank.d397.s12|13-18|deaths|group
DDI-DrugBank.d397.s12|97-108|erythromycin|drug
DDI-DrugBank.d397.s13|30-36|reports|group
DDI-DrugBank.d397.s13|46-57|interactions|group
DDI-DrugBank.d397.s13|64-75|erythromycin|drug
DDI-DrugBank.d397.s13|149-158|arrythmias|group
DDI-DrugBank.d397.s13|215-222|torsades|group
DDI-DrugBank.d397.s13|227-233|pointes|group
DDI-DrugBank.d397.s13|253-262|inhibition|group
DDI-DrugBank.d397.s13|64-75|erythromycin|drug
DDI-DrugBank.d397.s14|0-9|Fatalities|group
DDI-DrugBank.d397.s15|0-7|Patients|group
DDI-DrugBank.d397.s15|46-57|erythromycin|drug
DDI-DrugBank.d397.s16|0-4|cases|group
DDI-DrugBank.d397.s16|9-22|rhabdomyolysis|group
DDI-DrugBank.d397.s16|60-67|patients|group
DDI-DrugBank.d255.s0|29-40|interactions|group
DDI-DrugBank.d346.s0|0-6|Studies|group
DDI-DrugBank.d346.s0|29-40|interactions|group
DDI-DrugBank.d346.s0|50-54|REVIA|brand
DDI-DrugBank.d346.s0|60-64|drugs|group
DDI-DrugBank.d346.s0|77-83|opiates|group
DDI-DrugBank.d346.s1|70-74|REVIA|brand
DDI-DrugBank.d346.s1|86-90|drugs|group
DDI-DrugBank.d346.s2|46-50|REVIA|brand
DDI-DrugBank.d346.s2|134-144|medications|group
DDI-DrugBank.d346.s2|176-181|unless|group
DDI-DrugBank.d346.s2|196-203|benefits|group
DDI-DrugBank.d346.s2|224-228|risks|group
DDI-DrugBank.d346.s3|53-57|doses|group
DDI-DrugBank.d346.s3|62-66|REVIA|brand
DDI-DrugBank.d346.s4|0-7|Patients|group
DDI-DrugBank.d346.s4|16-20|REVIA|brand
DDI-DrugBank.d346.s4|61-69|medicines|group
DDI-DrugBank.d346.s4|95-106|preparations|group
DDI-DrugBank.d346.s4|95-106|preparations|group
DDI-DrugBank.d346.s4|148-157|analgesics|group
DDI-DrugBank.d346.s5|92-96|REVIA|brand
DDI-MedLine.d74.s0|0-8|Responses|group
DDI-MedLine.d74.s0|38-45|pancreas|group
DDI-MedLine.d74.s1|40-47|hamsters|group
DDI-MedLine.d74.s2|24-30|effects|group
DDI-MedLine.d74.s2|41-46|agents|group
DDI-MedLine.d74.s2|126-135|pancreases|group
DDI-MedLine.d74.s2|168-175|hamsters|group
DDI-MedLine.d74.s2|192-198|various|group
DDI-MedLine.d74.s2|200-211|combinations|group
DDI-MedLine.d74.s3|68-76|diabetics|group
DDI-MedLine.d74.s3|82-88|normals|group
DDI-MedLine.d74.s4|89-92|less|group
DDI-MedLine.d74.s4|133-142|diabectics|group
DDI-MedLine.d74.s4|156-162|normals|group
DDI-MedLine.d74.s5|130-138|diabetics|group
DDI-MedLine.d74.s6|94-102|diabetics|group
DDI-MedLine.d74.s6|94-102|diabetics|group
DDI-MedLine.d74.s6|160-166|normals|group
DDI-MedLine.d74.s9|6-12|results|group
DDI-MedLine.d74.s9|86-93|responds|group
DDI-MedLine.d74.s10|0-3|This|group
DDI-MedLine.d74.s11|15-21|results|group
DDI-MedLine.d74.s11|82-86|cells|group
DDI-DrugBank.d744.s0|12-19|patients|group
DDI-DrugBank.d744.s0|26-33|diabetes|group
DDI-DrugBank.d744.s0|35-42|mellitus|group
DDI-DrugBank.d744.s0|96-101|agents|group
DDI-DrugBank.d744.s0|120-129|reductions|group
DDI-DrugBank.d744.s0|96-101|agents|group
DDI-DrugBank.d744.s0|196-203|SOMAVERT|brand
DDI-DrugBank.d744.s1|12-18|studies|group
DDI-DrugBank.d744.s1|21-28|patients|group
DDI-DrugBank.d744.s1|33-39|opioids|group
DDI-DrugBank.d744.s1|79-92|concentrations|group
DDI-DrugBank.d744.s1|21-28|patients|group
DDI-DrugBank.d744.s1|33-39|opioids|group
DDI-DrugBank.d65.s0|14-25|preparations|group
DDI-DrugBank.d65.s0|14-25|preparations|group
DDI-DrugBank.d549.s0|3-9|studies|group
DDI-DrugBank.d549.s0|21-30|volunteers|group
DDI-DrugBank.d549.s0|82-92|intravenous|group
DDI-DrugBank.d549.s0|114-123|nifedipine|drug
DDI-DrugBank.d549.s1|74-85|vasodilators|group
DDI-DrugBank.d549.s1|108-113|agents|group
DDI-DrugBank.d549.s2|15-22|inhibits|group
DDI-DrugBank.d549.s2|112-119|patients|group
DDI-DrugBank.d549.s2|135-148|anticoagulants|group
DDI-DrugBank.d549.s3|16-21|trials|group
DDI-DrugBank.d549.s3|60-73|anticoagulants|group
DDI-DrugBank.d549.s3|76-84|diuretics|group
DDI-DrugBank.d549.s3|95-104|glycosides|group
DDI-DrugBank.d549.s3|123-130|blockers|group
DDI-DrugBank.d549.s3|133-142|analgesics|group
DDI-DrugBank.d549.s3|145-156|antipyretics|group
DDI-DrugBank.d549.s3|159-170|nonsteroidal|group
DDI-DrugBank.d549.s3|172-189|antiinflammatories|group
DDI-DrugBank.d549.s3|192-206|corticosteroids|group
DDI-DrugBank.d549.s3|219-229|medications|group
DDI-DrugBank.d549.s4|0-10|Intravenous|group
DDI-DrugBank.d549.s4|54-69|pharmacokinetics|group
DDI-DrugBank.d549.s4|74-80|digoxin|drug
DDI-DrugBank.d549.s5|50-65|pharmacokinetics|group
DDI-DrugBank.d549.s6|18-24|studies|group
DDI-DrugBank.d549.s6|18-24|studies|group
DDI-DrugBank.d549.s6|106-115|inhibition|group
DDI-DrugBank.d44.s0|27-33|studies|group
DDI-DrugBank.d44.s0|60-66|RAPTIVA|brand
DDI-DrugBank.d44.s1|0-6|RAPTIVA|brand
DDI-DrugBank.d44.s1|56-60|drugs|group
DDI-DrugBank.d44.s2|36-43|vaccines|group
DDI-DrugBank.d44.s2|79-85|RAPTIVA|brand
DDI-DrugBank.d44.s3|21-32|Interactions|group
DDI-DrugBank.d44.s3|34-42|Increases|group
DDI-DrugBank.d44.s3|58-63|counts|group
DDI-DrugBank.d44.s3|145-151|RAPTIVA|brand
DDI-DrugBank.d694.s0|0-6|Digoxin|drug
DDI-DrugBank.d694.s0|124-130|digoxin|drug
DDI-DrugBank.d694.s0|188-191|days|group
DDI-DrugBank.d694.s1|0-7|Patients|group
DDI-DrugBank.d694.s1|19-25|digoxin|drug
DDI-DrugBank.d694.s2|24-30|digoxin|drug
DDI-DrugBank.d694.s2|35-41|JANUVIA|brand
DDI-DrugBank.d640.s0|0-8|Diuretics|group
DDI-DrugBank.d640.s0|21-30|reductions|group
DDI-DrugBank.d640.s0|63-70|patients|group
DDI-DrugBank.d640.s0|101-110|inhibitors|group
DDI-DrugBank.d640.s1|31-37|effects|group
DDI-DrugBank.d640.s1|44-50|UNIVASC|brand
DDI-DrugBank.d640.s1|118-121|days|group
DDI-DrugBank.d640.s1|44-50|UNIVASC|brand
DDI-DrugBank.d640.s2|10-20|Supplements|group
DDI-DrugBank.d640.s2|44-52|Diuretics|group
DDI-DrugBank.d640.s2|55-61|UNIVASC|brand
DDI-DrugBank.d640.s2|106-114|decreases|group
DDI-DrugBank.d640.s3|25-33|diuretics|group
DDI-DrugBank.d640.s3|89-99|supplements|group
DDI-DrugBank.d640.s3|124-133|inhibitors|group
DDI-DrugBank.d640.s4|38-43|agents|group
DDI-DrugBank.d640.s5|5-18|Anticoagulants|group
DDI-DrugBank.d640.s5|33-39|studies|group
DDI-DrugBank.d640.s5|46-53|warfarin|drug
DDI-DrugBank.d640.s5|119-132|concentrations|group
DDI-DrugBank.d640.s5|141-153|anticoagulant|group
DDI-DrugBank.d640.s5|141-153|anticoagulant|group
DDI-DrugBank.d640.s6|33-38|levels|group
DDI-DrugBank.d640.s6|44-51|symptoms|group
DDI-DrugBank.d640.s6|95-102|patients|group
DDI-DrugBank.d640.s6|118-127|inhibitors|group
DDI-DrugBank.d640.s7|6-10|drugs|group
DDI-DrugBank.d640.s7|92-97|levels|group
DDI-DrugBank.d640.s9|6-11|Agents|group
DDI-DrugBank.d640.s9|54-65|interactions|group
DDI-DrugBank.d640.s9|81-87|UNIVASC|brand
DDI-DrugBank.d640.s9|149-155|digoxin|drug
DDI-DrugBank.d640.s9|161-170|cimetidine|drug
DDI-DrugBank.d640.s10|0-6|UNIVASC|brand
DDI-DrugBank.d640.s10|37-42|trials|group
DDI-DrugBank.d640.s10|88-93|agents|group
DDI-DrugBank.d640.s10|96-104|diuretics|group
DDI-DrugBank.d640.s10|110-117|blockers|group
DDI-DrugBank.d640.s10|120-126|digoxin|drug
DDI-DrugBank.d640.s10|88-93|agents|group
DDI-DrugBank.d640.s10|88-93|agents|group
DDI-DrugBank.d640.s11|54-65|interactions|group
DDI-DrugBank.d168.s0|0-3|This|group
DDI-DrugBank.d168.s0|28-34|alcohol|drug
DDI-DrugBank.d168.s0|49-59|depressants|group
DDI-DrugBank.d168.s0|96-102|effects|group
DDI-DrugBank.d168.s0|120-130|medications|group
DDI-DrugBank.d168.s0|135-148|antihistamines|group
DDI-DrugBank.d168.s0|152-167|anticholinergics|group
DDI-DrugBank.d168.s0|120-130|medications|group
DDI-DrugBank.d168.s0|96-102|effects|group
DDI-DrugBank.d168.s0|120-130|medications|group
DDI-DrugBank.d168.s0|135-148|antihistamines|group
DDI-DrugBank.d168.s0|335-343|monoamine|drug
DDI-DrugBank.d168.s0|359-368|inhibitors|group
DDI-DrugBank.d168.s0|135-148|antihistamines|group
DDI-DrugBank.d168.s0|96-102|effects|group
DDI-DrugBank.d168.s0|135-148|antihistamines|group
DDI-DrugBank.d287.s0|50-57|patients|group
DDI-DrugBank.d287.s0|82-92|antagonists|group
DDI-DrugBank.d287.s0|136-147|disturbances|group
DDI-DrugBank.d287.s1|0-4|Drugs|group
DDI-DrugBank.d287.s1|31-37|effects|group
DDI-DrugBank.d287.s1|31-37|effects|group
DDI-DrugBank.d287.s2|57-63|effects|group
DDI-DrugBank.d287.s2|68-72|drugs|group
DDI-DrugBank.d287.s3|0-4|Drugs|group
DDI-DrugBank.d287.s3|12-18|inhibit|group
DDI-DrugBank.d287.s3|12-18|inhibit|group
DDI-DrugBank.d287.s4|42-52|individuals|group
DDI-DrugBank.d287.s4|118-125|previous|group
DDI-DrugBank.d287.s4|182-187|events|group
DDI-DrugBank.d287.s5|38-45|isozymes|group
DDI-DrugBank.d287.s5|95-103|inhibited|group
DDI-DrugBank.d17.s0|0-13|Anticoagulants|group
DDI-DrugBank.d17.s1|1-7|Effects|group
DDI-DrugBank.d17.s1|63-71|diuretics|group
DDI-DrugBank.d17.s2|7-17|adjustments|group
DDI-DrugBank.d17.s3|9-19|medications|group
DDI-DrugBank.d17.s4|10-18|diuretics|group
DDI-DrugBank.d17.s5|30-40|medications|group
DDI-DrugBank.d17.s6|17-27|medications|group
DDI-DrugBank.d17.s6|91-96|agents|group
DDI-DrugBank.d17.s6|133-141|relaxants|group
DDI-DrugBank.d17.s7|1-7|Effects|group
DDI-DrugBank.d17.s7|65-73|diuretics|group
DDI-DrugBank.d17.s8|7-17|adjustments|group
DDI-DrugBank.d17.s9|18-32|Corticosteroids|group
DDI-DrugBank.d17.s9|52-55|ACTH|brand
DDI-DrugBank.d17.s10|30-38|diuretics|group
DDI-DrugBank.d17.s11|8-17|glycosides|group
DDI-DrugBank.d17.s12|30-38|diuretics|group
DDI-DrugBank.d17.s12|71-79|digitalis|group
DDI-DrugBank.d17.s14|5-11|inhibit|group
DDI-DrugBank.d17.s14|57-65|diuretics|group
DDI-DrugBank.d17.s15|34-38|hours|group
DDI-DrugBank.d17.s16|0-12|Hypoglycemics|group
DDI-DrugBank.d17.s17|10-18|diuretics|group
DDI-DrugBank.d17.s17|44-49|levels|group
DDI-DrugBank.d17.s18|16-24|diabetics|group
DDI-DrugBank.d17.s18|61-71|medications|group
DDI-DrugBank.d17.s19|8-19|requirements|group
DDI-DrugBank.d17.s20|8-12|salts|group
DDI-DrugBank.d17.s21|30-38|diuretics|group
DDI-DrugBank.d17.s22|0-10|Methenamine|drug
DDI-DrugBank.d17.s23|1-13|Effectiveness|group
DDI-DrugBank.d17.s23|69-77|diuretics|group
DDI-DrugBank.d17.s24|0-11|Nonsteroidal|group
DDI-DrugBank.d17.s24|31-36|agents|group
DDI-DrugBank.d17.s25|9-16|patients|group
DDI-DrugBank.d17.s25|23-31|steroidal|group
DDI-DrugBank.d17.s25|51-55|agent|group
DDI-DrugBank.d17.s25|116-122|effects|group
DDI-DrugBank.d17.s25|165-173|diuretics|group
DDI-DrugBank.d17.s26|39-50|nonsteroidal|group
DDI-DrugBank.d17.s26|70-75|agents|group
DDI-DrugBank.d17.s27|0-13|Norepinephrine|drug
DDI-DrugBank.d17.s28|1-9|Thiazides|group
DDI-DrugBank.d17.s28|33-46|responsiveness|group
DDI-DrugBank.d17.s28|51-64|norepinephrine|drug
DDI-DrugBank.d17.s29|0-3|This|group
DDI-DrugBank.d17.s29|46-58|effectiveness|group
DDI-DrugBank.d17.s29|75-79|agent|group
DDI-DrugBank.d17.s31|10-14|drugs|group
DDI-DrugBank.d17.s31|33-46|responsiveness|group
DDI-DrugBank.d17.s32|0-9|DIAGNOSTIC|brand
DDI-DrugBank.d17.s32|11-22|INTERFERENCE|brand
DDI-DrugBank.d17.s32|50-56|effects|group
DDI-DrugBank.d17.s32|83-88|levels|group
DDI-DrugBank.d17.s32|107-114|patients|group
DDI-DrugBank.d17.s32|83-88|levels|group
DDI-DrugBank.d17.s32|83-88|levels|group
DDI-DrugBank.d17.s32|264-272|diuretics|group
DDI-DrugBank.d17.s32|325-329|tests|group
DDI-DrugBank.d17.s32|83-88|levels|group
DDI-DrugBank.d17.s32|83-88|levels|group
DDI-DrugBank.d17.s33|16-21|levels|group
DDI-DrugBank.d17.s33|46-53|patients|group
DDI-DrugBank.d17.s33|16-21|levels|group
DDI-DrugBank.d17.s33|115-123|Thiazides|group
DDI-DrugBank.d17.s33|168-172|tests|group
DDI-DrugBank.d252.s0|9-15|BETAGAN|brand
DDI-DrugBank.d252.s0|67-75|mydriasis|group
DDI-DrugBank.d252.s0|9-15|BETAGAN|brand
DDI-DrugBank.d252.s0|129-139|epinephrine|drug
DDI-DrugBank.d252.s1|87-94|patients|group
DDI-DrugBank.d252.s1|130-134|drugs|group
DDI-DrugBank.d252.s1|144-152|reserpine|drug
DDI-DrugBank.d252.s1|184-190|effects|group
DDI-DrugBank.d252.s2|0-7|Patients|group
DDI-DrugBank.d252.s2|35-42|blocking|group
DDI-DrugBank.d252.s2|44-49|agents|group
DDI-DrugBank.d252.s2|77-87|intravenous|group
DDI-DrugBank.d252.s2|97-107|antagonists|group
DDI-DrugBank.d252.s2|170-181|disturbances|group
DDI-DrugBank.d252.s3|3-10|patients|group
DDI-DrugBank.d252.s3|44-55|simultaneous|group
DDI-DrugBank.d252.s4|39-46|blocking|group
DDI-DrugBank.d252.s4|48-53|agents|group
DDI-DrugBank.d252.s4|60-68|digitalis|group
DDI-DrugBank.d252.s4|82-92|antagonists|group
DDI-DrugBank.d252.s4|112-118|effects|group
DDI-DrugBank.d252.s5|22-30|compounds|group
DDI-DrugBank.d252.s5|52-59|blocking|group
DDI-DrugBank.d252.s5|61-66|agents|group
DDI-DrugBank.d252.s5|98-104|effects|group
DDI-DrugBank.d252.s5|117-126|inhibition|group
DDI-DrugBank.d109.s0|27-36|Macrolides|group
DDI-DrugBank.d109.s0|49-60|Erythromycin|drug
DDI-MedLine.d132.s0|13-17|roles|group
DDI-MedLine.d132.s0|59-68|inhibitors|group
DDI-MedLine.d132.s1|64-72|inhibitor|group
DDI-MedLine.d132.s1|75-79|NNRTI|brand
DDI-MedLine.d132.s1|88-95|regimens|group
DDI-MedLine.d132.s1|128-135|concerns|group
DDI-MedLine.d132.s1|64-72|inhibitor|group
DDI-MedLine.d132.s1|189-200|disturbances|group
DDI-MedLine.d132.s1|226-231|shifts|group
DDI-MedLine.d132.s1|246-254|practices|group
DDI-MedLine.d132.s2|12-19|regimens|group
DDI-MedLine.d132.s2|38-47|advantages|group
DDI-MedLine.d132.s2|12-19|regimens|group
DDI-MedLine.d132.s2|188-199|interactions|group
DDI-MedLine.d132.s2|214-220|nervous|group
DDI-MedLine.d132.s3|34-39|trials|group
DDI-MedLine.d132.s3|82-87|agents|group
DDI-MedLine.d132.s3|101-110|nevirapine|drug
DDI-MedLine.d132.s4|19-28|nevirapine|drug
DDI-MedLine.d132.s4|97-101|weeks|group
DDI-MedLine.d132.s4|136-144|responses|group
DDI-MedLine.d132.s4|19-28|nevirapine|drug
DDI-MedLine.d132.s4|177-184|regimens|group
DDI-MedLine.d132.s5|38-47|nevirapine|drug
DDI-MedLine.d132.s6|28-35|patients|group
DDI-MedLine.d132.s6|53-57|loads|group
DDI-MedLine.d132.s6|105-112|regimens|group
DDI-MedLine.d132.s7|61-66|trials|group
DDI-MedLine.d132.s7|108-115|regimens|group
DDI-MedLine.d132.s7|126-133|patients|group
DDI-MedLine.d132.s8|50-57|regimens|group
DDI-MedLine.d132.s8|112-119|patients|group
DDI-MedLine.d132.s8|137-141|loads|group
DDI-MedLine.d132.s9|25-32|patients|group
DDI-MedLine.d132.s9|77-82|agents|group
DDI-MedLine.d132.s9|25-32|patients|group
DDI-MedLine.d132.s10|81-88|patients|group
DDI-MedLine.d132.s10|118-123|agents|group
DDI-MedLine.d132.s10|166-178|circumstances|group
DDI-MedLine.d132.s11|20-25|NNRTIs|group
DDI-MedLine.d132.s11|27-33|appears|group
DDI-MedLine.d132.s11|59-69|individuals|group
DDI-MedLine.d132.s11|97-103|studies|group
DDI-MedLine.d132.s11|133-138|events|group
DDI-MedLine.d132.s12|24-29|events|group
DDI-MedLine.d132.s12|36-41|NNRTIs|group
DDI-DrugBank.d371.s0|35-41|studies|group
DDI-DrugBank.d371.s0|64-75|interactions|group
DDI-DrugBank.d371.s0|80-87|TAXOTERE|brand
DDI-DrugBank.d371.s0|100-110|medications|group
DDI-DrugBank.d371.s1|9-15|studies|group
DDI-DrugBank.d371.s1|114-122|compounds|group
DDI-DrugBank.d371.s1|137-143|inhibit|group
DDI-DrugBank.d371.s1|197-208|cyclosporine|drug
DDI-DrugBank.d371.s1|224-235|ketoconazole|drug
DDI-DrugBank.d371.s1|238-249|erythromycin|drug
DDI-DrugBank.d371.s1|256-269|troleandomycin|drug
DDI-DrugBank.d371.s2|39-43|drugs|group
DDI-DrugBank.d371.s2|59-66|patients|group
DDI-DrugBank.d371.s2|78-85|TAXOTERE|brand
DDI-MedLine.d1.s0|28-36|disorders|group
DDI-MedLine.d1.s0|41-48|patients|group
DDI-MedLine.d1.s0|41-48|patients|group
DDI-MedLine.d1.s1|58-65|patients|group
DDI-MedLine.d1.s2|41-46|causes|group
DDI-MedLine.d1.s2|94-103|activities|group
DDI-MedLine.d1.s2|124-133|kilometers|group
DDI-MedLine.d1.s3|111-117|persons|group
DDI-MedLine.d1.s4|76-80|users|group
DDI-MedLine.d1.s5|33-40|patients|group
DDI-MedLine.d1.s5|60-67|nitrates|group
DDI-MedLine.d1.s5|60-67|nitrates|group
DDI-MedLine.d1.s6|3-14|interactions|group
DDI-MedLine.d1.s6|54-61|blockers|group
DDI-MedLine.d1.s6|72-82|antagonists|group
DDI-MedLine.d1.s6|103-111|diuretics|group
DDI-MedLine.d1.s6|121-130|inhibitors|group
DDI-MedLine.d1.s7|64-71|patients|group
DDI-MedLine.d1.s7|173-183|backgrounds|group
DDI-MedLine.d1.s8|45-51|factors|group
DDI-MedLine.d1.s9|0-7|Patients|group
DDI-DrugBank.d734.s0|9-17|diuretics|group
DDI-DrugBank.d734.s0|82-95|phenothiazines|group
DDI-DrugBank.d734.s1|17-23|effects|group
DDI-DrugBank.d734.s1|28-39|guanethidine|drug
DDI-DrugBank.d734.s1|53-61|compounds|group
DDI-DrugBank.d734.s1|88-101|phenothiazines|group
DDI-DrugBank.d734.s2|30-40|propranolol|drug
DDI-DrugBank.d734.s2|47-60|phenothiazines|group
DDI-DrugBank.d734.s2|62-68|results|group
DDI-DrugBank.d734.s2|90-95|levels|group
DDI-DrugBank.d734.s2|105-109|drugs|group
DDI-DrugBank.d227.s0|11-21|potentiates|group
DDI-DrugBank.d227.s0|64-72|relaxants|group
DDI-DrugBank.d227.s0|64-72|relaxants|group
DDI-DrugBank.d227.s1|4-11|CLINICAL|brand
DDI-DrugBank.d227.s1|13-24|PHARMACOLOGY|brand
DDI-MedLine.d138.s0|136-139|rats|group
DDI-MedLine.d138.s1|20-28|exogenous|group
DDI-MedLine.d138.s1|34-43|endogenous|group
DDI-MedLine.d138.s1|170-173|rats|group
DDI-MedLine.d138.s3|7-11|basis|group
DDI-MedLine.d138.s3|20-29|principles|group
DDI-MedLine.d138.s3|44-57|concentrations|group
DDI-MedLine.d138.s3|68-75|hormones|group
DDI-MedLine.d138.s3|112-115|dogs|group
DDI-MedLine.d138.s3|141-144|days|group
DDI-MedLine.d43.s0|70-83|subpopulations|group
DDI-MedLine.d43.s0|105-109|cells|group
DDI-MedLine.d43.s1|44-49|events|group
DDI-MedLine.d43.s1|55-58|hits|group
DDI-MedLine.d43.s1|95-100|tumors|group
DDI-MedLine.d43.s1|114-119|agents|group
DDI-MedLine.d43.s2|109-117|apparatus|group
DDI-MedLine.d43.s3|0-7|Analyses|group
DDI-MedLine.d43.s3|113-127|characteristics|group
DDI-MedLine.d43.s3|146-151|tumors|group
DDI-MedLine.d43.s5|111-118|numerous|group
DDI-MedLine.d43.s5|126-131|tumors|group
DDI-MedLine.d43.s5|203-221|hepatotumorigenesis|group
DDI-MedLine.d43.s6|100-117|diethylnitrosamine|drug
DDI-MedLine.d43.s7|28-34|numbers|group
DDI-MedLine.d43.s7|56-60|types|group
DDI-MedLine.d43.s7|71-76|tumors|group
DDI-MedLine.d43.s7|86-91|livers|group
DDI-MedLine.d43.s7|163-170|stimulus|group
DDI-MedLine.d43.s8|0-5|Tumors|group
DDI-MedLine.d43.s9|6-13|findings|group
DDI-MedLine.d43.s9|58-64|results|group
DDI-MedLine.d43.s10|14-18|cells|group
DDI-MedLine.d43.s10|147-155|exogenous|group
DDI-MedLine.d43.s10|95-102|progress|group
DDI-DrugBank.d110.s0|39-47|solutions|group
DDI-DrugBank.d110.s0|60-70|epinephrine|drug
DDI-DrugBank.d110.s0|75-88|norepinephrine|drug
DDI-DrugBank.d110.s0|93-100|patients|group
DDI-DrugBank.d110.s0|112-120|monoamine|drug
DDI-DrugBank.d110.s0|130-139|inhibitors|group
DDI-DrugBank.d110.s0|152-166|antidepressants|group
DDI-DrugBank.d110.s0|171-184|phenothiazines|group
DDI-DrugBank.d110.s1|24-29|agents|group
DDI-DrugBank.d110.s2|3-12|situations|group
DDI-DrugBank.d110.s3|41-45|drugs|group
DDI-DrugBank.d110.s3|102-107|blocks|group
DDI-DrugBank.d110.s3|41-45|drugs|group
DDI-DrugBank.d110.s3|201-209|accidents|group
DDI-DrugBank.d110.s4|56-63|inhibits|group
DDI-DrugBank.d110.s4|79-90|sulfonamides|group
DDI-DrugBank.d107.s0|13-20|Patients|group
DDI-DrugBank.d107.s0|13-20|Patients|group
DDI-DrugBank.d107.s0|55-63|diuretics|group
DDI-DrugBank.d107.s1|31-37|effects|group
DDI-DrugBank.d107.s2|119-123|hours|group
DDI-DrugBank.d107.s3|0-5|Agents|group
DDI-DrugBank.d107.s3|121-126|agents|group
DDI-DrugBank.d107.s3|160-168|diuretics|group
DDI-DrugBank.d107.s4|32-37|Agents|group
DDI-DrugBank.d107.s4|48-55|patients|group
DDI-DrugBank.d107.s4|116-127|nonsteroidal|group
DDI-DrugBank.d107.s4|147-151|drugs|group
DDI-DrugBank.d107.s5|6-12|effects|group
DDI-DrugBank.d107.s6|92-99|patients|group
DDI-DrugBank.d107.s6|111-117|VASOTEC|brand
DDI-DrugBank.d107.s7|84-90|VASOTEC|brand
DDI-DrugBank.d107.s8|9-15|reports|group
DDI-DrugBank.d107.s8|30-35|NSAIDs|group
DDI-DrugBank.d107.s8|85-94|inhibitors|group
DDI-DrugBank.d107.s9|0-3|This|group
DDI-DrugBank.d107.s9|50-57|patients|group
DDI-DrugBank.d107.s9|66-71|NSAIDs|group
DDI-DrugBank.d107.s9|96-105|inhibitors|group
DDI-DrugBank.d107.s10|21-26|Agents|group
DDI-DrugBank.d107.s10|115-120|agents|group
DDI-DrugBank.d107.s10|123-132|methyldopa|drug_n
DDI-DrugBank.d107.s10|135-142|nitrates|group
DDI-DrugBank.d107.s10|115-120|agents|group
DDI-DrugBank.d107.s10|196-202|digoxin|drug
DDI-DrugBank.d107.s10|255-266|interactions|group
DDI-DrugBank.d107.s11|46-54|digitalis|group
DDI-DrugBank.d107.s11|107-115|reactions|group
DDI-DrugBank.d107.s12|0-5|Agents|group
DDI-DrugBank.d107.s12|82-85|loss|group
DDI-DrugBank.d107.s12|111-119|diuretics|group
DDI-DrugBank.d107.s13|18-26|diuretics|group
DDI-DrugBank.d107.s13|89-99|supplements|group
DDI-DrugBank.d107.s13|131-141|substitutes|group
DDI-DrugBank.d107.s13|167-175|increases|group
DDI-DrugBank.d107.s14|39-44|agents|group
DDI-DrugBank.d107.s15|18-23|agents|group
DDI-DrugBank.d107.s15|57-64|patients|group
DDI-DrugBank.d107.s16|47-54|patients|group
DDI-DrugBank.d107.s16|93-97|drugs|group
DDI-DrugBank.d107.s16|148-157|inhibitors|group
DDI-DrugBank.d107.s17|37-42|levels|group
DDI-MedLine.d59.s0|77-85|carbachol|drug
DDI-MedLine.d59.s1|42-47|glands|group
DDI-MedLine.d59.s2|19-24|glands|group
DDI-MedLine.d59.s2|31-39|carbachol|drug
DDI-MedLine.d59.s3|38-46|carbachol|drug
DDI-MedLine.d59.s3|121-130|inhibitors|group
DDI-MedLine.d59.s4|43-49|blocked|group
DDI-MedLine.d59.s4|75-83|carbachol|drug
DDI-MedLine.d59.s4|114-120|whereas|group
DDI-MedLine.d59.s5|15-23|inhibited|group
DDI-MedLine.d59.s6|17-22|glands|group
DDI-MedLine.d59.s6|173-181|membranes|group
DDI-MedLine.d59.s7|6-13|findings|group
DDI-MedLine.d59.s7|254-267|microfilaments|group
DDI-DrugBank.d237.s1|8-12|cases|group
DDI-DrugBank.d237.s1|20-26|serious|group
DDI-DrugBank.d237.s1|40-50|arrhythmias|group
DDI-DrugBank.d237.s1|74-81|torsades|group
DDI-DrugBank.d237.s1|86-92|pointes|group
DDI-DrugBank.d237.s1|184-193|inhibitors|group
DDI-DrugBank.d237.s1|221-226|levels|group
DDI-DrugBank.d237.s2|0-10|Antibiotics|group
DDI-DrugBank.d237.s2|52-65|clarithromycin|drug
DDI-DrugBank.d237.s2|68-79|erythromycin|drug
DDI-DrugBank.d237.s2|86-99|troleandomycin|drug
DDI-DrugBank.d237.s2|110-116|inhibit|group
DDI-DrugBank.d237.s2|199-204|levels|group
DDI-DrugBank.d237.s3|0-15|Anticholinergics|group
DDI-DrugBank.d237.s3|71-79|compounds|group
DDI-DrugBank.d237.s3|101-109|alkaloids|group
DDI-DrugBank.d237.s3|175-181|effects|group
DDI-DrugBank.d237.s4|0-13|Anticoagulants|group
DDI-DrugBank.d237.s4|26-33|patients|group
DDI-DrugBank.d237.s4|50-63|anticoagulants|group
DDI-DrugBank.d237.s4|70-80|coagulation|group
DDI-DrugBank.d237.s4|82-86|times|group
DDI-DrugBank.d237.s4|111-115|cases|group
DDI-DrugBank.d237.s5|25-35|coagulation|group
DDI-DrugBank.d237.s5|63-66|days|group
DDI-DrugBank.d237.s5|164-176|anticoagulant|group
DDI-DrugBank.d237.s6|0-14|Antidepressants|group
DDI-DrugBank.d237.s6|56-63|inhibits|group
DDI-DrugBank.d237.s6|146-151|levels|group
DDI-DrugBank.d237.s7|0-10|Antifungals|group
DDI-DrugBank.d237.s7|56-66|fluconazole|drug
DDI-DrugBank.d237.s7|69-80|itraconazole|drug
DDI-DrugBank.d237.s7|92-103|ketoconazole|drug
DDI-DrugBank.d237.s7|114-120|inhibit|group
DDI-DrugBank.d237.s7|203-208|levels|group
DDI-DrugBank.d237.s8|46-57|ketoconazole|drug
DDI-DrugBank.d237.s8|68-75|inhibits|group
DDI-DrugBank.d237.s9|37-46|volunteers|group
DDI-DrugBank.d237.s9|48-55|suggests|group
DDI-DrugBank.d237.s9|96-107|ketoconazole|drug
DDI-DrugBank.d237.s10|12-22|Antagonists|group
DDI-DrugBank.d237.s10|25-34|Cimetidine|drug
DDI-DrugBank.d237.s10|53-57|leads|group
DDI-DrugBank.d237.s10|197-206|ranitidine|drug
DDI-DrugBank.d237.s11|35-44|cimetidine|drug
DDI-DrugBank.d237.s11|50-59|ranitidine|drug
DDI-DrugBank.d237.s12|9-18|Inhibitors|group
DDI-DrugBank.d237.s12|82-88|inhibit|group
DDI-DrugBank.d237.s12|170-175|levels|group
DDI-DrugBank.d237.s13|59-67|increases|group
DDI-DrugBank.d237.s14|54-58|drugs|group
DDI-DrugBank.d237.s14|102-116|antiarrhythmics|group
DDI-DrugBank.d237.s14|138-142|Class|group
DDI-DrugBank.d237.s14|156-164|quinidine|drug
DDI-DrugBank.d237.s14|138-142|Class|group
DDI-DrugBank.d237.s14|207-213|sotalol|drug
DDI-DrugBank.d237.s15|10-24|antidepressants|group
DDI-DrugBank.d237.s16|20-34|antidepressants|group
DDI-DrugBank.d237.s17|22-32|medications|group
DDI-DrugBank.d237.s19|14-18|lists|group
DDI-DrugBank.d237.s19|23-27|drugs|group
DDI-DrugBank.d237.s20|95-99|drugs|group
DDI-DrugBank.d237.s21|0-7|Patients|group
DDI-DrugBank.d237.s21|44-48|drugs|group
DDI-DrugBank.d237.s21|44-48|drugs|group
DDI-DrugBank.d237.s22|10-15|levels|group
DDI-DrugBank.d446.s0|35-49|antidepressants|group
DDI-DrugBank.d446.s0|61-72|barbiturates|group
DDI-DrugBank.d446.s0|75-87|bromocriptine|drug
DDI-DrugBank.d446.s0|98-108|supplements|group
DDI-DrugBank.d446.s0|111-125|corticosteroids|group
DDI-DrugBank.d446.s0|143-154|cyclosporine|drug
DDI-DrugBank.d446.s0|169-176|nicotine|drug
DDI-DrugBank.d446.s0|206-213|warfarin|drug
DDI-DrugBank.d514.s0|0-6|Opioids|group
DDI-DrugBank.d514.s0|27-33|nervous|group
DDI-DrugBank.d514.s0|42-52|depressants|group
DDI-DrugBank.d514.s0|67-71|users|group
DDI-DrugBank.d514.s0|134-140|dosages|group
DDI-DrugBank.d514.s1|34-40|nervous|group
DDI-DrugBank.d514.s1|49-59|depressants|group
DDI-DrugBank.d514.s1|101-105|users|group
DDI-DrugBank.d514.s2|11-17|studies|group
DDI-DrugBank.d514.s2|37-42|deaths|group
DDI-DrugBank.d514.s2|89-95|nervous|group
DDI-DrugBank.d514.s2|104-114|depressants|group
DDI-DrugBank.d514.s2|127-133|alcohol|drug
DDI-DrugBank.d514.s2|136-150|benzodiazepines|group
DDI-DrugBank.d514.s2|160-167|diazepam|drug
DDI-DrugBank.d514.s3|12-26|benzodiazepines|group
DDI-DrugBank.d514.s3|125-132|symptoms|group
DDI-DrugBank.d514.s4|8-16|sometimes|group
DDI-DrugBank.d514.s4|18-23|proves|group
DDI-MedLine.d73.s0|29-40|consequences|group
DDI-MedLine.d73.s0|98-101|MPTP|brand
DDI-MedLine.d73.s0|108-122|methamphetamine|drug
DDI-MedLine.d73.s1|33-44|consequences|group
DDI-MedLine.d73.s1|56-59|MPTP|brand
DDI-MedLine.d73.s1|126-132|effects|group
DDI-MedLine.d73.s1|144-158|methamphetamine|drug
DDI-MedLine.d73.s2|21-24|MPTP|brand
DDI-MedLine.d73.s2|47-56|depletions|group
DDI-MedLine.d73.s2|70-77|dopamine|drug
DDI-MedLine.d73.s2|79-92|concentrations|group
DDI-MedLine.d73.s3|72-78|effects|group
DDI-MedLine.d73.s3|83-93|amphetamine|drug
DDI-MedLine.d73.s3|72-78|effects|group
DDI-MedLine.d73.s3|162-165|rats|group
DDI-MedLine.d73.s4|0-14|Methamphetamine|drug
DDI-MedLine.d73.s4|22-25|MPTP|brand
DDI-MedLine.d73.s4|37-46|depletions|group
DDI-MedLine.d73.s4|60-67|dopamine|drug
DDI-MedLine.d73.s4|79-85|actions|group
DDI-MedLine.d73.s5|6-17|observations|group
DDI-MedLine.d73.s5|58-68|deleterious|group
DDI-MedLine.d73.s5|70-76|effects|group
DDI-MedLine.d73.s5|123-130|patients|group
DDI-DrugBank.d416.s0|16-27|measurements|group
DDI-DrugBank.d416.s0|84-91|patients|group
DDI-DrugBank.d416.s0|103-114|sulfonamides|group
DDI-DrugBank.d416.s1|6-14|compounds|group
DDI-DrugBank.d416.s1|86-95|procedures|group
DDI-DrugBank.d416.s2|11-19|depresses|group
DDI-DrugBank.d416.s2|55-59|acids|group
DDI-DrugBank.d416.s3|11-18|patients|group
DDI-DrugBank.d416.s3|67-70|ERPF|brand
DDI-DrugBank.d416.s3|83-88|values|group
DDI-MedLine.d23.s0|4-10|effects|group
DDI-MedLine.d23.s0|15-22|ketamine|drug
DDI-MedLine.d23.s0|53-61|digitalis|group
DDI-MedLine.d23.s0|76-79|dogs|group
DDI-MedLine.d23.s1|19-27|digitalis|group
DDI-MedLine.d23.s1|42-45|dogs|group
DDI-MedLine.d23.s1|65-72|ketamine|drug
DDI-MedLine.d23.s1|65-72|ketamine|drug
DDI-MedLine.d23.s2|70-74|sinus|group
DDI-MedLine.d23.s2|120-127|ketamine|drug
DDI-DrugBank.d759.s0|17-24|suggests|group
DDI-DrugBank.d759.s0|99-116|bishydroxycoumarin|drug
DDI-DrugBank.d339.s0|0-12|Carbamazepine|drug
DDI-DrugBank.d339.s0|24-36|carbamazepine|drug
DDI-DrugBank.d339.s0|38-43|levels|group
DDI-DrugBank.d339.s0|97-102|SUPRAX|brand
DDI-DrugBank.d339.s1|50-60|alterations|group
DDI-DrugBank.d339.s1|65-77|carbamazepine|drug
DDI-DrugBank.d339.s1|86-99|concentrations|group
DDI-DrugBank.d339.s2|0-7|Warfarin|drug
DDI-DrugBank.d339.s2|13-26|Anticoagulants|group
DDI-DrugBank.d339.s3|21-32|Interactions|group
DDI-DrugBank.d339.s3|64-70|ketones|group
DDI-DrugBank.d339.s3|100-104|tests|group
DDI-DrugBank.d339.s4|22-27|SUPRAX|brand
DDI-DrugBank.d339.s5|31-35|tests|group
DDI-DrugBank.d339.s5|72-80|reactions|group
DDI-DrugBank.d339.s6|24-29|Coombs|group
DDI-DrugBank.d339.s6|96-106|antibiotics|group
DDI-DrugBank.d339.s7|51-56|Coombs|group
DDI-DrugBank.d776.s0|43-54|interactions|group
DDI-DrugBank.d776.s0|64-71|DIFLUCAN|brand
DDI-DrugBank.d776.s1|45-52|DIFLUCAN|brand
DDI-DrugBank.d776.s2|51-63|hypoglycemics|group
DDI-DrugBank.d776.s2|80-93|anticoagulants|group
DDI-DrugBank.d776.s2|96-104|Phenytoin|drug
DDI-DrugBank.d776.s2|107-118|Cyclosporine|drug
DDI-DrugBank.d776.s2|192-201|Tacrolimus|group
DDI-DrugBank.d776.s2|217-231|benzodiazepines|group
DDI-DrugBank.d776.s2|51-63|hypoglycemics|group
DDI-DrugBank.d776.s2|325-332|DIFLUCAN|brand
DDI-DrugBank.d776.s2|357-362|agents|group
DDI-DrugBank.d776.s3|78-85|DIFLUCAN|brand
DDI-DrugBank.d776.s4|0-7|DIFLUCAN|brand
DDI-DrugBank.d776.s4|9-15|reduces|group
DDI-DrugBank.d776.s4|77-85|increases|group
DDI-DrugBank.d776.s4|121-126|agents|group
DDI-DrugBank.d776.s5|5-12|DIFLUCAN|brand
DDI-DrugBank.d776.s5|87-92|agents|group
DDI-DrugBank.d776.s5|109-122|concentrations|group
DDI-DrugBank.d776.s6|14-27|anticoagulants|group
DDI-DrugBank.d776.s6|67-74|patients|group
DDI-DrugBank.d776.s6|98-105|DIFLUCAN|brand
DDI-DrugBank.d776.s6|14-27|anticoagulants|group
DDI-DrugBank.d776.s7|44-48|azole|drug
DDI-DrugBank.d776.s7|50-60|antifungals|group
DDI-DrugBank.d776.s7|72-77|events|group
DDI-DrugBank.d776.s7|90-98|epistaxis|group
DDI-DrugBank.d776.s7|190-198|increases|group
DDI-DrugBank.d776.s7|223-230|patients|group
DDI-DrugBank.d776.s7|242-252|fluconazole|drug
DDI-DrugBank.d776.s7|272-279|warfarin|drug
DDI-DrugBank.d776.s8|42-49|patients|group
DDI-DrugBank.d776.s8|61-68|DIFLUCAN|brand
DDI-DrugBank.d776.s8|88-101|anticoagulants|group
DDI-DrugBank.d776.s9|33-40|CLINICAL|brand
DDI-DrugBank.d776.s9|42-53|PHARMACOLOGY|brand
DDI-DrugBank.d776.s9|73-79|Studies|group
DDI-DrugBank.d776.s10|0-8|Phenytoin|drug
DDI-DrugBank.d776.s10|11-18|DIFLUCAN|brand
DDI-DrugBank.d776.s10|20-28|increases|group
DDI-DrugBank.d776.s10|41-54|concentrations|group
DDI-DrugBank.d776.s10|59-67|phenytoin|drug
DDI-DrugBank.d776.s11|22-30|phenytoin|drug
DDI-DrugBank.d776.s11|32-45|concentrations|group
DDI-DrugBank.d776.s11|50-57|patients|group
DDI-DrugBank.d776.s11|69-76|DIFLUCAN|brand
DDI-DrugBank.d776.s11|22-30|phenytoin|drug
DDI-DrugBank.d776.s12|33-40|CLINICAL|brand
DDI-DrugBank.d776.s12|42-53|PHARMACOLOGY|brand
DDI-DrugBank.d776.s12|73-79|Studies|group
DDI-DrugBank.d776.s13|0-11|Cyclosporine|drug
DDI-DrugBank.d776.s13|14-21|DIFLUCAN|brand
DDI-DrugBank.d776.s13|50-61|cyclosporine|drug
DDI-DrugBank.d776.s13|63-68|levels|group
DDI-DrugBank.d776.s13|90-97|patients|group
DDI-DrugBank.d776.s14|22-33|cyclosporine|drug
DDI-DrugBank.d776.s14|35-48|concentrations|group
DDI-DrugBank.d776.s14|89-96|patients|group
DDI-DrugBank.d776.s14|108-115|DIFLUCAN|brand
DDI-DrugBank.d776.s14|22-33|cyclosporine|drug
DDI-DrugBank.d776.s15|5-12|CLINICAL|brand
DDI-DrugBank.d776.s15|14-25|PHARMACOLOGY|brand
DDI-DrugBank.d776.s15|45-51|Studies|group
DDI-DrugBank.d776.s16|19-26|enhances|group
DDI-DrugBank.d776.s16|72-79|DIFLUCAN|brand
DDI-DrugBank.d776.s17|22-34|circumstances|group
DDI-DrugBank.d776.s17|93-100|DIFLUCAN|brand
DDI-DrugBank.d776.s18|14-21|DIFLUCAN|brand
DDI-DrugBank.d776.s18|23-31|increases|group
DDI-DrugBank.d776.s18|43-56|concentrations|group
DDI-DrugBank.d776.s19|41-54|concentrations|group
DDI-DrugBank.d776.s19|59-66|patients|group
DDI-DrugBank.d776.s19|78-85|DIFLUCAN|brand
DDI-DrugBank.d776.s20|42-48|serious|group
DDI-DrugBank.d776.s20|58-69|dysrhythmias|group
DDI-DrugBank.d776.s20|120-127|patients|group
DDI-DrugBank.d776.s20|139-143|azole|drug
DDI-DrugBank.d776.s20|145-155|antifungals|group
DDI-DrugBank.d776.s20|202-208|studies|group
DDI-DrugBank.d776.s21|36-46|fluconazole|drug
DDI-DrugBank.d776.s22|51-61|fluconazole|drug
DDI-DrugBank.d776.s22|81-88|DIFLUCAN|brand
DDI-DrugBank.d776.s22|99-103|doses|group
DDI-DrugBank.d776.s22|148-156|increases|group
DDI-DrugBank.d776.s22|165-170|levels|group
DDI-DrugBank.d776.s23|20-30|fluconazole|drug
DDI-DrugBank.d776.s23|35-39|doses|group
DDI-DrugBank.d776.s24|24-34|fluconazole|drug
DDI-DrugBank.d776.s24|39-43|doses|group
DDI-DrugBank.d776.s25|27-33|reports|group
DDI-DrugBank.d776.s25|46-51|events|group
DDI-DrugBank.d776.s25|75-81|pointes|group
DDI-DrugBank.d776.s25|86-93|patients|group
DDI-DrugBank.d776.s25|103-113|fluconazole|drug
DDI-DrugBank.d776.s26|42-52|fluconazole|drug
DDI-DrugBank.d776.s26|97-101|times|group
DDI-DrugBank.d776.s26|160-165|levels|group
DDI-DrugBank.d776.s27|20-30|fluconazole|drug
DDI-DrugBank.d776.s28|23-33|fluconazole|drug
DDI-DrugBank.d776.s28|38-45|patients|group
DDI-DrugBank.d776.s28|87-91|drugs|group
DDI-DrugBank.d776.s28|158-167|elevations|group
DDI-DrugBank.d776.s28|178-183|levels|group
DDI-DrugBank.d776.s28|87-91|drugs|group
DDI-DrugBank.d776.s29|86-96|fluconazole|drug
DDI-DrugBank.d776.s30|0-7|Patients|group
DDI-DrugBank.d776.s31|27-33|reports|group
DDI-DrugBank.d776.s31|38-44|uveitis|group
DDI-DrugBank.d776.s31|49-56|patients|group
DDI-DrugBank.d776.s31|66-76|fluconazole|drug
DDI-DrugBank.d776.s32|0-7|Patients|group
DDI-DrugBank.d776.s32|33-43|fluconazole|drug
DDI-DrugBank.d776.s33|0-9|Tacrolimus|group
DDI-DrugBank.d776.s33|28-34|reports|group
DDI-DrugBank.d776.s33|57-64|patients|group
DDI-DrugBank.d776.s33|74-84|fluconazole|drug
DDI-DrugBank.d776.s33|90-99|tacrolimus|group
DDI-DrugBank.d776.s34|0-7|Patients|group
DDI-DrugBank.d776.s34|19-28|tacrolimus|group
DDI-DrugBank.d776.s34|34-44|fluconazole|drug
DDI-DrugBank.d776.s35|13-27|Benzodiazepines|group
DDI-DrugBank.d776.s35|63-71|midazolam|drug
DDI-DrugBank.d776.s35|74-84|fluconazole|drug
DDI-DrugBank.d776.s35|110-118|increases|group
DDI-DrugBank.d776.s35|63-71|midazolam|drug
DDI-DrugBank.d776.s35|133-146|concentrations|group
DDI-DrugBank.d776.s35|164-170|effects|group
DDI-DrugBank.d776.s36|0-3|This|group
DDI-DrugBank.d776.s36|15-23|midazolam|drug
DDI-DrugBank.d776.s36|25-31|appears|group
DDI-DrugBank.d776.s36|88-98|fluconazole|drug
DDI-DrugBank.d776.s36|88-98|fluconazole|drug
DDI-DrugBank.d776.s37|16-30|benzodiazepines|group
DDI-DrugBank.d776.s37|122-132|fluconazole|drug
DDI-DrugBank.d776.s37|16-29|benzodiazepine|drug
DDI-DrugBank.d776.s37|214-221|patients|group
DDI-DrugBank.d776.s38|0-10|Fluconazole|drug
DDI-DrugBank.d776.s38|12-18|tablets|group
DDI-DrugBank.d776.s38|94-107|contraceptives|group
DDI-DrugBank.d776.s38|183-188|levels|group
DDI-DrugBank.d776.s39|17-24|patients|group
DDI-DrugBank.d776.s39|37-45|decreases|group
DDI-DrugBank.d776.s39|105-110|levels|group
DDI-DrugBank.d776.s40|47-55|decreases|group
DDI-DrugBank.d776.s40|117-122|values|group
DDI-DrugBank.d776.s40|129-139|fluconazole|drug
DDI-DrugBank.d776.s41|29-39|fluconazole|drug
DDI-DrugBank.d776.s41|45-51|inhibit|group
DDI-DrugBank.d776.s41|29-39|fluconazole|drug
DDI-DrugBank.d776.s42|35-41|effects|group
DDI-DrugBank.d776.s43|0-9|Physicians|group
DDI-DrugBank.d776.s43|44-50|studies|group
DDI-DrugBank.d776.s43|57-67|medications|group
DDI-DrugBank.d776.s43|128-135|CLINICAL|brand
DDI-DrugBank.d776.s43|137-148|PHARMACOLOGY|brand
DDI-DrugBank.d776.s43|192-203|interactions|group
DDI-DrugBank.d30.s0|41-52|interactions|group
DDI-DrugBank.d30.s0|85-91|studies|group
DDI-DrugBank.d30.s0|119-125|digoxin|drug
DDI-DrugBank.d30.s0|128-135|warfarin|drug
DDI-DrugBank.d30.s0|138-147|cimetidine|drug
DDI-DrugBank.d30.s1|55-68|concentrations|group
DDI-DrugBank.d30.s2|3-8|humans|group
DDI-DrugBank.d30.s2|15-24|inhibitors|group
DDI-DrugBank.d30.s3|0-11|Ketoconazole|drug
DDI-DrugBank.d30.s3|86-96|intravenous|group
DDI-DrugBank.d30.s3|130-141|erythromycin|drug
DDI-DrugBank.d30.s4|0-10|Fluconazole|drug
DDI-DrugBank.d30.s4|16-24|inhibitor|group
DDI-DrugBank.d30.s5|20-31|consequences|group
DDI-DrugBank.d30.s5|68-77|inhibitors|group
DDI-DrugBank.d30.s6|0-7|Subjects|group
DDI-DrugBank.d30.s8|0-1|As|group
DDI-DrugBank.d30.s8|14-18|drugs|group
DDI-DrugBank.d30.s8|25-29|block|group
DDI-DrugBank.d30.s8|53-59|effects|group
DDI-DrugBank.d30.s8|99-107|diuretics|group
DDI-DrugBank.d30.s8|167-177|supplements|group
DDI-DrugBank.d30.s8|188-198|substitutes|group
DDI-DrugBank.d30.s8|233-241|increases|group
DDI-DrugBank.d30.s9|0-1|As|group
DDI-DrugBank.d30.s9|31-36|agents|group
DDI-DrugBank.d622.s0|5-12|atropine|drug
DDI-DrugBank.d622.s0|53-57|signs|group
DDI-DrugBank.d622.s0|88-96|mydriasis|group
DDI-DrugBank.d622.s0|112-118|dryness|group
DDI-DrugBank.d622.s0|5-12|atropine|drug
DDI-DrugBank.d622.s1|0-3|This|group
DDI-DrugBank.d622.s1|45-52|atropine|drug
DDI-DrugBank.d622.s2|20-30|precautions|group
DDI-DrugBank.d622.s2|173-184|barbiturates|group
DDI-DrugBank.d622.s2|209-227|anticholinesterases|group
DDI-DrugBank.d622.s2|281-291|convulsions|group
DDI-DrugBank.d622.s3|56-64|reserpine|drug
DDI-DrugBank.d622.s3|90-102|tranquilizers|group
DDI-DrugBank.d622.s3|125-132|patients|group
DDI-DrugBank.d22.s0|47-53|digoxin|drug
DDI-DrugBank.d22.s0|56-62|Lanoxin|drug
DDI-DrugBank.d22.s0|65-74|Lanoxicaps|group
DDI-DrugBank.d22.s0|82-85|gets|group
DDI-DrugBank.d22.s1|32-38|digoxin|drug
DDI-DrugBank.d22.s1|81-85|doses|group
DDI-DrugBank.d22.s1|32-38|digoxin|drug
DDI-MedLine.d44.s0|0-6|Effects|group
DDI-MedLine.d44.s0|62-70|emulsions|group
DDI-MedLine.d44.s0|75-82|patients|group
DDI-MedLine.d44.s1|109-113|drugs|group
DDI-MedLine.d44.s1|138-144|process|group
DDI-MedLine.d44.s2|19-25|effects|group
DDI-MedLine.d44.s2|111-118|kinetics|group
DDI-MedLine.d44.s2|163-170|patients|group
DDI-MedLine.d44.s2|215-219|years|group
DDI-MedLine.d44.s2|258-270|triglycerides|group
DDI-MedLine.d44.s3|60-66|periods|group
DDI-MedLine.d44.s4|0-7|Patients|group
DDI-MedLine.d44.s4|146-155|treatments|group
DDI-MedLine.d44.s5|92-97|levels|group
DDI-MedLine.d44.s5|92-97|levels|group
DDI-MedLine.d44.s8|61-69|lipolysis|group
DDI-MedLine.d44.s8|192-198|studies|group
DDI-DrugBank.d429.s0|0-7|Antacids|group
DDI-DrugBank.d429.s0|0-7|Antacids|group
DDI-DrugBank.d429.s1|26-30|hours|group
DDI-DrugBank.d429.s1|56-61|agents|group
DDI-DrugBank.d429.s2|0-9|Cimetidine|drug
DDI-DrugBank.d429.s2|0-9|Cimetidine|drug
DDI-DrugBank.d429.s2|27-33|inhibit|group
DDI-DrugBank.d429.s3|19-28|cimetidine|drug
DDI-DrugBank.d429.s4|34-43|volunteers|group
DDI-DrugBank.d429.s5|28-32|hours|group
DDI-DrugBank.d429.s5|57-61|agent|group
DDI-DrugBank.d658.s0|62-68|effects|group
DDI-DrugBank.d658.s0|78-91|anticoagulants|group
DDI-DrugBank.d658.s1|19-31|anticoagulant|group
DDI-DrugBank.d658.s2|21-32|Interactions|group
DDI-DrugBank.d658.s2|47-53|effects|group
DDI-DrugBank.d658.s2|105-118|concentrations|group
DDI-DrugBank.d658.s2|125-141|radioimmunoassays|group
DDI-DrugBank.d658.s2|105-118|concentrations|group
DDI-DrugBank.d658.s2|242-249|creatine|drug
DDI-DrugBank.d269.s0|0-9|Inhibitors|group
DDI-DrugBank.d269.s1|5-16|metabolizers|group
DDI-DrugBank.d269.s1|34-45|Interactions|group
DDI-DrugBank.d269.s1|50-59|carvedilol|drug
DDI-DrugBank.d269.s1|73-82|inhibitors|group
DDI-DrugBank.d269.s1|103-111|quinidine|drug
DDI-DrugBank.d269.s1|114-123|fluoxetine|drug
DDI-DrugBank.d269.s1|126-135|paroxetine|drug
DDI-DrugBank.d269.s1|188-192|drugs|group
DDI-DrugBank.d269.s1|230-235|levels|group
DDI-DrugBank.d269.s1|50-59|carvedilol|drug
DDI-DrugBank.d269.s2|14-21|analysis|group
DDI-DrugBank.d269.s2|31-37|effects|group
DDI-DrugBank.d269.s2|51-56|trials|group
DDI-DrugBank.d269.s2|79-90|metabolizers|group
DDI-DrugBank.d269.s2|113-121|dizziness|group
DDI-DrugBank.d269.s2|31-37|effects|group
DDI-DrugBank.d269.s2|205-218|concentrations|group
DDI-DrugBank.d269.s3|24-29|Agents|group
DDI-DrugBank.d269.s3|32-39|Patients|group
DDI-DrugBank.d269.s3|53-58|agents|group
DDI-DrugBank.d269.s3|76-85|properties|group
DDI-DrugBank.d269.s3|115-128|catecholamines|group
DDI-DrugBank.d269.s3|137-145|reserpine|drug
DDI-DrugBank.d269.s3|151-159|monoamine|drug
DDI-DrugBank.d269.s3|169-178|inhibitors|group
DDI-DrugBank.d269.s3|212-216|signs|group
DDI-DrugBank.d269.s4|0-8|Clonidine|drug
DDI-DrugBank.d269.s4|41-49|clonidine|drug
DDI-DrugBank.d269.s4|56-61|agents|group
DDI-DrugBank.d269.s4|79-88|properties|group
DDI-DrugBank.d269.s4|145-151|effects|group
DDI-DrugBank.d269.s5|32-37|agents|group
DDI-DrugBank.d269.s5|55-64|properties|group
DDI-DrugBank.d269.s5|70-78|clonidine|drug
DDI-DrugBank.d269.s5|32-36|agent|group
DDI-DrugBank.d269.s6|0-8|Clonidine|drug
DDI-DrugBank.d269.s6|51-54|days|group
DDI-DrugBank.d269.s7|0-11|Cyclosporine|drug
DDI-DrugBank.d269.s7|21-29|increases|group
DDI-DrugBank.d269.s7|46-57|cyclosporine|drug
DDI-DrugBank.d269.s7|59-72|concentrations|group
DDI-DrugBank.d269.s7|112-121|carvedilol|drug
DDI-DrugBank.d269.s7|156-163|patients|group
DDI-DrugBank.d269.s8|16-23|patients|group
DDI-DrugBank.d269.s8|38-49|cyclosporine|drug
DDI-DrugBank.d269.s8|38-49|cyclosporine|drug
DDI-DrugBank.d269.s8|103-116|concentrations|group
DDI-DrugBank.d269.s9|42-53|cyclosporine|drug
DDI-DrugBank.d269.s9|86-93|patients|group
DDI-DrugBank.d269.s10|96-107|cyclosporine|drug
DDI-DrugBank.d269.s10|109-122|concentrations|group
DDI-DrugBank.d269.s10|165-174|carvedilol|drug
DDI-DrugBank.d269.s10|96-107|cyclosporine|drug
DDI-DrugBank.d269.s11|0-6|Digoxin|drug
DDI-DrugBank.d269.s11|0-6|Digoxin|drug
DDI-DrugBank.d269.s11|17-30|concentrations|group
DDI-DrugBank.d269.s11|64-70|digoxin|drug
DDI-DrugBank.d269.s11|76-85|carvedilol|drug
DDI-DrugBank.d269.s12|5-11|digoxin|drug
DDI-DrugBank.d269.s12|17-21|COREG|brand
DDI-DrugBank.d269.s13|35-41|digoxin|drug
DDI-DrugBank.d269.s13|103-107|COREG|brand
DDI-DrugBank.d269.s14|0-7|Inducers|group
DDI-DrugBank.d269.s14|13-22|Inhibitors|group
DDI-DrugBank.d269.s14|71-84|concentrations|group
DDI-DrugBank.d269.s14|89-98|carvedilol|drug
DDI-DrugBank.d269.s15|0-9|Cimetidine|drug
DDI-DrugBank.d269.s16|16-23|Blockers|group
DDI-DrugBank.d269.s16|35-39|cases|group
DDI-DrugBank.d269.s16|128-132|COREG|brand
DDI-DrugBank.d269.s17|0-1|As|group
DDI-DrugBank.d269.s17|14-19|agents|group
DDI-DrugBank.d269.s17|37-46|properties|group
DDI-DrugBank.d269.s17|52-56|COREG|brand
DDI-DrugBank.d269.s17|108-115|blockers|group
DDI-DrugBank.d269.s18|16-28|Hypoglycemics|group
DDI-DrugBank.d269.s18|31-36|Agents|group
DDI-DrugBank.d269.s18|54-63|properties|group
DDI-DrugBank.d269.s18|129-141|hypoglycemics|group
DDI-DrugBank.d269.s19|14-21|patients|group
DDI-DrugBank.d269.s19|46-58|hypoglycemics|group
DDI-DrugBank.d580.s0|12-18|studies|group
DDI-DrugBank.d580.s0|58-64|ASMANEX|brand
DDI-DrugBank.d580.s0|66-75|TWISTHALER|brand
DDI-DrugBank.d580.s0|98-102|drugs|group
DDI-DrugBank.d580.s0|189-194|events|group
DDI-DrugBank.d580.s1|9-20|ketoconazole|drug
DDI-DrugBank.d580.s1|32-40|inhibitor|group
DDI-DrugBank.d580.s1|86-91|levels|group
DDI-MedLine.d29.s2|31-44|concentrations|group
DDI-MedLine.d29.s2|49-59|penicillins|group
DDI-MedLine.d29.s2|65-77|cephaloridine|drug
DDI-MedLine.d29.s3|155-162|patients|group
DDI-MedLine.d29.s4|53-58|values|group
DDI-MedLine.d29.s4|148-153|liters|group
DDI-MedLine.d29.s5|0-3|Thus|group
DDI-MedLine.d29.s5|10-19|hypothesis|group
DDI-MedLine.d29.s6|42-49|patients|group
DDI-MedLine.d29.s8|0-3|This|group
DDI-MedLine.d29.s8|29-36|blockade|group
DDI-DrugBank.d14.s0|17-23|effects|group
DDI-DrugBank.d14.s0|78-89|vasodilators|group
DDI-DrugBank.d14.s1|0-6|Alcohol|drug
DDI-DrugBank.d14.s1|59-65|effects|group
DDI-DrugBank.d14.s2|82-89|blockers|group
DDI-DrugBank.d14.s2|103-110|nitrates|group
DDI-DrugBank.d14.s3|5-15|adjustments|group
DDI-DrugBank.d14.s3|27-31|class|group
DDI-DrugBank.d14.s3|36-41|agents|group
